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The mortality rate for patients undergoing operation for ruptured abdominal aortic
aneurysm is about 30-50% and has not significantly decreased over the last 20 years.
Rupture may be complicated by a coagulopathy in up to 50% of cases, the presence
of which is associated with a mortality rate in excess of 80%. Little is known about
the pathogenesis of this coagulopathy and treatment remains empirical. The aim of
this thesis is to investigate the pathological process which leads to this coagulopathy
and thus provide a rational basis for the development of new therapeutic strategies.
A retrospective case-control study of patients requiring re-operation for control of
haemorrhage following elective and emergency aortic aneurysm repair was
performed. The incidence of haemorrhage was 1.9% after elective surgery and 2.7%
after operation for rupture. The mortality rate was 58% in the study group and 21%
in the control group. The patients requiring re-operation appeared to have undergone
more complicated primary operations and nearly all patients had a coagulopathy at
the end of the first procedure which may have been the cause of the haemorrhage.
Coagulation studies were performed in a series of 24 patients with asymptomatic
abdominal aortic aneurysm. Levels of fibrinogen were high but within the normal
range and there was no evidence of systemic activation of the soluble coagulation or
fibrinolytic system. Platelet counts were low but usually within the normal range
and levels of glycocalicin were elevated suggesting either increased platelet turnover
or increased activation.
Coagulation studies were performed in a series of six patients undergoing elective
aortic aneurysm repair. It was found that thrombin, fibrinolytic and platelet
activation increases during the period of initial dissection in a time dependent
manner. After the administration of heparin and the application of the aortic cross
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clamp, thrombin, fibrinolytic and platelet activation reduced. After reperfusion there
was an increase in platelet activation which correlated with the duration of cross-
clamping.
Coagulation studies were performed in a series of 22 patients presenting with
ruptured aortic aneurysm. At time of admission there was marked activation of
platelets and thrombin in all patients which increased greatly by the end of operation.
Platelet count at the end of operation was significantly lower in patients who died
than in survivors.
Samples of subcutaneous fat and skeletal muscle were taken at the start of operation
in six patients with ruptured aneurysm. Transmission electron microscopy was used
to examine the endothelial cells in small vessels in these samples. When compared
with samples from six control patients undergoing elective aortic surgery it was
found that there were significant ultrastructural differences in the endothelial cells
from patients with rupture.
A randomised controlled study of fibrin sealant as a topical haemostatic agent at
vascular anastomoses was carried out in 57 patients undergoing aortic aneurysm
repair, carotid endarterectomy or arterial bypass graft using polytetrafluoroethylene
bypass graft. The time taken to achieve haemostasis at the anastomoses was
significantly reduced in patients treated with fibrin sealant. The reduction was most
marked in patients undergoing carotid endarterectomy.
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Surgery for abdominal aortic aneurysm
There are accounts of arterial aneurysms as long ago as Egyptian times but the first
recorded operations were carried out in Roman times. Antyllus, who lived in the 2nd
century A.D., is widely regarded as performing the first operations for aneurysms.1
He described both true and false aneurysms and clearly perceived the difference
between them. The operative technique he described involved proximal and distal
ligature with opening of the sac and evacuation of it contents. This technique, with
some variations, remained the standard operation until the middle of the Twentieth
century when arterial reconstruction became possible.
These early operations were performed on peripheral aneurysms and it was not until
the Nineteenth century that operations on the abdominal aorta were attempted. The
techniques used were variations on those described by Antyllus. The first such
operation was attempted in 1817 by Sir Astley Cooper who had considerable
previous experience of arterial ligation, including the first successful ligation of a
carotid artery in 1808 and a number of successful external iliac ligations. He had
also demonstrated that ligation of the aorta was compatible with survival in several
animal experiments. In 1817 a 38 year old porter with a rapidly enlarging iliac artery
aneurysm was admitted to Guy's Hospital. This aneurysm had ulcerated through the
skin, bleeding externally intermittently over a period of 5 days. Sir Astley Copper,
foreseeing the possible need to ligate the aorta, experimented with various means of
exposing the aorta in the post-mortem room. When the bleeding became so profuse
that the patient's life was in immediate danger he first attempted to ligate the feeding
artery by opening the sac and placing his finger in the orifice of the feeding artery.
- 16-
This proved unsuccessful and in a bold attempt he exposed the aorta through a
transperitoneal approach and placed a silk ligature above the bifurcation. This was
not a true aortic aneurysm but as the ligature was placed on the aorta it can be
considered the first aortic operation. The patient initially recovered but unfortunately
died some 40 hours post-operatively.
Despite this lack of success further attempts were made, though on occasion these
o o o
met with disapproval from the surgical community at large. One such attempt
was reported in an editorial in the Lancet as "an appalling operation, and we hope
not to hear of it repetition" 9 Despite this exhortation, surgeons persevered such that
by 1891 eleven such procedures had been carried out, all with fatal results.10
However it should be noted that some achieved limited success with one patient in
1842 surviving for 10 days before succumbing to secondary haemorrhage.5
The first successful ligation of the abdominal aorta was reported in 1925 by Rudolph
Matas, more than one hundred years after the first attempt by Sir Astley Cooper.11,12
This patient survived for 1 year, 5 months and 5 days before succumbing to
pulmonary tuberculosis. Aortic ligation did not become widely popular and by 1940
1 ^
there were only 24 recorded cases of which 5 had been successful. A notable
proponent of ligation was Brooks who described several successful cases and carried
out animal experiments on the effects of aortic ligation.14,15
During this time another approach to the treatment of aortic aneurysm was also being
pursued; the promotion of thrombosis within the aneurysm by various means. The
first such attempt was in 1831 when Velpeau introduced three pairs of knitting
needles into an aortic aneurysm.16 In 1864 Moore passed 26 yards of iron wire into
i n
an aneurysm and Corradi modified this technique by passing an electric current
through the wire in an attempt to induce thrombosis. This manoeuvre became
known as the Moore-Corradi technique and, with some variation, continued to be
- 17-
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popular until the early part of the Twentieth century. Indeed a series of patients
treated by wiring was reported recently as 1968.19 However, it was recognised that
although these procedures relieved pain they did not prevent rupture and thus the
technique fell out of favour as other forms of management became more successful.
It had been shown both experimentally and clinically that complete occlusion of the
abdominal aorta below the renal arteries was compatible with survival but it was
thought that it would be preferable to maintain blood flow to the lower limbs.14
Various techniques were developed such as partial ligation of the aorta or ligation
91
with fascia lata which would later loosen and allow restoration of flow. It was the
introduction of arterial reconstruction using arterial homografts that finally allowed
the development of modern aortic surgery. The first successful aortic resection
23and reconstruction was reported in 1952 by Dubost. The use of arterial homografts
was soon superseded by the development of prosthetic grafts. The early
24.
development of these grafts was largely the work of Voorhees but it was
DeBakey who introduced the knitted dacron graft which, with some modifications, is
2Sstill used today.
The final step towards aortic surgery as we now know it was the development of the
"inlay" operative technique, first described by Creech, which avoided the extensive
dissection required to excise the aneurysm. This technique greatly reduced
intraoperative bleeding and operating time and led to a reduction in the mortality
rate.26
In parallel with improvement in surgical technique there have been considerable
advances in anaesthesia and intensive care with the introduction of adequate
anaesthesia, artificial ventilators, muscle relaxants, invasive monitoring, intravenous
fluids, heparin and blood transfusion not to mention other aspects of modern care
such as oxygen, antibiotics, x-rays, angiography, ultrasound scanning and routine
- 18-
biochemical and haematological investigation. This has led to a reduction in
mortality and broadening of the indications for operation. When considering the
sophistication of modern anaesthetic and intensive care required in aortic surgery, it
is interesting to note that during the first aortic procedure carried out by Sir Astley
Cooper, the anaesthetic consisted of brandy and ether. It is now difficult to envisage
undertaking aortic surgery in those circumstances.
- 19-
Acquired coagulopathy
The earliest recognition of inherited bleeding disorders was in the 2nd century A.D.
when Rabbi Judah exempted from circumcision a new-born boy whose brothers had
97
died from bleeding following circumcision. In comparison, the recognition of
acquired bleeding disorders as a clinical entity is relatively recent.
Early philosophers and medical practitioner proposed a variety of hypotheses
concerning how and why blood clotting occurs. The first step forward in
determining the true nature of coagulation was in the mid-seventeenth century when
Malpighi (1686) separated fibrin from blood clot. The origin of fibrin remained a
subject of debate over the next century. Some believed that it was produced from
albumin, others that it was derived from red cell nuclei but the views of Hewson
(1846) and Babington (1830) who believed that fibrin was formed from a precursor
in plasma eventually became accepted. The plasma precursor was later extracted,
97
purified and given the name fibrinogen.
Buchanan, in 1845, observed that hydrocoele fluid clotted upon the addition of fresh
serum and concluded that serum contained some agent which converted fibrinogen
99
into fibrin. Some years later this agent, thrombin, was identified. It was soon
realised that this also must exist in an inactive form otherwise it would cause the
coagulation of circulating blood. This precursor, prothrombin, was sought and
identified.30
It had previously been demonstrated that blood clotted rapidly both in vivo and in
vitro on the addition of tissue suspensions and Schmidt (1892) drew upon this
observation to formulate a hypothesis that tissue contained some factor, which he
22termed tissue thromboplastin, which converted prothrombin to thrombin.
Platelets were first described by Donne in 1842 but their function was unknown.
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The role of platelets in haemostasis was suggested by the observation that some
patients with purpura were thrombocytopenic.34 Osier (1874) observed that platelets
tended to clump together and Hayem (1882) suggested that this process might
play a role in haemostasis. This was confirmed by the observations of Bizzozero
(1882) and Eberth and Schimmelbusch (1886) that platelets adhered to injured vessel
walls and that more platelets then adhered to these clumps.
Thus by the beginning of the Twentieth century the basic haemostatic mechanism
07
was understood and classic theory of coagulation was formulated. It was also at
this time that the first acquired coagulopathies were described. The Hippocratic
school had observed that the blood of those who die suddenly or violently may be
97
incoagulable, an observation also made by Hunter at the end of the Eighteenth
9R
century, but there were no descriptions of acquired bleeding disorders in living
patients.
It is interesting that disseminated intravascular coagulation was described and
investigated in an animal model long before it was recognised clinically. In a classic
and much repeated experiment de Blainville (1834) injected an intravenous bolus of
brain tissue suspension into dogs.31 This led to the immediate death of the animals
and post mortem examination demonstrated widespread fibrin deposition within
blood vessels. In a modification of this experiment Woolridge in 1881 slowly
administered tissue extract intravenously and found that, rather than clotting, the
blood became incoagulable. It was later demonstrated that the animal's blood was
depleted of fibrinogen.39"41
It was in field of obstetrics that acquired bleeding disorders as a clinical entity were
first described and investigated. In 1901 DeLee reported a case of a patient with
abruptio placenta whose blood failed to clot even several days later.42 He described
this condition as temporary haemophilia. Defective clotting in patients with both
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abruptio placenta and placenta praevia was noted by Williams (1915) who likened
the abnormal bleeding to that found after snake bites and hypothesised that it might
be due to the release of some toxin, although it was suggested that the pathological
injury was to the blood vessel wall rather than the coagulation system.43 Subsequent
investigations revealed that these patients had markedly reduced levels of fibrin and
this was proposed as the cause of the excessive bleeding.44 In animal experiments it
was shown that the infusion of placental extract caused a clotting defect 45 and the
causative factor was identified as thromboplastin.46'47 The hypothesis evolved that
the escape of placental thromboplastin into the maternal circulation caused activation
of the coagulation cascade producing defibrination.48
At the same time as these studies in obstetric patients were being carried out, a
fortuitous observation led MacFarlane (1937) to investigate the changes in the
coagulation systems of patients following general surgical operations.49 He noticed
that a clotted blood sample taken from a patient following cholecystectomy and left
overnight was fluid the following morning. The importance of this was that it was
not the case that the blood did not clot but that the blood had clotted and
subsequently lysed. This phenomenon had in fact been observed in 1893 by Dastre
in dogs which had bled extensively and he gave it the name "fibrinolysis".50 These
and other studies demonstrated that fibrinolytic activity was increased in patients
following major surgery.51 This activity was attributed to the action of plasmin, a
C'j
proteolytic enzyme described by Christensen and McLeod (1945).
Early reports describing excessive bleeding during and after general surgical
S3
operations laid the blame on blood transfusion. The bleeding tendency was
attributed to "citrate intoxication" or thrombocytopenia secondary to massive
CI
transfusion. However Coon and Hodgson formulated an alternative hypothesis.
The presence of excessive fibrinolysis in patients following surgery, trauma and
shock was well established by this time 49>51'55,56 ancj combining this with the
-22-
current understanding of coagulopathy in obstetric patients, they hypothesised that
the bleeding disorder was due to hypofibrinogenaemia secondary to excessive
fibrinolysis caused by shock. Subsequent clinical investigation indicated that in
most cases clinical bleeding was due to hypofibrinogenaemia and consumption of
en
clotting factors and that the effects of blood transfusion were less important.
-23-
Coagulopathy and aortic aneurysm
Fine et al (1967) are generally accredited with the first account of coagulopathy in
association with an aortic aneurysm but there are earlier reports.58-60 Krevans and
Jackson (1955) in a study of massive transfusion reported two cases of coagulopathy
complicating aortic surgery; a 50 year old man who, following elective abdominal
aortic aneurysm repair, developed excessive bleeding from the wound, rectal
bleeding and haematuria with thrombocytopenia and prolonged clotting times, and a
64 year old man who bled post-operatively following elective abdominal aortic
aneurysm repair and was found to have thrombocytopenia and
hypofibrinogenaemia.61 Both these patients died in the early post-operative period.
f\0
The next report was published some 12 years later by Phillips. A patient was
described who developed excessive bleeding during abdominal aortic aneurysm
repair that was associated with prolonged clotting times, thrombocytopenia and
hypofibrinogenaemia. This patient died 5 hours postoperatively from cardiac arrest.
There are also many early accounts of coagulopathy in patients with thoracic aortic
aneurysms and even femoral artery aneurysms.58'59,63,64
It was not until 1974 that more rigorous investigation of patients undergoing aortic
aneurysm revealed that coagulopathy was quite commonly found in patients post¬
operatively 65 The first report of coagulopathy occurring pre-operatively in a patient
with a ruptured abdominal aortic aneurysm was by ten Cate et al who described
"markedly low levels of coagulation factors, decreased level of fibrinogen, an
increase offibrin/fibrinogen degradation products and a distinct thrombocytopenia"
at the time of admission in a 71 year old woman with ruptured abdominal aortic
aneurysm.66
There has been some debate as to whether clinical disseminated intravascular
-24-
coagulation is a complication of intact abdominal aortic aneurysms.60 In 1969 a case
was reported of a 76 year old man with a chronic bleeding disorder and an abdominal
aortic aneurysm.67 However it was subsequently reported by Siebert and Natelson
that this patient continued to have DIC after operative repair and was subsequently
/"O
found to have pancreatic carcinoma. A second patient was reported by these
authors; a 68 year old man whose coagulopathy did resolve after operation but this
case is complicated by the fact that he also had liver cirrhosis and underwent
splenectomy at the time of aortic surgery.
Siebert and Natelson recommended that the presence of a coagulopathy complicating
abdominal aortic aneurysm should prompt the search for another cause of the
coagulopathy such as occult carcinoma. It should also be noted that DIC may be
idiopathic and that should the coagulopathy not correct after aneurysm repair, the
1f\
two conditions may have been coincidental. These authors recommended four
criteria for the diagnosis of coagulopathy complicating intact abdominal aortic
aneurysm: -
1. The presence of a chronic acquired bleeding disorder.
2. Laboratory evidence of DIC.
3. Correction of coagulopathy after operative repair.
4. Maintenance of normal coagulation for three months after surgery.
Many of the reported cases in the literature do not meet these criteria because the
aneurysm was never operated on58,64,67,69,70 or there was concurrent liver
f*l Z"Q
disease ' and many quoted cases were in fact patients with thoraco-abdominal
aneurysms.58'64'70 However there are a few reported cases that do fulfil these
• 71-7S
criteria.
In a prospective study Fisher et al looked for clinical and laboratory evidence of
11
DIC in a series of 76 patients prior to aortic surgery. Three patients with clinical
-25-
bleeding disorders were described but these were all patients with thoraco abdominal
aneurysms. None of the 26 patients with abdominal aortic aneurysms had clinical or
laboratory evidence of DIC, although some did have mild thrombocytopenia or
elevated fibrin degradation products. It must be considered that, although clinical




The earliest technique used to achieve haemostasis was cautery which remained
common up to the Eighteenth century. The more sophisticated technique of applying
ligatures to bleeding vessels was first described by Sushruta who lived in the period
70
800 - 600 B.C. in ancient India. The use of ligatures was also described in the
writings of several eminent Roman surgeons, Celsus, Rufus, Antyllus and Galen,
79
around the second century A.D. However this knowledge was lost and, although
ligatures were described by several authors after this time, cautery, either by
application of hot irons or boiling oil, remained the haemostatic technique of choice
80until the rediscovery of the ligature by Ambroise Pare in 1552. Thereafter there
was a period of debate as to whether cautery, compression or ligature was the best
means to control haemorrhage. By the end of the Eighteenth century, ligature was
generally accepted as the preferable technique.
These early techniques were devised to overcome the massive haemorrhage
associated with trauma and early surgical procedures such as amputation. The
development of increasingly sophisticated surgical procedures demanded better
haemostatic techniques to allow the control of haemorrhage without causing
extensive tissue damage. This was especially the case in neurosurgery where a wide
variety of techniques were developed. Sir Victor Horsley, one of the founders of
modern neurosurgery, described the use of wax to seal bone; a method still used
81
today. Harvey Cushing, another pioneer of neurosurgery, described a wide variety
of haemostatic techniques: hot cotton, pieces of muscle (also described by Horsley),
82well-solidified blood clots and silver wire clips. In this paper Cushing also
suggested that fibrin might be a useful agent, a suggestion taken up by Grey as
82
mentioned below.
An important technique promoted by Cushing, in association with Bovie, was
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electrocautery and electrocoagulation; a return to the principles of cautery but in a
Q/j
more controlled manner. In early clinical use an electric current was used to heat
o/-
an element which was then applied to the bleeding area, electrocautery. This is
fundamentally no different from the application of a hot iron, as used many centuries
earlier. A more sophisticated technique was developed in which current was passed
through the patient producing heat in the tissues by electrical power dissipation.
This technique reduces damage in surrounding tissues, produces more secure
07
haemostasis and quickly superseded earlier techniques. Since then equipment has
been refined and electrocoagulation is universally employed in nearly all branches of
surgery.
Thus present haemostatic methods are fundamentally the same as those employed by
Sushruta, a combination of ligature and cautery, albeit much more refined. The
introduction of topical haemostatic agents, such as fibrin sealant, therefore represents
a radical new approach.
Fibrin sealant - Historical aspects
It may be thought that fibrin based adhesives and sealants are likely to be the ideal
agents for surgical haemostasis and tissue adhesion since fibrin plays a central role in
the physiological processes of haemostasis and wound healing. Thus it might be
possible to avoid the problems of foreign body reaction, delayed healing and fibrosis
which are associated with other topical haemostatic agents such as those based on
collagen or oxidised cellulose. The first experiments using fibrin to control
OO
haemorrhage were performed by Bergel in 1909. The use of sheep fibrin as a
haemostatic agent in neurosurgical animal experiments was reported by Grey in
00
1915. Sheep fibrin was used because it was readily available as a by-product of
materials used to perform Wassermann tests. The combination of fibrinogen and
-28-
thrombin was first described in 1944, but poor adhesive effect was reported,
probably due to low concentration of fibrinogen.89'90
The advent of technology to extract concentrated and purified clotting factors
allowed the development of the fibrin sealant that is in current use 91 This consists
of two principle components, fibrinogen and thrombin, which are mixed, in the
presence of factors VIII and XIII, fibrinectin and calcium, to produce insoluble
fibrin. Thus the principle components of the final stage in the physiological pathway
of coagulation are present. Fibrin sealant of this form was first described in 1972.91
Fibrin sealant was initially developed as a tissue adhesive in nerve repairs but its
possibilities as a haemostatic agent were soon investigated. The haemostatic
92
properties of fibrin sealant were first clinically employed in cardiothoracic surgery.
Since then it has been used in a wide variety of settings but has only achieved
common use in cardiothoracic surgery, especially for aortic dissection, and in
92
otorhinolaryngology for procedures such as middle ear reconstructions.
Fibrin sealant appears to be extensively used throughout Europe but it is only used in
the UK by a small number of enthusiasts. To date there is no fibrin sealant
preparation with a product licence on the market in the UK.
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Epidemiology, Natural History and Management of
Abdominal Aortic Aneurysm
Epidemiology
Attempts to determine the precise prevalence of aortic aneurysms within a given
population founder upon the problem of the definition of an aneurysm. An aneurysm
can be defined as "an abnormal dilatation of a blood vessel" but the point at which
dilatation becomes abnormal is the debatable issue. Aortic diameter within a
population is a continuum and any measurement at which the aorta is called
aneurysmal is arbitrary.94 Furthermore an aorta of 2.5 cm in a large male may be
considered normal but an aorta of the same diameter in a small female would be
considered pathological. Some epidemiological studies have set an arbitrary size at
which the aorta is considered abnormal while others have considered the infrarenal
aorta to be aneurysmal if it is larger,95 5mm larger 96 or more than 50% greater
97than the suprarenal diameter. The next difficulty is the detection of such
aneurysms. The most practical method is to use ultrasound scanning, which has the
98
advantage of being non-invasive but has a margin of error of 0.5 cm.
Most studies have examined high risk populations, as predicted by age,96 sex,96
family history 99'100 and a history of vascular disease.101'102 One of the best
estimates of community prevalence comes from the Oxford screening programme; a
large community based study in men aged 65-74 years.96 This study reported a 2.3
per cent prevalence of aneurysm greater than 4 cm. A similar study, the Birmingham
Community Aneurysm Screening Project, examined 2669 men aged 65-75 and found
an aortic diameter >29mm in 8.4% of patients and aortic diameter >40mm in 3.0% of
103
patients. A study of the incidence of aneurysm in patients aged greater than 50
-30-
years undergoing abdominal ultrasound scan for non-vascular disease demonstrated a
prevalence of aortic diameter greater than 3cm of 8.8 per cent in men and 2.1 per
cent in women.104 However the population in this study is clearly a biased sample
of the general population.
Another approach to epidemiology of aortic aneurysms is to look at the end point -
death from ruptured aortic aneurysm - as shown on death certificates or as
determined by post-mortem examination. Studies such as these give figures in the
range of 2.9-14.1 per 100,000 population per year.105"113 The wide variation
between studies may be methodological in nature. The rate of post-mortem
examination varies between countries. People dying suddenly and unexpectedly, as
is often the case with ruptured aneurysms, are more likely to undergo post-mortem
examination and therefore the observed incidence may be an overestimate in
communities which have a low overall rate of post-mortem examination. In some
studies a low or unstated community post-mortem rate gives rise to some doubt over
the validity of the conclusions. However there may be genuine differences in
incidence between different countries. Most of the studies come either from the UK
or Sweden and mortality rates are consistently higher in the UK.
The prevalence of aortic aneurysm is strongly related to age, male sex, hypertension
cigarette smoking, prior vascular disease and family history.116 The mortality from
aortic aneurysm in men aged more than 80 years is ten times that of men aged 55-64
117
years and one hundred times that of men aged below 55 years.
The incidence of aortic aneurysm appears to be increasing. This has been shown by
an increase in the incidence of diagnosis of aortic aneurysm in the general population
in Scotland from 25.8 per 100,000 in 1971 to 63.6 per 100,000 in 1984.118 Similar
increases have been reported in Australia, Sweden and the USA.112'119'120 The
mortality from aortic aneurysm has risen twenty-fold in men and eleven-fold in
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women between 1950 and 1984. The incidence of ruptured aortic aneurysm has
likewise increased.108'122 These trends appear to be continuing. A more recent
study shows a steady rise in the numbers of elective and emergency aneurysm repairs
1 "23
and mortality from aortic aneurysm in Scotland during the period 1980-91. While
some these changes can be attributed to a greater awareness of the diagnosis and
greater ease of detection, due to ultrasound scanning, it does appear that there is an
underlying increase in incidence.
Natural history
The classic study of the natural history of abdominal aortic aneurysms was published
12*4.
in 1950 by Estes. This study comprised 102 patients and demonstrated that the 5
year survival was 19 per cent, with 63 per cent dying from rupture. Aneurysms
increase in diameter with time, although the rate of increase is highly variable
125 127between individuals and within the same individual at different times. ~ ~ The
growth rate is in the order of 0.2 - 0.5 cm diameter per year. Laplace's law states
that the tension in the wall varies with the square of the diameter. It can thus be
predicted that the risk of rupture should be related to diameter of aneurysm. This
prediction has been bourne out in practice; patients with larger aneurysms have a
greater risk of rupture and post-mortem examinations reveal that aneurysms that
128-130
have ruptured tend to be large. However even small aneurysms can rupture.
Some authors have considered that the shape of the aneurysm, the presence of
131
intraluminal thrombus and atherosclerosis may be related to the risk of rupture.
An important factor that is related both to rate of growth of aneurysms and risk of
130 132
rupture is hypertension. '
The accurate determination of the risk of rupture with an aneurysm of a given size
has remained elusive. One study reported that the risk of rupture was 6% at 5 years
and 8% at 10 years, with zero risk in aneurysms of less than 5cm diameter and 25%
127risk in aneurysms over 5 cm. A more recent study involving 300 patients
described a 1 per cent cumulative incidence per year of rupture for aneurysms less
i oo
than 4cm and 2.9 per cent for those 4-4.9 cm.
Treatment and outcome of ruptured aortic aneurysm
As stated above the natural history of aortic aneurysms is that they eventually
rupture unless death from another cause intervenes or they are repaired surgically.
The mortality rate for those who rupture in the community has been estimated at 90-
107 108 117 124.
95% as most patients do not survive to reach hospital. ''' Of those who
reach hospital alive a considerable number, 20-30%, are deemed unfit for surgery.
Of those who undergo emergency aortic aneurysm repair the mortality rate is about
30-50% (Table 1). Some investigators have shown that those who undergo a
successful aneurysm repair have a normal quality of life and normal life
1 or 1 ozr
expectancy. ' In a more recent study it was found that late survival was poorer
in patients having undergone successful operation for rupture compared with those
127who had undergone elective aortic surgery. However the figures were not
corrected for confounding variables, such as age, which might lead to reduced
survival rates in patients following operation for rupture.
Direct comparison between series is not valid as patient selection varies widely. For
example Gloviczki et al include patients admitted with ruptured aneurysm but who
died without operation and 24% of patients in their series had suffered a cardiac
arrest prior to operation. Other series only include patients who undergo operation
and it is likely that some centres were more selective than others and did not operate
on patients with poor prognosis. These difficulties in comparison led to the proposal
of a classification system for ruptured aortic aneurysms but this has not become
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widely adopted. Direct comparison is not valid but it is noteworthy that the
mortality rate from rupture has not decreased significantly over the last 30 years.
Some studies that compare different time periods within the same hospital report that
their mortality rate has decreased despite the fact that a higher proportion of patients
i i r-n i rc
admitted with rupture undergo operation, ' ' although one group report no
improvement in mortality rate over an eleven year period.156 This suggests that
although the performance of individual units may improve with increasing
experience, there have been no major advances that have improved the outcome for
these patients.
The most common causes of death are post-operative myocardial infarction,
uncontrolled intra-operative haemorrhage, continued post-operative haemorrhage
and multisystem failure.144,158 As well as a high mortality rate, surgery for ruptured
aortic aneurysm carries considerable post-operative morbidity. Respiratory failure,
renal failure, sepsis, stroke, lower limb ischaemia and ischaemic colitis are common
in the early post-operative period.
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Table 1 Reported results ofoperation for ruptured aortic aneurysm
Author Year No. patients Mortality rate
De Bakey 138 1964 117 34%
1
Mannick et al 1964 26 32%
Kouchoukos et al140 1967 36 61%
Hicks et al 141 1975 56 55%
Marsh 142 1980 29 41%
Diehl et al 143 1983 34 26%
Fielding et al 144 1984 198 43%
Donaldson et al145 1985 81 43%
Ingoldby et al107 1986 101 48%
Jenkins et al 122 1986 151 28%
Shackleton et al146 1987 106 41%
Amundsen et al147 1989 114 60%
Murphy et al 148 1990 172 49%
Ouriel et al 149 1990 243 55%
Harris et al 150 1991 113 64%
Johansen et al151 1991 186 70%
Cohen et al 152 1975-85 70 76%
1986-89 54%
1 O
Gloviczka et al 1992 214 45%
McCready et al154 1993 208 49%




Johnston 1994 147 51%
Katz et al136 1994 1829 50%
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Prognostic indicators
Given the high mortality rate for emergency surgery, a number of studies have been
carried out to identify the factors that are associated with poor outcome.150'159,160
Such studies may help to guide decision making as to which patients should be
offered operation and indicate patients in whom current treatment is inadequate and
for whom new treatment strategies should be developed.
Preoperative factors that have consistently been associated with poor prognosis are
increasing age, hypotension on admission, low admission haematocrit and chronic
obstructive airways disease. The intra-operative factors associated with poor
outcome are free intraperitoneal rupture, length of operation, blood loss and blood
transfusion. The post-operative factors associated with late death from multi-organ
failure are immediate post-operative thrombocytopenia and organ system failure
score (GORIS score) determined 48 hours post-op.161
A recent large multicentre prospective study of ruptured aneurysms showed that the
variables associated with outcome were pre-induction systolic blood pressure,
creatinine, total intraoperative urine output, total volume of blood administered, site
i -y~jof aortic cross clamp and cross clamp time. However no combination of factors
was associated with 100% mortality and it was thus concluded that the decision as to
whether to undertake operation could not be made on the basis of these factors.
Coagulopathy has been shown to be an indicator of poor outcome in a number of
14-2
papers. Davies et al examined this issue in a prospective study. Patients with
1
ruptured aneurysms had blood samples taken at the time of admission. A platelet
count, PTR, APPT, fibrinogen assay and d-dimer assay were performed on this
sample. Patients were followed until death or discharge. It was found that the
platelet count was closely associated with mortality. It is important to note that the
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cause of death in these patients was not restricted to bleeding complications but that
a significant number of patients died in the post-operative period from myocardial
infarction and multi-organ failure. Four patients had DIC at time of admission with
thrombocytopenia, prolonged clotting times and elevated D-dimers and all four
patients died.
Two further clinical studies have supported these findings. Johnson et al reported
that the presence of a coagulopathy at the end of operation is associated with
137
increased mortality rate. A coagulopathy was present in 12% of patients and
these patients had a mortality rate of 76%, the remaining 88% who did have a
coagulopathy had a mortality rate of only 25%. Bradbury et al in a study of 65
patients presenting with ruptured aortic aneurysm demonstrated a direct correlation
between platelet count at time of admission and mortality and between platelet count
i zro
at the end of operation and multi-organ failure. There was a 93% mortality rate in
those with an admission platelet count of less than 150 x 109/1 compared with 24% in
those with a platelet count greater than 150 x 109/1.
It is difficult to interpret these findings in terms of cause and effect; it may be that
the derangement in the coagulation system is simply a marker for blood loss,
prolonged hypotension etc. or it may be that there is a causal relationship between
coagulopathy and death.
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Current Understanding of Disseminated Intravascular
Coagulation
Introduction
Disseminated intravascular coagulation (DIC) is a clinical condition which is
associated with many diverse disease states (Table 2).164 DIC is characterised
clinically by platelet-fibrin thrombi deposition in the microvasculature of various
organs and a bleeding tendency, with evidence on laboratory testing of
thrombocytopenia, consumption of coagulation factors as demonstrated by prolonged
clotting times, low levels of plasma fibrinogen and elevated fibrin degradation
products.
There is spectrum of clinical presentation with varying degrees of thrombotic and
haemorrhagic features. There are three broad groups: firstly a chronic,
predominately thrombotic disorder associated with malignancy or connective tissue
disease, secondly an acute thrombotic disorder with multi-organ failure associated
mainly with infection and thirdly an acute haemorrhagic disorder associated with
obstetric accidents, trauma, head injury and ruptured aortic aneurysm.
The pathogenesis of DIC is a complex and confusing subject. DIC is thought to arise
when an otherwise normal haemostatic system is subjected to an abnormal,
overwhelming stimulus or when some component of the haemostatic mechanism is
defective. The haemostatic mechanism is complex with elaborate systems of
activation and control. It has several features, such as powerful positive feedback
mechanisms, which are necessary for optimal function but which also make it
susceptible to the development of DIC when it is subjected to certain stimuli. Thus a
clear understanding of the normal physiological controls on haemostasis is required
-38-
in order understand why this mechanism can produce DIC when subjected to
abnormal stimuli.
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The purpose of the haemostatic mechanism is to seal defects in blood vessels walls,
so preventing loss of blood from the intravascular space, without interrupting blood
flow more than is necessary. In order to achieve this, the haemostatic system has a
complex set of triggering and controlling mechanisms which result in rapid
production of a platelet - fibrin plug at the site of injury, but which at the same time
inhibit thrombosis within healthy vessels and initiate repair of the injury and removal
of the clot.
The two pivotal events in normal haemostasis at the site of injury are the generation
of the enzyme thrombin, which then converts soluble fibrinogen to insoluble fibrin,
and the adhesion and activation of platelets. These events are not isolated but
interact such that each promotes the other. There are controlling mechanisms which
ensure that the process of fibrin and platelet deposition does not extend to intact
blood vessels. These events are closely followed by the activation of the enzyme
plasmin; a fibrinolytic agent which clears excess thrombus around the area of injury
and later promotes recanalization and the restoration of blood flow. Fibrinolysis is




For many years the accepted theory of coagulation was that there were two separate
pathways, the intrinsic and extrinsic pathways, that led independently to the
generation of thrombin. It was also considered that the intrinsic pathway was more
important as deficiencies of factors in the intrinsic pathway, factor VIII and IX, led
to well known bleeding diatheses. However recently it has become accepted that in
vivo it is the extrinsic pathway (also known as the tissue factor pathway) of
coagulation which is responsible for the initiation of coagulation and that elements of
170
the intrinsic pathway are vital for amplification of thrombin production. The
tissue factor pathway of coagulation which will be described in detail below.
Injury to the vessel wall results in the exposure of collagen and tissue factor (also
known as tissue thromboplastin). Tissue factor is a membrane glycoprotein which is
present on the surface of many cells, although notably not on unactivated endothelial
cells or leucocytes. Tissue factor binds Factor VII which even when not activated
can, in combination with tissue factor, activate Factor X, although at a very slow
rate. Activated factor X in turn converts prothrombin (Factor II) to thrombin.171"173
Activation of Factor X and thrombin produces a positive feedback; both these
enzymes activate Factor VII which when activated is a more potent activator of
Factor X itself (Figure l).174 In addition the Factor Vll-tissue factor complex can
i nc
auto-activate by converting VII to Vila.
There is also a negative feedback pathway. Tissue factor pathway inhibitor, a serine
protease inhibitor which is found in the plasma and on the surface of endothelial
cells combines with, and inhibits, factor Xa. This complex is a potent inhibitor of
17f\
the tissue factor-Vila complex.
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This reaction proceeds quite slowly in isolation, and indeed may do so outside intact
vessels as these proenzymes are relatively small and may escape into the
extravascular space in undamaged vessels. There are three factors that cause this
reaction to be greatly accelerated when the blood vessel is injured. Firstly,
disruption of the vessel allows the large coagulation factors, Factor V, VII and VIII,
to reach the extravascular space; these co-factors accelerate various reactions in the
coagulation cascade. The presence of factor Va speeds up the action of Xa on
prothrombin by about 1,000 times. Secondly, all these reactions take place at much
greater rates at the surface of membranes, in particular negatively charged
membranes. Intact cell membranes are phospholipid bilayers with the negative
charges in the centre of the structure. The major source of this phospholipid is from
-42-
activated platelets. Thirdly, the presence of activated platelets promote thrombin
production by releasing prothrombotic factors and by providing a large area of
exposed phospholipid.
The combination of factor Xa, factor Va, calcium and phospholipid is known as
prothrombinase. This complex activates prothrombin at 300,000 times the rate of
177
factor Xa alone.
As stated above factor Xa combines with tissue factor pathway inhibitor and forms a
complex that inhibits the activation of factor X. This negative feedback loop
prevents the large-scale activation of factor X except when large amounts of tissue
factor are present.
Another means exists to overcome this negative feedback loop (Figure 2). The factor
Vila-tissue factor complex not only activates factor X directly, as detailed above, but
171
also indirectly via factor IX, antihaemophilic factor B. Tissue factor-Vila
activates factor IXa which in turn activates factor X. This latter reaction requires
calcium ions and is greatly accelerated in the presence of factor Villa, a large
178
coagulation co-factor, and negatively charged membrane. The complex of factor
IXa and Villa on phospholipid is known as tencise and is analogous to the
prothrombinase complex. The degree of acceleration produced by this complex is
such that in the presence of Villa and phospholipid, factor IXa can activate as much
factor X in one minute as would take 6 months for factor IXa alone to produce.
Factor IXa also converts factor VII to Vila in a positive feedback pathway similar to
that of factor Xa.
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Figure 2 Pathway of tenase formation
This pathway explains why haemophiliacs, either with factor VII deficiency
(haemophilia A) or factor IX deficiency (haemophilia B), tend to bleed at sites where
tissue factor is in low concentrations e.g. intra-articular haemorrhage but not
intracerebral haemorrhage. Where there are large quantities of tissue factor the
procoagulant forces may be great enough to overcome the tissue factor pathway
inhibitor negative feedback pathway and produce adequate amounts of thrombin
without the need for the tenase complex.
Thrombin promotes its own production by powerful positive feedback mechanisms
at several points. It acts on circulating factor VIII-vWF complex to release and
activate factor VIII. It activates factor V which then becomes a potent co-factor in
the generation of Xa. Finally thrombin is one of the most potent platelet activators.
The influence of platelets on the generation of thrombin will be discussed below.
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Thus it can be appreciated that if factor X activation occurs at a great enough rate to
overcome the negative feedback of Xa-TFPI complex, the generation of small
amounts of thrombin will trigger a series of reactions which result in the explosive
generation of large amounts of thrombin.
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Platelet adhesion and activation
At the site of vessel injury there are three principle platelet reactions: adhesion,
aggregation and release reaction. When the vessel wall is injured circulating von
Willebrand factor binds to exposed collagen and elastin fibres. Platelets adhere to
i no i on
von Willebrand factor via the platelet membrane glycoprotein lb (GPlb). '
This step is of vital importance in initiating normal haemostasis. For example in
both von Willebrand's disease, in which there is deficiency of von Willebrand factor,
and Bemard-Soulier syndrome, in which platelets lack GPlb receptors, the bleeding
time is markedly prolonged.
Platelets, once adherent at the site of injury, undergo a structural change and release
factors which both stimulate the aggregation of further platelets and promote
coagulation. This reaction is strongly stimulated by thrombin. The platelet changes
from a discoid shape to a spherical shape, then forms processes and finally flattens
and spreads. During these structural changes, glycoprotein expression on the platelet
membrane changes. The most significant of these is the expression of GPIIb/IIIa, a
binding site for other platelets and fibrin.
The principle agents which promote platelet aggregation are thromboxane, which is
synthesised de novo from membrane phospholipid after platelet adhesion, and
platelet activating factor, which is stored in intracellular granules. Platelets release
large amounts of factor V which, after being activated by thrombin, accelerates the
coagulation system as detailed above.
One of the most important mechanisms by which platelets accelerate coagulation is
1 01
the "flip-flop" reaction. As platelets undergo the release reaction, there is a
conformational change in the platelet membrane which exposes the negatively
charged end of phospholipids. This phospholipid is necessary for the formation of
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both the prothrombinase and tenase complex and increases the activity of IXa-Villa
and Xa-Va by about 1,000 times.
The physical presence of a platelet aggregate may be important in the process of
coagulation. The reduced blood flow in the region of the platelet aggregate allows
adequate concentrations of various coagulation factors to accumulate and remain in
close approximation for sufficient time to enable the series of reactions which
produce fibrin to take place.
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The contact pathway of coagulation.
When blood is placed in contact with foreign surface it clots. This process occurs
via the intrinsic pathway of coagulation, so called because all the components
required for coagulation are contained within the plasma. This pathway is shown in
Figure 3. The later stages from factor IXa are the same as in the tissue factor
pathway detailed above. The early steps which lead to factor IX activation are
known as the contact phase. This contact phase is also important in other
physiological systems such as the complement and kallikrein systems.
Pre-kallikrein activation is the trigger for the contact phase. Pre-kallikrein circulates
bound to high molecular weight (HMW) kininogen. When this complex comes into
contact with foreign surface the prekallikrein is released as kallikrein, a serine
protease. Kallikrein acts on high molecular weight kininogen producing bradykinin.
Factor XII, also known as Hageman factor, is activated by a numbers of enzymes,
factor Xlla, XIa, plasmin and kallikrein, with kallikrein being the most important of
these. There is a positive feedback loop with Xlla increasing the rate of activation of
pre-kallikrein. Factor Xlla activates factor XI which in turn acts on factor IX. All
these reactions take place at a negatively charged surface. The subsequent events are
as detailed above.
The contact system is interesting in that deficiency of any of the components does
not lead to a bleeding disorder. It has thus been considered that this pathway is not
important in the in vivo physiological haemostatic system. However this pathway
may be the means by which the coagulation system is activated during disease states.
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Formation of the platelet - fibrin plug
The principle substrate for thrombin is fibrinogen, one of the most plentiful
circulating plasma proteins. Thrombin cleaves two polypeptides from fibrinogen
creating fibrin monomer. The fibrin monomer rapidly polymerises to form insoluble
fibrin strands. Adjacent strands cross link by covalent bonds in a calcium dependent
process which is initiated by factor XHIa, a circulating enzyme which is activated by
1 o? 1 oo
thrombin. ' The cross-linked fibrin is mechanically stronger and more resistant
to fibrinolysis. Fibrin binds to activated platelets via the platelet membrane protein
glycoprotein Ilb/IIIa (GPIIb/IIIa) forming a strong platelet-fibrin plug. Identical
GPIIb/IIIa receptors are present on endothelial cells and may help to anchor the clot.
It must be considered that cross-linking is an important clinical process as deficiency
1 o.i
of factor XIII is associated with a bleeding tendency. Patients have poor wound
healing and frequently die from intracranial haemorrhage.
An important feature of the fibrin clot is that it is not a solid gel but is rather an open
mesh of long fibres. This structure allows fibroblasts to migrate easily through the




As detailed above, injury to the vessel wall results in explosive production of
thrombin. In order to prevent massive and inappropriate thrombosis there must be an
efficient mechanism to inactivate thrombin and to remove excess fibrin. This is
mainly mediated by the anticoagulant and fibrinolytic effects of intact endothelial
cells
Thrombin is inactivated and cleared from the circulation by a series of
antithrombins; principally by antithrombin III (70%), and to a lesser extent by a2
macroglobulin (20%) and al antitrypsin (10%). Thrombin binds to these
antithrombins and splits them. It remains attached to the split product and is thus no
longer active. The thrombin-antithrombin complex is cleared from the circulation by
i or
the liver in less than five minutes. The presence of heparin-like molecules on the
1 QZ.
surface of healthy endothelial cells greatly accelerates this reaction. This process
is highly efficient and free thrombin is rapidly removed from the circulation.
However the fact that antithrombins are consumed during this process means that the
ability to inactivate thrombin is limited and may be overcome if the rate of thrombin
generation is high.
Thrombomodulin, a protein which is found on the surface of endothelial cells, is a
major inhibitor of thrombotic activity (Figure 4). Thrombin binds to
thrombomodulin on the endothelial cell surface. This complex is then able to
activate protein C which in turn cleaves factors Va and Villa rendering them
inactive. This reaction is increased approximately ten-fold in the presence of protein
S - a vitamin K dependent cofactor which circulates bound to C4b binding protein.
Protein C has a much greater affinity for factor Va and Villa than for their precursors
factors V and VIII.
\
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Fibrinolysis is an essential process in normal haemostasis. It is by this means that
excess fibrin is removed and vessels are recanalised after repair of injury. The major
fibrinolytic enzyme is plasmin which circulates in the form of an inactive precursor
plasminogen synthesised by the liver. The principle activator of plasminogen is
tissue plasminogen activator (tPA) which is produced by endothelial cells.
Endothelial cells store tPA and thus a large amount can be released upon stimulation
of the endothelial cell. Various substances stimulate the release of tPA from
187
endothelial cells, the most potent being thrombin. tPA binds to fibrin and
undergoes a conformational change which increases it ability to activate
plasminogen. Plasminogen and plasmin also bind to fibrin. These interactions with
1RRfibrin mean that plasmin activity is maximal in the area of the clot.
Plasmin is a serine protease whose principle action is to lyse fibrin. This it does by
splitting a series of lysyl-arginine bonds to produce a number of fibrin degradation
products (FDPs). In addition to its fibrinolytic effects, plasmin also acts in a lytic
fashion on various coagulation factors such as V, VIII, fibrinogen and vWF.
As with other physiological processes there is a mechanism for inactivation and
inhibition of fibrinolysis and this occurs at two levels. The inactivation of tPA is
controlled by endothelial cells which produce plasminogen activator inhibitor 1
(PAI-1) and the inactivation of plasmin is effected by a-1 antiplasmin, a circulating
plasmin inhibitor. PAI-1 is normally produced at a greater rate than tPA and thus
there is net inhibition of tPA, except when the endothelial cell is stimulated and
releases large quantities of stored tPA. When plasmin is bound to fibrin it is
inaccessible to a-1 antiplasmin and thus avoids inactivation. However any freely
circulating plasmin is quickly inactivated by a-1 antiplasmin.
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Endothelial cells
Endothelial cells were at one time thought merely as inert lining cells. However it is
now well established that they play a vital role in the control of haemostasis, with
effects on coagulation, fibrinolysis, platelets and vessel tone, and have important
interactions with the immune system, regulating leucocyte adhesion and migration.
Healthy, intact endothelial cells have a strong anticoagulant effect by inhibiting
thrombin production, platelet aggregation and by removing thrombin and the
activated clotting factors.
Endothelial cells provide a physical barrier preventing the large clotting factors and
platelets from coming into contact with tissue factor and collagen which are
abundant in the sub-endothelium. The cell membrane contains large amounts of
heparans, endogenous heparin-like factors which enhance thrombin inactivation by
anti-thrombins. Endothelial cells are the main site of synthesis of tissue factor
pathway inhibitor, which is released into the general circulation and is also bound to
189the cell surface. Endothelial cells produce prostacyclin, a potent inhibitor of
platelet activation and a vasodilator.
Endothelial cells are important in the inactivation of thrombin. Thrombomodulin is
produced by endothelial cells and expressed on the luminal surface. Thrombin binds
to thrombomodulin on the endothelial cell surface forming a complex which
activates protein C. Activated protein C in conjunction with protein S, also produced
by endothelial cells, inactivates factors Va, Villa, tenase and prothrombinase.
Endothelial cells are important in the control of fibrinolysis as they may both
promote fibrinolysis, by production of tPA, and inhibit it by production of
plasminogen activator inhibitor. The means by which endothelial cells exert control
on this process remains obscure. The lack of understanding on this subject is largely
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due to the fact that endothelial cells in culture behave in a markedly different fashion
to endothelial cells in vivo in the expression of tPA. The difference in cellular
activity in this area also casts some doubt on the validity of results from studies of
other facets of endothelial cell behaviour which have largely been determined from
cell culture models.
Endothelial cells also play a vital role in the regulation of vascular tone through the
release of either vasodilator factors such as prostacyclin and endothelial derived
relaxing factor, or vasoconstrictor factors such as endothelin.
As well as this anti-coagulant and fibrinolytic role, endothelial cells have important
pro-coagulant functions. Endothelial cells produce nearly all of the circulating von
Willebrand factor. This released constitutively and is also stored intracellularly in
the Weibel-Palade bodies.190'191 The contents of the Weibel-Palade bodies are
released upon stimulation by factors such as thrombin and fibrin.
Tissue factor may be expressed by endothelial cells following stimulation by a
variety of means including endotoxin, cytokines and hypoxia. Tissue factor is an
integral membrane protein and is therefore released by the shedding of membrane
vesicles.192
While it was previously thought that denudation of the endothelial cells with
exposure of underlying collagen was required for initiation of platelet aggregation
and coagulation, it is becoming apparent that such processes may take place on the
surface of intact but activated endothelial cells. Animal models have shown that
endothelial cell injury, sufficient to activate cells but not destroy them, is followed
by platelet aggregation on the surface of endothelial cells.193'194
The luminal surface of the endothelial cell has receptors for a number of coagulation
factors and may increase the rate of various reactions in the coagulation cascade by
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bringing certain components closer to one another. Activation of factor X on the
surface of endothelial cell occurs at a slow rate via the intrinsic pathway, facilitated
by factor IX and XI binding to the cell surface, in unstimulated cells and at a much




As noted above, DIC is not a disease in its own right but is rather a secondary
response to an underlying primary pathology. It may be regarded as a final common
pathway for a number of conditions which are highly varied and otherwise
completely unconnected. Thus it can be expected that there is not one single all-
encompassing pathogenic mechanism but rather a multitude of pathways which lead
to a final common event. It is generally considered that this common event is
excessive thrombin generation.
The pathways which lead to this thrombin generation are varied. It may be quite
direct as with some snake venoms.169 The venom of Vipera Russelli (Russell viper)
directly activates factor X and Echis Carinatus venom directly activates
prothrombin. In other conditions it is considered that activation takes place via the
tissue factor pathway. For example in abruptio placenta and severe brain injury large
amounts of tissue factor are released into the circulation.
In septicaemia the pathway which leads to thrombin generation more complex
(Figure 5).196 The presence of circulating endotoxin lead to increased expression of
1 Q7 1 QQ
various cytokines, most notably tumour necrosis factor a (TNF-a). ' TNF-a
activates endothelial cells giving rise to increased tissue factor expression and
subsequent activation of coagulation via the extrinsic pathway.199'200 Monocytes
may also be important mediators in this process as these cell also express tissue
factor when activated by endotoxin. In addition monocytes can activate endothelial
cells.201
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Whatever the cause of its production, the presence of large amounts of thrombin
within the circulation leads to a self promoting downward spiral. At this point it is
important to reiterate that in normal circumstance these events are prevented by the
rapid removal of thrombin from the circulation by antithrombins and the
thrombomodulin/protein C/protein S system on intact endothelial cells. Thus in
order for the following sequence of events to occur, either thrombin generation must
be so great that it overcome the inhibitory process or the inhibitory process itself
must be defective.
An example of a defective inhibitory system is found in liver failure. Patients with
liver disease have a reduced ability to synthesise clotting factors, including inhibitory
factors such as antithrombin III and protein C, and have a reduced ability to clear
activated clotting factors from the circulation. These patients are at much greater
risk of developing DIC when subjected to a procoagulant stimulus. In animal
models the administration of thoratrast, which affects liver function, induces DIC.202
In septicaemia increased levels of TNF-a can reduce expression of thrombomodulin
by endothelial cells.203,204 This reduces the capacity to inactivate thrombin.
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Inhibition of the protein C-protein S pathway in primate experiments results in the
2QC
production of DIC with 10 times lower doses of E Coli.
The sequence of events that follows excessive thrombin production is as follows.
Thrombin via a number of positive feedback loops promotes its own production.
Circulating thrombin activates platelets, producing circulating platelet-fibrin
microthrombi which themselves are potent stimulants of thrombin production.
Activated platelets release procoagulant substances and provide a source of
phospholipid which increases the rate of production of thrombin. This process leads
to the consumption of fibrinogen and clotting factors which is exacerbated by the
widespread activation of plasmin.
Thrombin stimulates endothelial cells to produce tPA which in turn promotes
plasmin production. Plasmin performs its physiological role and lyses fibrin leading
to the production of fibrin degradation products. Fibrin degradation products have
an anticoagulant effect; they bind to fibrin monomers preventing polymerisation to
fibrin and producing soluble fibrin monomer.
Plasmin is a relatively non-specific serine protease, unlike thrombin, and has effects
on a number of proteins. It lyses fibrinogen and various clotting factors, most
notably factors V, VIII, IX and XI, and a number of other plasma proteins. This
further reduces the amount of circulating fibrinogen and clotting factors and
increases fibrinogen degradation products which have a similar anticoagulant effect
9rV;
to fibrin degradation products. Plasmin also has effects on platelets causing
reduced GPlb expression either by lysis or redistribution within the platelet.
This increased plasmin activity has been described as inappropriate but it should be
remembered that in DIC there is widespread deposition of fibrin in the
microvasculature and the increased plasmin activity required to remove this is
appropriate. The inhibition of plasmin, using drugs such as aprotinin and tranexamic
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acid may therefore be detrimental to the patient.
Whether increased plasmin activity is the primary agent in producing DIC, rather
than a secondary event to thrombin activity, has been much debated. In some cases,
such as the administration of large amounts of tPA, it may be the primary event but it
is most often secondary to excess thrombin production. Fibrinolysis as a primary
907
cause of bleeding is uncommon, although documented, and the bleeding disorder
in DIC is thought to be due to reduced levels of clotting factors and platelets rather
than direct fibrinolysis of clot at the site of injury.
By this combination of events the end state of DIC is reached: There is widespread
fibrinolysis with elevated fibrin degradation products and increased thrombin
activity as shown by increased fibrinopeptide A and thrombin-antithrombin
-complexes. Levels of fibrinogen, clotting factors and platelets are markedly
reduced such that normal haemostasis is severely impaired.
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Management of DIC
A great deal of controversy surrounds the management of DIC. There is much
opinion and dogma but little hard evidence available from clinical trials. Much of
the problem lies in the fact that DIC is not a single clinical entity but varies in
clinical presentation and has a large number of underlying causes. Thus it is unlikely
that a single management strategy will be adequate for all patients. This diversity
also produces problems in clinical trials. In some studies patients with DIC from a
variety of causes are grouped together and a benefit from treatment in some patients
may be obscured by there being no benefit, or a detrimental effect, in patients with
DIC of a different aetiology.
The mainstay of therapy for DIC is to treat the underlying disorder and thus remove
the stimulus for thrombin production. The patient should be generally supported to
maintain adequate oxygenation and perfusion of vital tissues. In many patients, for
example those with sepsis, who are not actively bleeding, this may be all that is
necessary. In patients who are actively bleeding further intervention may be
required. Treatment options include the replacement of clotting factors and platelets,
blocking thrombin production with heparin, inhibiting thrombin with the serine
protease inhibitor gabexate or hirudin, increasing clearance of thrombin by
administering anti-thrombin III and inhibiting plasmin with a serine protease
inhibitor such as tranexamic acid or aprotinin. All of these treatments are
controversial.
Clotting factors are replaced in the form of fresh frozen plasma and cryoprecipitate.
Fresh frozen plasma contains all clotting factors in approximately physiological
concentrations. Cryoprecipitate is mainly used to provide fibrinogen, containing
0.15-0.3g fibrinogen in 50ml, and does not contain significant amounts of other
clotting factors. Some authors advocate that fibrinogen should not be given in
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ongoing DIC as it will only "stoke the fire" and lead to greater consumption of
clotting factors, increased fibrin degradation products and increased fibrin deposition
in vital tissues.208
The transfusion of platelet in patients with DIC and a bleeding problem has few
drawbacks although platelet life span is likely to be severely limited and massive
quantities may be required to keep the platelet count at near normal levels. Platelets
are normally supplied as a suspension of platelet in plasma. The plasma may contain
significant amounts of clotting factors and fibrinogen. Each unit of platelets contains
about 30 x 1010 platelets, however the proportion of these which are fully functional
depends on the age of the platelets.
Heparin is a well established treatment for DIC.209 The rationale behind heparin
therapy is that it reduces thrombin production and activity and thus breaks the cycle
that causes DIC. In addition it should reduce fibrin deposition in the
microvasculature of vital organs. It seems to be particularly effective in patients with
the chronic thrombotic form of DIC that is commonly associated with malignancy.
Heparin has been used successfully to correct the DIC associated with a non-
910 911
ruptured aortic aneurysm prior to elective surgery. '
However the use of heparin in situations where bleeding is the predominant problem
208
is controversial. Some authors advocate an aggressive approach administering
heparin even in the presence of severe bleeding. However others express concern
that heparin may exacerbate the bleeding tendency. In a randomised trial of heparin
use in patients with DIC following trauma excessive bleeding was reported in those
212
patients treated with heparin. In addition there are practical problems in
establishing the correct dosage. The dosage of heparin is normally adjusted
according to two parameters - the APPT and the presence of bleeding. Both these
are unreliable in a patients with DIC who is bleeding excessively.
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While some of authors who advocate heparin therapy state that it should be given
alone, others recommend that clotting factor replacement and platelet transfusion
should be given concomitantly as there will be some delay between inhibiting the
DIC process and the manufacture of clotting factors and platelets which are required
21 "3
to stop the bleeding.
Antithrombin III has several features which indicate that it might be useful in DIC:
antithrombin III is the principle physiological means by which thrombin is removed
from the circulation and levels of antithrombin III are low in DIC. The first report of
214the use of antithrombin III in DIC was published in 1974. There have been many
subsequent reports, including some randomised trials and animal studies, which
212 21^216
have suggested a benefit from antithrombin III. ' ' A recent review
208 217recommended the use of antithrombin III in acute DIC, ' but it has not yet
21 Q 91 o
become established as first line treatment. '
Activated protein C has been suggested as a possible therapeutic agent for much the
same reasons as antithrombin III. Protein C is an important inhibitor of coagulation
and levels are reduced in DIC.196 Its use has been reported in 3 patients with DIC
21 Q
and was said to be effective. Clinical trials of protein C in patients with DIC are
now underway.220
There are a number of case reports and small studies concerning the use of gabexate
mesilate in DIC. Gabexate mesilate is a serine protease inhibitor with particular
affinity for thrombin. Published reports have been favourable, and it appears to be
well established in Japan, but larger clinical trials will be required to establish its use
elsewhere.221"224
Tissue factor pathway inhibitor has been shown to be effective in preventing DIC in
22S
a rabbit model of DIC induced by tissue thromboplastin infusion. However
further evidence of efficacy, for example from primate models of septicaemia, will
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be required before clinical trials could be contemplated. Another substance at an
early stage of development is hirudin, a specific thrombin inhibitor produced by
00f\
medicinal leeches. It can be produced using recombinant DNA technology.
Some animal studies have indicated that it may be useful in DIC but clinical studies
are awaited.
In summary there are a number of management strategies in acute DIC with severe
haemorrhage and all combinations of heparin, antithrombin III and clotting factor
replacement have been recommended. Unfortunately there are few well designed
and conducted trials of these modalities on which to base recommendations and there
is little consensus at present.
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Coagulopathy and abdominal aortic aneurysms
Relatively little detailed research has been carried out concerning the coagulation
system in patients with aortic aneurysms. Most publications on this subject have
been clinical in nature, describing the epidemiology, clinical features and outcome
for patients with coagulopathy in association with aortic aneurysms. In addition
there is no suitable animal model. However some investigation has been carried out
as will be detailed below.
Some patients with asymptomatic aortic aneurysms have deranged coagulation
77
systems on laboratory testing and may rarely present with symptoms of
71 7S
coagulopathy such as gingival bleeding and excessive bruising. In the study by
Fisher et al about 10% of patients with non-ruptured aneurysm had elevated levels of
77 797
fibrin degradation products and a mild thrombocytopenia. ' It has been
suggested that this is due to consumption of clotting factors and platelets during
turnover of the clot within the aneurysm sac. This is supported by studies using
radiolabeled platelets and fibrinogen which have demonstrated platelet and fibrin
778 779
deposition within the aneurysm sac. ' A more recent study using radiolabeled
monoclonal antibodies to tissue plasminogen activator has demonstrated fibrinolytic
7^0
activity within the aneurysm sac which was not present after aneurysm repair.
The development of coagulopathy during elective aneurysm repair is a well
recognised, although uncommon, complication of elective aortic surgery. The
pathological process which leads to the development of this coagulopathy remains
obscure and very little is known of the changes which occur in the coagulation
system during operation. In one study of the coagulation system during aorto-
femoral bypass grafting for occlusive disease it was shown that levels of fibrinogen
70 1
dropped throughout operation, most markedly after aortic cross-clamping. A
more recent study has examined the coagulation system in patients undergoing aorto-
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femoral grafting for a mixture of occlusive and aneurysmal disease. This
indicated that fibrinolytic activity, as determined by B-Beta 15-42 and fibrin
degradation products, increased during operation. Platelet count decreased steadily
through operation. There was a slight drop in levels of inhibitory factors such as a2-
antiplasmin and anti-thrombin III. However a policy of haemodilution during the
early stages of operation and the administration of large amounts of fresh frozen
plasma during operation mean that the validity of these findings are doubtful. No
examination of thrombin activation was carried out.
The coagulopathy reported in association with ruptured aortic aneurysm may be
present on admission or may rise intra-operatively. The laboratory findings are of
DIC although some patients on admission have thrombocytopenia without
11 1 f\9
prolongation of clotting times or elevated fibrin degradation products. ' Most
studies have presented findings in post-operative patients with well established DIC
and there is a lack of information about the early changes in the coagulation as found
on admission and the changes which occur during operation.
On the basis of on this knowledge, and the understanding of the haemostatic system
derived from in vitro studies, a hypothesis can be formulated to explain the
pathogenesis of the coagulopathy associated with aortic aneurysms.
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Hypothesis
Patients with intact abdominal aortic aneurysms have constant turnover of clotting
factors and platelets in the clot within the aneurysm sac. This is usually compensated
but in the case of very large aneurysms or reduced ability to synthesise clotting
factors there may be DIC evident on laboratory studies or even clinically apparent
abnormal bleeding. Thus the haemostatic system is "primed" and thus more easily
perturbed by the effects of rupture and operation.
Rupture has two effects: firstly there is active bleeding and a large blood clot within
the abdominal cavity, secondly there is hypovolaemic shock. Blood loss, active
bleeding and fibrinolysis within the blood clot produce large amounts of thrombin
and consume platelets and clotting factors. Hypovolaemic shock leads to tissue
hypoperfusion and hypoxia. Endothelial cells and leucocytes are directly and
indirectly activated by hypoxia and in turn trigger the coagulation and fibrinolytic
system.
During operation, tissue trauma, continued blood loss and blood transfusion
contribute to increasing production of thrombin and consumption of clotting factors
and platelets. Aortic cross-clamping leads to hypoperfusion and hypoxia in tissue
distal to the clamp with effects as described above. In particular there is bowel
ischaemia resulting from a combination of clamping the inferior mesenteric artery,
hypovolaemic shock and the effects of retracting the small bowel from the abdominal
900 'YXA
cavity. ' This leads to bacterial translocation across the gut mucosa resulting in
endotoxaemia. Endotoxaemia alone can produce DIC and may well contribute in this
situation.
Finally reperfusion of ischaemic tissues on release of the aortic clamp washes out
noxious metabolites and activated leucocytes with further adverse effects on the
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haemostatic system.235
At some stage in this sequence of events, the forces driving activation of the
haemostatic system may so consume vital components of the haemostatic system and
overcome the normal homeostatic mechanism that disseminated intravascular
coagulation occurs.
It is on this hypothesis that the studies in this thesis have been designed and most of
the elements of this hypothesis will be examined, in the hope of proving, disproving
or refining this hypothesis.
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Chapter 2
Post-operative Haemorrhage Following Aortic
Aneurysm Repair: A Retrospective Case-control Study
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Introduction
Haemorrhage both during and after operation used to account for the majority of
deaths after aneurysm repair. The incidence of this complication was much reduced
by the introduction of the "inlay" technique, which avoids the need for extensive
dissection and reduces the length of operation. However haemorrhage remains one
i yy i /jo yif. 'J'l'l
of the more common complications of aneurysm repair. ' ' Most authors
have concentrated on technical operative errors as the cause of these complications -
e.g. bleeding from anastomoses or unrecognised lumbar arteries. The primary
aim of this study was to determine whether technical errors are to blame for most of
these bleeding episodes or whether they could be attributed to the presence of a
coagulopathy. The secondary aims were to determine the incidence of post-operative
haemorrhage after elective and emergency aortic surgery and what factors (e.g.




Patients undergoing laparotomy for control of haemorrhage following aortic
aneurysm repair during the period 31st July 1988 - 1st August 1994 in the Vascular
Surgery Unit of the Royal Infirmary of Edinburgh were identified by means of the
Vascular Audit system. Nineteen patients were identified, 11 male and 8 female,
with a mean age of 73 ± 5 years. In 7 cases the first operation had been elective and
in 12 the operation had been performed for rupture. During this period 378 elective
operations and 408 emergency operations were carried out for abdominal aortic
aneurysm in this unit giving an incidence of operation for post-operative bleeding of
1.9% after elective operations and 2.7% after emergency operations. Case-controls,
matched for sex and indication for operation, were selected from operation records
during the same period by the following method. For each study patient undergoing
laparotomy for the control of haemorrhage the next patient of the same sex
undergoing aortic aneurysm repair for the same indication was selected. The mean
age of the control group was 71 ± 8 years.
Operations were carried out either by a Consultant vascular surgeon or by a Senior
Registrar with considerable experience in vascular surgery. All patients undergoing
elective operation were given systemic heparin (5,000 iu) prior to cross-clamping.
Those undergoing operation for rupture were not given systemic heparin but
heparinised saline (5,000iu / 500ml 0.9% saline) was used for irrigation.
Statistical analysis was carried out using Systat for windows v5.0®. Mann-Whitney
U-test, Chi-squared and Fisher exact tests were used where appropriate. Data are




Mean operating time, cross clamp time, blood loss and transfusion requirements
were all greater in patients who bled post-operatively than in the controls, although
these differences were not statistically significant except for blood loss - p< 0.05 by
Mann-Whitney test (Table 3 & 4). The study group had a lower mean temperature at
the end of operation - p < 0.05 by Mann-Whitney test. These data suggest that
patients who bled post-operatively had more complicated primary operations.
At re-exploration a single bleeding point was found in only 5 patients. Of these three
were bleeding from the proximal anastomosis, one from a lumbar artery and one
from the median sacral artery. In 2 patients no active bleeding point was found
although there was a considerable volume of blood in the peritoneal cavity. In the
remaining 12 multiple minor bleeding points and/or diffuse oozing were found.
Clinical Outcome
In total there were 11 deaths (58%) within 30 days in the study group compared with
4 deaths (21%) in the control group - p < 0.05 Pearson chi-squared (Table 5). The
mortality rate for the patients who had undergone an elective primary operation (5/7)
was greater than for those who had undergone operation for rupture (6/12).
Eight of those who died in the study group followed a clinical course of progressive
deterioration and death from continuing haemorrhage and multi-organ failure. Ten
patients made a good initial recovery and were discharged from the intensive care
unit back to the general ward. In this group there were three late deaths; two from
cerebro-vascular accident (CVA), both at ten days post-operatively and one from
-72-
cardiac arrest on the fourteenth post-operative day, subsequent to a myocardial
infarction diagnosed on electrocardiogram findings earlier that day. In addition to
these deaths a further patient suffered a non-fatal CVA 19 days after operation. In
two of the three CVA cases the diagnosis was made on clinical grounds and in the
other the diagnosis was confirmed by CT scanning. There were no late deaths in the
control group but one patient suffered a non-fatal MI on the second post-operative
day.
Coagulation studies
All but two patients who required re-operation had abnormal results on coagulation
screen following the first operation (Tables 3 & 4). The two patients who did not
have a coagulopathy both bled because of a technical error - failure to under-run a
lumbar artery and bleeding from the proximal anastomosis. Of the seven elective
patients who required re-laparotomy for haemorrhage, 4 had platelet counts of less
than 100 x 109 /I and a further patient had a platelet count less than 150 x 109 /I
following the first operation (normal range 150-450 x 109 /I ). Only one of the
elective patients in the control group developed post-operative thrombocytopenia
with a platelet count of 93 x 109 /l.
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Table 3 Clinical and operative details ofpatients requiring re-operation after
primary operation for ruptured aneurysm. ( Figures are median and
range)
Study Group Control Group
Pre-operative platelet
count (xlO9 /I)
103 81-385 253 244-336 NS
Platelet count after first
operation (xlO9 /I)
92 40-140 112 64-175 NS
Fibrinogen after first
operation (g/1)
1.12 0.6-2.9 1.30 0.6-3.8 NS
Prothrombin ratio after
first operation
1.6 1.1-3.3 1.4 1.0-2.2 NS
Temperature at the end
of operation( °C)
34 31.6-36 35 32.5-37 p<0.05
Operation length (mins) 180 85-320 112 80-300 NS
Cross-clamp time (mins) 65 44-100 45 40-70 NS
Blood Loss(ml) 5150 2000-12500 2035 840-10700 p<0.05
Transfusion RCC (units)
during first operation
12 6-18 6 1-16 NS
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Table 4 Clinical and operative details ofpatients requiring re-operation after
elective primary operation for aortic aneurysm. ( Figures are median
and range)
Study Group Control Group
Pre-operative platelet
count (xlO9 /I)
163 120-304 201 124-395 NS
Platelet count after first
operation (xlO9 /I)
81 41-181 173 93-220 NS
Fibrinogen after first
operation (g/1)
1.59 1.1-2.2 3.28 1.7-4.8 NS
Prothrombin ratio after
first operation
1.6 1.0-1.8 1.2 1.0-1.4 NS
Temperature at the end
of operation ( °C )
35.2 35-36.1 36.5 36-37 NS
Operation length (mins) 160 160-240 120 110-220 NS
Cross-clamp time (mins) 80 44-100 45 40-70 NS
Blood Loss (ml) 2125 390-3665 1200 450-2000 NS
Transfusion RCC (units)
during first operation
3 0-8 2.0 0-3 NS
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Table 5 Outcome ofpatients requiring re-operation after aortic aneurysm
repair
Type Outcome Operative findings
1 Elective Died Early Death Proximal anastomosis
2 Elective Died MI day 12 Diffuse bleeding
3 Elective Survived Lumbar artery
4 Elective Died Early Death Diffuse bleeding
5 Elective Died CVA day 10 Proximal anastomosis
6 Elective Survived Proximal anastomosis
7 Elective Died Multi-organ failure Diffuse bleeding
8 Rupture Died CVA day 10 Diffuse bleeding
9 Rupture Survived Renal Failure Diffuse bleeding
10 Rupture Survived Median sacral artery
11 Rupture Died Early Death Diffuse bleeding
12 Rupture Died Early Death Diffuse bleeding
13 Rupture Survived Renal Failure Diffuse bleeding
14 Rupture Survived Diffuse bleeding
15 Rupture Survived CVA day 19 Diffuse bleeding
16 Rupture Survived Diffuse bleeding
17 Rupture Died Early Death No active bleeding
18 Rupture Died Renal Failure and MI No active bleeding
19 Rupture Died Early Death Diffuse bleeding
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Discussion
This study confirms that operation for control of haemorrhage after aortic aneurysm
repair is an uncommon but serious complication which is nearly always associated
with a coagulopathy and thrombocytopenia. The mortality rate of 58% in this study
was lower than that reported elsewhere. Slootmans et al and Gloviczki et al reported
mortality rates of 85% and 90% respectively for series of patients operated on for
1 CO ?OQ
haemorrhage after repair of ruptured aneurysm. However a remarkably low
mortality rate of 11% was reported by Fielding in a study of 9 patients undergoing
laparotomy for post-operative haemorrhage.144
The importance of coagulopathy has not been emphasised in previous reviews on
this subject. ' From the data available in this study it is impossible to determine
whether the coagulopathy is the cause of the haemorrhage or vice-versa. However,
the fact that patients who bled had lower platelet counts prior to the first operation
and that very often no significant bleeding point could be found suggests that
coagulopathy is an important causal factor in most patients. It should also be noted
that many of the patients with ruptured aneurysms received platelet transfusions
(median 5 units, range 0-20 units) and it may be that without them the severity of
post-operative thrombocytopenia would have been greater.
The role of coagulopathy as a causal factor of haemorrhage is easily understood in
patients with ruptured aneurysms, as it is well established that many of them have
1 AO
coagulopathy on admission. It may also be the case that coagulopathy is a causal
factor in patients who undergo elective repairs. Coagulopathy is an established
complication of elective aortic aneurysm repair. It was first reported in 1955 and
subsequent studies have revealed that laboratory evidence of abnormal coagulation
1 c 99'7 O""} 1
following aortic surgery is common ''' In the present study 5 out of 7
patients who required re-operation after elective operations had thrombocytopenia
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following the primary operation. Examination of the records of 20 consecutive
patients undergoing elective aneurysm repair revealed that only one had post¬
operative thrombocytopenia. This is a significantly lower incidence of post¬
operative thrombocytopenia than in the study group - p < 0.02 by Fisher exact test.
It is notable that the two patients who had normal platelets counts both bled because
of a technical error and both had a good outcome. Thus it appears that there are two
distinct causes of haemorrhage after elective aneurysm repair:- one group of patients
bleed because of an operative error. These patient have normal coagulation and a
good outcome - 100% survival in this study. A second group of patients bleed
secondary to a coagulopathy which has developed intra-operatively. These patients
have a poor outcome - 100% mortality in this study.
It is interesting to note that many patients were hypothermic at the end of operation.
The hypothermia in the patients who bled may simply reflect the fact that they had
undergone longer and more complicated operations but it should be noted that
hypothermia itself is associated with a bleeding tendency. Hypothermia may cause a
bleeding tendency due to a direct effect on the coagulation system; the coagulation
cascades are enzymatic processes which function optimally at 37°C and are less
efficient at lower temperatures. This phenomenon is not detected by laboratory
testing as laboratory tests, such as prothrombin time and activated partial
thromboplastin time, are performed at a standard temperature and not at the
temperature of the patient. Hypothermia causes reversible platelet dysfunction,
possibly due to effects on thromboxane activity, and potentiates the activation of
platelets by plasmin in vitro.240
These theoretical effects of hypothermia on the coagulation system have been bourne
out in clinical studies. In one study it was found that bleeding times during aortic
"24-1
aneurysm surgery become more prolonged as core temperature falls. It may be
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advisable that greater efforts are made to avoid heat loss in these patients through
precautions such as heated water blankets, polythene bags around the lower legs, the
use of an efficient blood warmer and placing the small intestine in a "gut-bag".
There was a high incidence of stroke in this study. In one case it is known that the
stroke was thrombo-embolic in nature rather than haemorrhagic but in the other two
cases this information is not available. If these events and the post-operative MI
were thrombotic it might reasonably be thought that these patients with a
perioperative coagulopathy are developing a "rebound" pro-thrombotic state some
days later. Further evidence for this hypothesis is the fact that at the time of these
events the platelet count was rising; in two cases the platelet count had more than
doubled in the preceding 48 hours.
The presence of a pro-thrombotic state after ruptured aneurysm has been suggested
1
in a recent publication. In a clinical study of patients presenting with ruptured
aortic aneurysm it was found that 15/35 patients who survived operation developed a
thrombocytosis (platelet count > 400 x 109/1) and 10 of these 15 suffered a deep vein
thrombosis, 8 also suffered a pulmonary embolus.
An association between coagulopathy and post-operative thrombotic events is also
suggested by data published in another study of ruptured aortic aneurysms. Davies
et al reported that in a group of 12 patients who developed a coagulopathy in
association with a ruptured aneurysm there were 3 post-operative deaths which might
be attributed to thrombotic events; two from MI on days 1 and 9 and one from stroke
on day 14. In contrast, in the group of 23 patients who had no evidence of
coagulopathy there were no deaths from MI or stroke (p = 0.05 by Fischer exact
t fO
test). The presence of a prothrombotic state may account for the high incidence
of MI in the early post-operative period found in most published series of aortic
aneurysm surgery.
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In conclusion the evidence from this study indicates that
1. Patients requiring re-operation for control of haemorrhage following aortic
aneurysm repair usually have a coagulopathy.
2. Haemorrhage following aortic surgery is uncommonly due to an operative
error.
3. Patients requiring re-operation for control of haemorrhage following
operation for ruptured aneurysm had greater blood loss during primary
operation and had a lower core temperature at the end of the primary
operation
4. The development of a coagulopathy is probably responsible for the




Methodology for Coagulation Studies
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Except where indicated in the text all coagulation assays, sample handling,
processing and storage were performed by the staff of the coagulation laboratory of
the South-East Scotland Blood Transfusion Service in the Royal Infirmary of
Edinburgh. The tests were carried out using the laboratory's standard methods which
have been satisfactorily assessed by the National External Quality Control Assurance
Scheme (NEQAS).
Blood sampling
In patients with asymptomatic aortic aneurysm venous blood samples were taken
from an antecubital vein using a 19 gauge needle with no tourniquet occlusion. In
patients undergoing elective and emergency aortic aneurysm repair blood samples
were taken from an indwelling intra-arterial line placed in the radial artery. The first
5ml were discarded. After sampling the line was flushed with heparinised saline -
10,000iu in 500ml 0.9% NaCl. All samples were separated within 20 minutes of
sampling
A 2.7ml sample was taken into an EDTA (ethylene diamine tetra-acetic acid)
anticoagulant - Monovette®, Sarstedt.
A 9ml blood sample was taken into sodium citrate anticoagulant on ice. The
anticoagulant comprised of 3.12% trisodium citrate, 5% HEPES in 1,000ml distilled
water. 1ml of anticoagulant was placed in a Monoject Z/10 tube. The sample was
spun at 2,500 rpm for 10 minutes, the serum was separated and stored at -40°C for
later analysis.
For fibrinopeptide A assay a 4.5 ml blood sample was taken into aprotinin/heparin
anticoagulant on ice. The anticoagulant comprised of 5mls aprotinin (20,000
KlU/ml), 4mls heparin (25,0000 iu/ml) 9mls 0.9% sodium chloride and 82mls
distilled water. 0.5 ml of this anticoagulant was placed in a 10ml siliconised glass
tube. The tubes were stored at -70°C until required. The sample was spun at 4°C at
2,500rpm for 30 minutes. The middle third of the plasma was separated and stored
at -40°C for later analysis.
For B-thromboglobulin assay a 2.7ml blood sample was taken into
EDTA/PGEi/theophylline anticoagulant on ice. The anticoagulant comprised of 0.1
ml EDTA (lOg/dl disodium ethylene diamine tetra-acetic acid adjusted to pH 7.4
with NaOH), 0.1 ml PGEi (Ipig/ml of prostaglandin El in aqueous solution of
20mg/dl of sodium carbonate) and 0.1 ml theophylline (5.4 mg/ml theophylline in
distilled water adjusted to pH 7.4) which were added to a siliconised glass tube. The
tubes were stored at -70°C until required. The sample was spun at 4°C at 2,500rpm





The platelet count was determined on an EDTA sample using a Coulter® T-890
counter.
Fibrinogen
The time to coagulation in a plasma sample activated with thrombin is dependent on
the concentration of fibrinogen. A standard thrombin reagent is added to known
concentrations of fibrinogen, the time to coagulation is measured and a standard
curve is drawn. Plasma samples from patients are activated with the standard
thrombin reagent, coagulation times are measured and the fibrinogen concentration is
interpolated from the standard curve. Fibrinogen assay was performed on a citrated
plasma sample using a Coag-A-mate®-X2, General Diagnostics and Fibriquik®
reagent kit, General Diagnostics.
Fibrin degradation products
The assay was performed on a citrated plasma sample using a Diagnostica Stago kit
for fibrinogen degradation products.
Pro-thrombin ratio (PTR)
In this test coagulation is activated via the extrinsic pathway by adding
thromboplastin and calcium to citrated plasma. The time to coagulation is measured
and expressed as a ratio using a control plasma sample. The time is prolonged by
low levels of Factors V, VII or X and by low levels of fibrinogen. The test is
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performed on a citrated plasma sample. lOOpl of brain thromboplastin is added to
each of two wells. lOOpl of control plasma is added to the first well and 100pi of
patient plasma is added to the second sample. The samples are warmed to 37°C and
then lOOpl of CaCl2 is added to start the reaction. Reagents were obtained from
General Diagnostics and the test was carried out on a Coag-A-mate®-X2, General
Diagnostics.
Activated partial thromboplastin time (APPT)
The principle is similar to that of the prothrombin time but the coagulation pathway
is activated via the intrinsic pathway using an activator of the contact system such as
kaolin. This results in activation of Factor XII which initiates activation of other
contact phase factors. After these reaction are established dilute thromboplastin is
added, followed by calcium and the time to coagulation is measured. The APPT is
expressed as a ration with normal plasma. The test is prolonged by low levels of
factors II, V, VIII, IX, X, XI, XII, kallikrein high molecular weight kininogen or
fibrinogen. The test was performed on a citrated plasma sample. Reagents were
obtained from General Diagnostics and the test was carried out on a Coag-A-mate®-
X2, General Diagnostics.
D-dimers
D-dimer is a sensitive marker of fibrinolytic activity.242 D-dimer consists of two
cross-linked D domains cleaved from cross-linked fibrin by the action of plasmin.
Analysis was performed using a commercially available enzyme linked





Fibrinopeptide A (FPA) is a sensitive marker of thrombin activity. ' When
thrombin acts on fibrinogen to produce fibrin monomers, two small polypeptides are




Fibrinopeptide A + B
Fibrin monomer
FPA is a 16 amino acid polypeptide with an in vivo half-life of 3-5 minutes.249 FPA
is useful for demonstrating changes occurring within the coagulation system over
short periods of time because the conversion of fibrinogen to fibrin occurs rapidly
early during the course of thrombosis and because it has a short half-life.
Assay
Assays for fibrinopeptide A were performed by Dr Drummond at the National
Science Laboratory, Scottish National Blood Transfusion Service, Edinburgh. The
assay was performed by a double antibody radioimmunoassay. The plasma sample
is first treated with bentonite (Sigma B-3378) to remove any fibrinogen from the
sample. The sample is incubated overnight with the primary antibody, rabbit anti-
human FPA (IMCO, Stockholm), in tris buffer. The amount of primary antibody
added is in excess of the amount of FPA and thus all the FPA is bound to the primary
antibody. To this is added a radiolabeled secondary antibody - Donkey anti-rabbit
IgG (SAPU) coupled with Sephacryl S1000. Sufficient secondary antibody is added
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to react with all the primary antibody. The sample is mixed thoroughly and left to
stand for 15 minutes at room temperature. The supernatant, containing unbound
primary and secondary antibody, is aspirated from the tube leaving the solid phase,
with FPA-primary antibody-secondary antibody complexes, undisturbed at the
bottom of the tube. The amount of radioactivity in each tube is determined using a
counter. A standard curve is drawn using samples of known concentration and the




B-Thromboglobulin (B-TG) is a specific marker of platelet activation. It is a
protein, molecular weight 35,800, specific to platelets. It is the most abundant
platelet specific protein, is contained within a-granules and is released during
platelet activation. It is cleared from plasma with a half time of 100 minutes at
37°C.254
Assay
Assays for B-TG were performed by staff at the coagulation laboratory, South-West
Blood Transfusion Service, Southmead Hospital , Bristol. Analysis was performed
using an enzyme linked immunosorbant assay (ELISA), Asserachrom® B-TG,
(Diagnostica Stago, Asnieres-sur-Seine, France). This is a sandwich type ELISA.
The well is coated with rabbit anti-human B-thromboglobulin antibodies. The test
sample is added to this and the B-TG in the sample binds to the rabbit anti-BTG
antibodies. The well is washed leaving the BTG bound. Next rabbit anti-BTG
antibody coupled with peroxidase is added. This binds to the BTG. The excess is
washed off. Ortho-phenylenediamine is reacted upon by the peroxidase in the
presence of hydrogen peroxide undergoing a colour change. The speed of reaction,
and hence the intensity of colour change is determined by the amount of peroxidase
presence, which is dependent on the amount of BTG within the test sample. The
absorbance is measured at 492nm by a spectrometer. A calibration curve of
absorbance against BTG level is drawn for samples of known concentration. The test




Glycocalicin is a marker of platelet activity and turnover. Glycocalicin is soluble
glycoprotein lb (GPlb). GPlb is the platelet receptor which binds to von Willebrand
factor, initiating platelet adhesion and activation. GPlb can be cleaved from the cell
surface by the action of plasmin, thrombin, calpain and elastase. The presence of
increased serum glycocalicin indicates platelet activation and turnover.
The half-life of glycocalicin is relatively long - in the region of 2-3 days. It is
therefore unsuitable for the identification of rapid changes in platelet activation.
However it is useful in determining platelet turnover and whether there is a state of
chronic or repeated activation.
Glycocalicin activity in the plasma is found in two forms: free plasma glycocalicin
and platelet microvesicle associated glycocalicin. Microvesicles can be removed
either by centrifugation at high g-force or by filtration. About 75% of glycocalicin
activity is free glycocalicin. Glycocalicin level is directly correlated to platelet count
and is therefore usually expressed as u/platelet x 108.
Principles of competitive enzyme-linked immunosorbant assay
The concentration of glycocalicin in the plasma was determined using a competitive
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binding enzyme-linked immunosorbent assay (ELISA). The principles of the
ELISA method are outlined in Figure 6. The well is first coated with a known
amount of the antigen of interest. The sample to be assayed is added to the well
followed by a monoclonal antibody to the antigen of interest - the primary antibody.
There is competition for the monoclonal antibody between the antigen coating the
well and the antigen contained within the sample being tested. The more antigen
-89-
there is in the sample the less the monoclonal antibody will bind to the antigen
coating the bottom of the well. The well is then washed leaving the antigen coating
the bottom of the well with the primary antibody bound to it. A secondary antibody
is added which is specifically active against the primary monoclonal antibody. This
secondary antibody is also bound covalently to an enzyme such as peroxidase. The
well is then washed leaving a complex of antigen-primary monoclonal antibody-
secondary monoclonal antibody bound to the bottom of the well. Horseradish
peroxide developing agent is added which reacts with peroxidase enzyme bound to
the secondary antibody producing a colour change which varies in intensity
according the amount of secondary antibody present. The colour intensity is
determined using a absorbance spectrometer. Thus the greater the intensity, the more
antibody which was bound to the coating antigen and thus the less antigen in the
sample. The actual concentration is determined by putting known concentrations of
antigen in some wells of every plate then drawing a curve of intensity against the
known concentration. The concentration of the antigen in the test samples can be
determined from this curve.
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Figure 6 Competitive binding enzyme linked immunosorbant assay
Well coated with glyococalicin (GC)
after overnight incubation at 4°C GC
Well "blocked" with bovine serum
albumen (BSA) BSA "blocking" well
Test sample and mouse anti-GPlb
antibody added to well. Mouse anti-
GPlb bind to both GC in sample and
GC coating well.
GC in test sample
Mouse anti-GPlb
monoclonal antibody
Well washed removing the mouse anti-
GPlb bound to GC in sample. The
mouse anti-GPlb which bound to GC
coating well is left.
Goat anti-mouse (GAM) monoclonal
antibody added which binds to mouse
anti-GPlb
Well washed to remove excess




The plate was coated with 100pl/well 10% glycocalicin in coating buffer (50mM
bicarbonate adjusted to pH9.6). The plate was covered and left overnight at room
temperature. The glycocalicin/coating buffer was decanted and the well were
washed with ELISA buffer (137mM NaCl, 8.1mM Na2HP0412H20, 1.5 mM
KH2P04j 2.7mM KC1, 0.05% Tween 20) 300 pl/well three times. The wells were
blocked with 3% bovine serum albumin in ELISA buffer for 1 hour at room
temperature. The plate was washed 3 times with ELISA buffer 300 pl/well.
Standard dilutions of glycocalicin were prepared. In wells 1-3 A,B,C ELISA buffer
lOOpl/well was added. The standard were dilutions 50pl/well were added. Samples
50pl/well were added to remaining wells. Anti GPlb monoclonal antibody, 25
ng/ml, 50pl/well was added to all wells except 1-3 A,B,C. The plate was covered
and left for 1 hour at room temperature and then washed 3 times with ELISA buffer
300 pl/well. Goat anti-mouse antibody was prepared at 1:400 dilution and 100
pi/well was added to all wells. The plate was covered and left for 1 hour at room
temperature and then washed 3 times with ELISA buffer 300 pl/well. The colour
developing agent was prepared. Solution (a) 10 mg TMB was added to 1ml DMSO.
Solution (b) 100 pi 30% hydrogen peroxide in 10ml 0.1M acetate buffer. 50 pi of
solution (a) and 50 pi of solution (b) were added to 10 ml 0.1M acetate buffer. The
colour developing agent 100 pl/well was added to each well and left for 5 minutes to
develop. The reaction was stopped with H2S04 50 pl/well. The plate was read in a
absorbance spectrometer producing a measure of absorbance in each well. The
absorbance in for the standard dilution were plotted against the dilution and the best
fit curve was drawn. The glycocalicin level for the test samples was determined by
reading off the standard curve.
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Reagents
Glycocalicin was produced by Dr H Bessos, SNBTS by DEAE Sepharose fast flow.
Mouse anti-GPlb monoclonal antibody was purchased from Dakopatts a/s Denmark
No M719. Goat anti-mouse monoclonal antibody was purchased from Bio-Rad
laboratories, Richmond Ca. Coating buffer and ELISA buffer were prepared freshly
for each assay.
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The effect of aspirin on plasma glycocalicin levels
Glycocalicin is a relatively new test of platelet activity and while much is known of
the factors which influence plasma levels knowledge is as yet incomplete. Studies
concerning factors such as tourniquet application prior to venepuncture, various
04c Q/i f.
types of anticoagulant and the influence of age and sex have been carried out.
However the effect of aspirin on glycocalicin levels is unknown. As many of the
patients in the present studies might be expected to be taking aspirin it is important to
determine the effect of aspirin on glycocalicin levels and therefore the following
study was performed.
Methods and materials
Eight healthy adult males were recruited, mean age 33 years. Five were assigned to
take aspirin and three to acts as controls. No subjects had taken aspirin or any non¬
steroidal anti-inflammatory in the two weeks before the study started. In the group
assigned to take aspirin a venous blood samples was taken two days before the start
of the study. On the first day of the study a venous blood sample was taken, from the
subjects who then took aspirin 300mg orally. Further blood samples were taken 1
hour and 6 hours after taking aspirin. On the following four days a venous blood
sample was taken in the morning and each subject took aspirin 300mg after
venesection. In the control group daily venous blood samples were taken.
At each time of venesection a 3ml EDTA sample was taken to determine platelet
count and a 5ml citrated sample was taken and immediately spun, separated and
frozen at -4CPC for glycocalicin assay in one batch at a later date.
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Results
Glycocalicin levels did not alter significantly in those taking aspirin during the time
course of the study (Figure 7). There was no significant difference in absolute values
or day-to-day variability in the subjects taking aspirin compared with controls
(Figure 8).
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Figure 7 Glycocalicin levels in normal subjects commenced on aspirin 300mg
daily on day 1
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Figure 8 Glycocalicin levels in control subjects over a 4 day period
GC/plt 10A8
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Discussion
This study does not demonstrate any effect of aspirin on levels of glycocalicin. The
lack of change at one hour and 6 hours indicates that recent ingestion of aspirin does
not affect either plasma levels of glycocalicin and does not have an ex-vivo effect on
the assay. The time course of this study was relatively short and it may be that a
longer period of study would demonstrate more subtle effects of aspirin on
glycocalicin levels.
An important finding of this study which is of some concern is that there is
considerable day-to-day variation in glycocalicin levels. This may be due to genuine
fluctuations in the level of glycocalicin or it may be due to inaccuracy in the assay
method. Previous studies of the reliability of this assay have shown it to have good
reproducibility and it may well be that this day-to-day variation is a genuine finding
whose cause and significance remains obscure.
It should be remembered that this study was carried out on healthy subjects. It
therefore does not provide data on the effect of aspirin on glycocalicin levels in
patients with increased platelet activation. Such patient would have elevated
glycocalicin levels. It may be that aspirin would reduce platelet activation and thus
glycocalicin levels in these patients.
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Chapter 4




As noted above some patients with asymptomatic aortic aneurysms have been shown
nn
to have derangement of the coagulation systems on laboratory testing and may
rarely present with symptoms of coagulopathy such as gingival bleeding and
71 7S
excessive bruising. In one study about 10% of patients with non-ruptured
aneurysm had elevated levels of fibrin degradation products and a mild
77 221 r
thrombocytopenia. ' This is thought to be due to consumption of clotting factors
22R 220
and platelets during turnover of the clot within the aneurysm sac.
On close examination of case reports of coagulopathy with non-ruptured aortic
aneurysms, it is notable that most patients are elderly, >80 years of age, and have
large aneurysms. Furthermore coagulopathy is much more common in patients with
thoraco-abdominal aneurysms. It has been suggested that in patients with aneurysms
there is a balance between destruction of clotting factors and platelets within the
aneurysm and synthesis in the liver and bone marrow and that DIC occurs when
77
consumption is greater than synthesis. Patients with larger aneurysm volumes may
have greater destruction of clotting factors and elderly patients, or patients with liver
disease, are less able to synthesise new factors and platelets. This may be of
relevance to the coagulopathy related with rupture as these patients are more elderly
and have larger aneurysms than patients undergoing elective operation.122'148'237
Thus these patients may be more likely to have a coagulopathy prior to rupture.
The aims of this study were to determine the degree of activation of platelets and the
coagulation and fibrinolytic systems in a population of patients with non-ruptured
aneurysms and secondarily to determine whether factors such as age of patient and
size of aneurysm were correlated to changes in the haemostatic system..
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Patients and methods
Patients with a diagnosis of abdominal aortic aneurysm were identified in the out¬
patient department. In all cases the diagnosis had been confirmed by
ultrasonography. The antero-posterior diameter, as measured by ultrasonography,
was recorded as were clinical details such as age, past medical history and drug
history.
Twenty-four patients were recruited. The mean age of patients was 12 ±1 years. The
male:female ratio was 4.5:1. The mean aneurysm diameter was 48 mm range 32-65
mm. Blood samples for glycocalicin levels were also taken from sixteen patients
referred to the vascular clinic with carotid artery disease as part of a separate study.
The mean age of these patients was 65+ 9 years and the male to female ration was
1.3:1.
In addition to the above patient on whom complete coagulation studies were
performed there are data on platelet count in further 33 patients with aortic aneurysm
and 16 patients with carotid artery stenoses. Data on these patients are available as




Platelets counts were in the lower part of the normal range and 3/44 were below the
normal range (Figure 9). Platelet counts were significantly lower in patients with
aortic aneurysm, mean 214 ± 44 x 109/1, than those with carotid stenoses, mean 269
± 57 x 109/1 (p = < 0.001 by T-test) (Figure 10). The platelet count did not correlate
with size of aneurysm or age.
Fibrinogen
All patients had plasma fibrinogen levels within the normal range, although these
tended to be at the upper end of the normal range (Figure 11). The fibrinogen levels
in patients with carotid artery disease were similar, tending to be at the upper limit of
the normal range.
Fibrin degradation products
Only one patient had an elevated level of fibrin degradation products. This was not
associated with any other abnormality on coagulation screen
Prothrombin ratio
All patients had a prothrombin ratio within the normal range.
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Activated partial thromboplastin time
All patients had an APTT within the normal range.
Glycocalicin
The level of glycocalicin per platelet, was elevated in 7/24 patients (Figure 12).
There was no correlation between glycocalicin level and size of aneurysm or age.
The glycocalicin levels, both corrected and uncorrected for platelet count, were
significantly higher in the group of patients with aneurysm than the group of patients
with carotid artery disease (p = 0.0001 by Mann Whitney U test).
- 103 -















^ Lower limit ofnormal range
100
- 104-
Figure 10 Platelet counts in patients with asymptomatic infrarenal aortic
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Figure 11 Fibrinogen levels in patients with asymptomatic infrarenal aortic
















Figure 12 Glycocalicin levels in patients with asymptomatic infrarenal aortic





















This study of patients with asymptomatic aneurysms has confirmed that there is
some activation of the soluble coagulation system in patients with abdominal aortic
aneurysms. However the degree of activation is quite slight and is only found in a
small number of patients.
Platelet counts were low, although generally within the normal range. The difference
is quite slight when compared to a normal population but it must be remembered that
patients with aortic aneurysms generally have widespread atherosclerosis and thus
may be expected to have the abnormalities of the coagulation system associated with
vascular disease. Thus a more useful group for comparison would be patients of a
similar age, with vascular disease but without an aneurysm - for example patients
with carotid stenoses as used in this study. Both groups of patients may be expected
to be quite closely matched in terms of having widespread atherosclerosis, and
having similar risk factors for atherosclerosis such as smoking, age, male sex,
hyperlipidaemia, hypertension and genetic predisposition. The difference in age
between the two groups was statistically significant but the actual difference was
relatively small, about 6 years. Thus the major difference between the two groups
was that one group had aortic aneurysms while the other did not. The differences in
platelet count between the group of patients with aortic aneurysms and those with
carotid stenoses were quite marked. It would therefore appear that the presence of an
aortic aneurysm has a significant effect on platelet numbers.
There was a difference in glycocalicin levels in patients with aneurysms compared to
patients who had carotid disease with elevated levels being found in patients with
aneurysms. Using the same argument as applied to the difference in platelet numbers
between these groups it can be concluded that the elevated glycocalicin level is
related to the presence of an aneurysm rather than atherosclerosis. These data are
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supported by a previous study of glycocalicin levels in various groups of patients and
normal subjects which reported that patients with peripheral vascular and
24S
cardiovascular disease had significantly lower levels of glycocalicin.
Fibrinogen levels in all patients were within normal limits but at the upper end of the
normal range. This is to be expected in a group of patients with atherosclerosis:
peripheral vascular disease, coronary heart disease and cerebrovascular disease are
ore
all associated with elevated plasma fibrinogen. Thus there is no evidence that the
presence of a aortic aneurysm has an independent effect on fibrinogen levels.
There are four mechanisms of thrombocytopenia: (1) decreased rate of production
(2) increased rate of destruction (3) platelet sequestration, e.g. in the spleen (4)
dilution. The data on glycocalicin levels give some indication as to which of these
mechanisms is the likely cause for the low platelet counts in the patients in this
study. It should be remembered that glycocalicin is produced when GPlb, the
platelet membrane glycoprotein receptor for vWF, is lysed and released from the
373
platelet membrane. Therefore the elevated levels of glycocalicin suggest that the
most likely explanation is an increased rate of destruction.
The simplest explanation is that platelets are activated by the clot in the aneurysm
sac, adhere and become incorporated into the clot. GPlb is released at the time of
activation accounting for the elevated glycocalicin. This process might be termed
consumption within the sac. If this is this case then the remaining circulation
platelets would have normal expression of GPlb.
However the explanation may be more complex. Platelets have a normal life span of
about ten days but the ageing process which marks them for destruction is poorly
understood. It is known that coming into contact with a foreign surface, such as
subendothelium, can activate platelets and such platelets are cleared from the
circulation regardless of their age.379 Such activation of the platelet without
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adhesion may occur within the sac producing changes to the circulating platelet
which mark it for early destruction.
The elevated glycocalicin may then be accounted for by one of two explanations. It
may simply be that GPlb is released at the time of platelet destruction in the
reticuloendothelial system. The other explanation concerns the mechanism by which
platelets are marked for early clearance from the circulation. It has been proposed
that platelets undergo gradual loss of GPlb throughout their life span and that this is
the means by which senescent platelets are identified by the reticuloendothelial
system.373 It has been demonstrated in vitro that activation of platelets can lead to
the generation of a protease which cleaves glycoprotein lb (GPlb) close to the site of
its insertion onto the platelet membrane. Thus it may be that activation within the
sac causes release of GPlb marking the platelet for early clearance. If this is the case
then there may be circulating platelets which are deficient in GPlb receptors.
GPlb is central to the process of platelet adhesion at the site of vessel wall injury
and thus vital for clot formation and haemostasis. It is therefore easy to envisage
that platelets deficient in GPlb would be dysfunctional. Such loss of GPlb occurs
during platelet storage in blood banks and has been proposed as the reason for the
373decreased functional ability of stored platelets. Thus in these patients there may
be a combination of dysfunctional platelets and a mild degree of thrombocytopenia
which could significantly compromise the coagulation system. Haemostatic function
in the resting state might be near normal but the threshold at which clinical bleeding
problems occur would be much lower and there would be little reserve in the face of
a major challenge to the haemostatic system such as aneurysm rupture or aortic
operation.
In order to resolve these questions more detailed studies of expression of cell surface
receptors are required using techniques such as flow cytometry. Such studies would
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not only provide information about platelet function in these patients but may also
help to explain the mechanism by which senescent platelets are identified and
destroyed by the reticuloendothelial system.
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Chapter 5
Changes in the Haemostatic System during Elective
Infrarenal Aortic Aneurysm Repair
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Introduction
The development of coagulopathy during elective aneurysm repair is a well
recognised although uncommon complication. As shown in Chapter 3, it may have a
causal relationship to post-operative haemorrhage. The pathological process which
leads to the development of this coagulopathy remains obscure and very little is
known of the changes which occur in the coagulation system during operation.
In one study of the coagulation system during aorto-femoral bypass grafting for
occlusive disease it was shown that levels of fibrinogen dropped throughout
ryy i
operation, most markedly after aortic cross-clamping. A study which included
assays of thromboxane A2, a marker of platelet activation which correlates well with
9
B-thromboglobulin, indicated that there was marked platelet activation during
9S7
cross-clamping which then reduced on reperfusion. However in neither of these
studies were patients given systemic heparin prior to cross-clamping. This is now
common practice and may be expected to have considerable effects on the
haemostatic system.
A more recent study has been carried out in patients undergoing aortobifemoral
9^9
grafting for occlusive disease (8/10) and aneurysmal disease (2/10). This study
included more sophisticated investigation of the haemostatic system but a policy of
deliberate haemodilution during the early stages of operation and the administration
of large amounts of fresh frozen plasma during operation produce some difficulty in
the interpretation of the findings. The significant findings of this study were that
there was increasing fibrinolytic activity during operation in association with falling
platelet counts and that these events were not related to aortic cross-clamping. No
examination of thrombin activation was made.
The primary aim of this study was to determine the timing and degree of activation
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of the various components of the haemostatic system - thrombin activation, platelet
activation and plasmin activation. The secondary aims were to determine whether
these changes were related to the operative factors identified in Chapter 3, such as
length of operation, length of cross clamping, blood loss and transfusion, which
appeared to be related to post-operative haemorrhage.
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Methods and materials
A series of 6 consecutive patients undergoing elective aortic surgery for abdominal
aortic aneurysm were studied. Age, size of aneurysm, past medical history and drug
history were recorded and a venous blood sample was taken pre-operatively for
haemoglobin estimation, white cell count, platelet count, prothrombin time and
activated partial thromboplastin time. Patients with abnormal coagulation or who had
taken aspirin within the previous ten days were excluded.
Blood samples were taken from an indwelling arterial cannula at four time points
during surgery. The first sample was taken after the induction of anaesthesia but
prior to the start of operation, the second was taken immediately prior to aortic cross-
clamping, the third was taken immediately prior to the release of the aortic cross-
clamp and the fourth was taken ten minutes after the release of the cross-clamp. The
first 5ml was discarded. Thereafter samples were prepared as described above for
estimation of APTT and assays of FPA, B-TG, and D-dimers. The time at which the
samples were taken, relative to the start of operation, was recorded. Operative details
for each patient are shown in Table 6.
Similar blood sampling was carried out during operation for ruptured aortic
aneurysm in one patient (R). This patient presented with contained rupture and was
not shocked on admission. Intra operative heparin was not used. Operative details
for this patient are shown in Table 6 and FPA and BTG levels are shown in Figure
20.
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A 73 2,000 iu 77 mins 50 mins None 3000 ml 2,000 ml
B 73 3,000 iu 134 mins 49 mins None 2000 ml 1,000 ml
C 78 5,000 iu 110 mins 63 mins None 2500 ml 1,500 ml
D 78 3,000 iu 171 mins 80 mins 4 units RCC 2000 ml 2,500 ml
E 74 5,000 iu 125 mins 65 mins 4 units RCC 3000 ml 3,000 ml
F 65 5,000 iu 110 mins 50 mins 1 unit RCC 2500 ml 1,700 ml
R 58 None 110 mins 63 mins 2 unit RCC 2500ml 3990 ml
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Results
Activated partial thromboplastin time
All patients had a normal APTT at the start of operation and until heparin was
administered. The APTT for each patient, as a ratio to control sample, at time of
release of cross-clamp and after 10 minutes of reperfusion are shown in table 7.
Patient A who had the smallest dose of heparin, 2,000 iu, had a much shorter APTT
than the other patients. There was no relationship between the length of cross-clamp,
and therefore the time between administration of heparin and blood sampling, and
the APTT.









A 73 2,000 iu 50 mins 2:1 1.6:1
B 73 3,000 iu 49 mins not coagulable 5.5:1
C 78 5,000 iu 63 mins not coagulable not coagulable
D 78 3,000 iu 80 mins 3.5:1 3.5:1
E 74 5,000 iu 65 mins 4:1 3.5:1
F 65 5,000 iu 50 mins 6.5:1 5.5:1
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Fibrinopeptide A
The level of fibrinopeptide A (FPA) rose significantly during the period of initial
dissection (Figure 13). This rise was proportional to the duration of this period of
dissection r2 = 0.75 p = 0.025 (Figure 14). Following cross-clamping and
administration of heparin the levels of FPA dropped except in patient A. This patient
was only given 2,000 iu heparin compared with 3,000 or 5,000iu given to the other
patients in this study and had a much shorter APTT. Following reperfusion there
was no significant change in levels of FPA except in patient A who had a marked
increase in level of FPA.
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Figure 13 Fibrinopeptide A levels at 4 time points during elective aortic
aneurysm repair; after induction, before cross-clamping, after
removal ofcross-clamp and after 10 minutes reperfusion.
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Figure 14 Fibrinopeptide A increase from induction to sampling prior to cross-




The level of beta-thromboglobulin (BTG) rose significantly during the period of
initial dissection p = 0.046 (Figure 15). This rise was proportional to the duration of
this period of dissection r2 = 0.91 p = 0.003 (Figure 16). Following cross-clamping
and administration of heparin the levels of BTG dropped significantly p = 0.027.
Patient A who had received a smaller dose of heparin than the other patients had only
a small drop in BTG level, within the limits of the error of the assay. After ten
minutes of reperfusion levels of BTG rose in four patients and dropped in two
patients. When this change is related to the length of cross-clamping there is good
correlation, with a greater BTG rise being observed in those with longer cross-clamp
times (Figure 17). One patient did not fit in well with this pattern and this was
patient A who received a smaller dose of heparin. If this patient is excluded the
correlation is excellent r2 = 0.98 p < 0.05 .
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Figure 15 Beta thromboglobulin levels at 4 time points during elective aortic
aneurysm repair; after induction, before cross-clamping, after
removal ofcross-clamp and after 10 minutes reperfusion.
Time points during operation
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Figure 16 Beta thromboglobulin increase from induction to sampling prior to
cross-clamping against time from induction to cross-clamping
Time (minutes)
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Figure 17 Beta thromboglobulin increase from release of cross-clamp to 10
minutes after reperfusion against duration ofcross-clamping
(excluding patient A)
Duration of cross-clamping (mins)
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D-dimer
The level of D-dimer rose significantly during the period of initial dissection p =
0.0022 (Figure 18). The rise was proportional to the duration of this period of
dissection r2 = 0.845 p = 0.018 (Figure 19). Following cross-clamping and
administration of heparin the levels of D-dimer dropped in 4/6 patients. The two
patients who had a rise in D-dimer, patients A and D, had received the smallest doses
of heparin, 2,000 iu and 3,000 iu heparin respectively, and who had the lowest APTT
at 2.11 and 3.4 respectively. After ten minutes of reperfusion levels of D-dimer rose
in four patients and dropped in two patients. The rise or fall in D-dimer after
reperfusion was not related to the length of cross-clamping
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Figure 18 D-Dimer levels at 4 time points during elective aortic aneurysm
repair; after induction, before cross-clamping, after removal ofcross-





Time points during operation
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Figure 19 D-dimer increase from induction to sampling prior to cross-clamping
against time from induction to cross-clamping
Time (minutes)
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Figure 20 Intraoperative levels ofBTG and FPA in patient R who presented
with contained rupture at 4 time points; after induction, before cross-






The results from this study were to a large extent quite unexpected. The limited
amount of information from the two previous studies on this subject suggested that
the major changes in the haemostatic system would take place during aortic cross-
clamping and/or reperfusion. In contrast it was found that thrombin and platelet
activation actually reduced markedly during the period of cross-clamping. Plasmin
activation, as demonstrated by level of D-dimer, reduced during cross clamping in
4/6 patients.
These changes during cross-clamping could either be due to the effects of cross-
clamping or as a result of heparin administration. It seems most likely that heparin
was the cause and it may be thrombin, platelet and fibrinolytic activation would
increase during cross-clamping and reperfusion if heparin were not given prior to
cross-clamping. Increasing thrombin activation during cross-clamping was found in
one patient who received a lower dose of heparin and who had the shortest APTT. In
addition this patient also had a marked increase in FPA after reperfusion. The two
patients who had a rise in D-dimer after cross-clamping received the smallest doses
of heparin and had the shortest APTT. In the study by Utsunomiya et al platelet
activation, as determined by level of thromboxane A2, markedly increased during
2S7
cross-clamping in a group of patients who were not given systemic heparin. This
effect was not found in patients who were given aspirin 650mg ten hours prior to
operation.
Further evidence that heparin is the cause of the drop in FPA and BTG during cross-
clamping is provided by the data on patient R who underwent operation without the
administration of heparin. In this patient there was a marked rise in BTG and a small
rise in FPA during cross-clamping. Of course there are other possible confounding
factors in this patient as he had suffered a ruptured aneurysm but there was no
- 129-
evidence of hypovolaemic shock prior to surgery and the length of operation, cross-
clamping, blood loss and transfusion requirements were similar to those undergoing
elective repair.
It would be interesting to repeat these studies without administering heparin.
Unfortunately there are ethical difficulties with such a study as it has recently been
shown that intra-operative heparin confers a significant benefit by reducing the rate
of post-operative myocardial infarction. The mechanism by which heparin
produces this effect is unknown but it is presumably due to some effect on the
haemostatic system during operation. In this study a marked reduction in platelet
and thrombin activation was shown after heparin administration. If this is important
in the mechanism by which heparin reduces peri-operative MI, it could be proposed
that a greater benefit would be gained by administering heparin at an earlier stage
during operation since thrombin and platelet activation increases during a time
dependent manner during the period of initial dissection. However the relevant
effect of heparin may be elsewhere. Heparin has many effects apart from those
on the coagulation cascades; for example heparin has been shown to reduce
endothelial permeability and hydrogen ion accumulation in muscle ischaemia-
reperfusion injury.
The effects of reperfusion are of some interest. Platelet activation occurred
following reperfusion in a manner that was dependent on the length of cross-
clamping. There was no corresponding increase in thrombin or fibrinolytic activity.
This suggests that platelet activation is occurring via a mechanism which does not
involve activation of the coagulation cascade. Similar findings have been reported in
r\cr
studies of patients undergoing knee surgery with tourniquet ischaemia. An
increase in B-thromboglobulin was found after 30 minutes of tourniquet ischaemia
and this markedly increased after 5 minutes of reperfusion. No increased fibrinolytic
activity was found either during ischaemia or reperfusion.
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This effect on platelets might be mediated directly by endothelial cells. It has been
shown in animal studies of myocardial ischaemia and reperfusion that ischaemia of
as little as 30 minutes causes alteration in endothelial function and that the degree of
dysfunction increases with length of ischaemia and markedly increases on
n/"1
reperfusion. One of the effects of ischaemia on endothelial cells is to reduce
the production of endothelial derived relaxing factor (EDRF) and prostacyclin which
are potent inhibitors of platelet adhesion and aggregation." It may be that
lower limb ischaemia during cross-clamping causes similar dysfunction in the
microvasculature of skeletal muscle resulting in platelet adhesion and aggregation
during reperfusion.
From the data presented in Figure 17 it would appear that about 45-60 minutes of
lower limb ischaemia are required before significant activation of platelets will take
place after reperfusion. This is somewhat longer than the 30 minutes of ischaemia
required to produce platelet activation in studies of tourniquet ischaemia.
However due to collateral circulation the degree of lower limb ischaemia produced
by aortic clamping is much less than that produced by tourniquet inflation above
systolic pressure.
This apparent time dependent effect of cross-clamping on platelet activation may be
an artefact due to a reduction in heparin effect with time. In patients undergoing
elective aorto-iliac surgery it has been shown that an intravenous bolus of heparin
results in maximal heparin effect, as determined by anti-Factor Xa activity, at 5-20
minutes with a fall in activity up to 120 minutes. The rate of fall in activity is
greatest between 30 and 60 minutes after administration. In the present study the 2/3
patients with the longer cross-clamp times did have shorter APTTs although these
were still greater than 3:1. One patient with a cross-clamp time of 63 minutes had an
APTT which was not coagulable and still had a significant rise in BTG on
reperfusion.
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In conclusion this study indicates that:-
1. Thrombin, platelet and fibrinolytic activation increase during the period of
initial dissection.
2. The increase in activation of platelets and fibrinolysis is related to the
length of time of initial dissection.
3. Thrombin, platelet and fibrinolytic activation decreases after the
administration of heparin and cross-clamping.
4. Platelet activation increases during reperfusion and this increase in
activation is related to the duration of cross-clamping.
5. The administration of systemic heparin appears to markedly inhibit
platelet, thrombin and fibrinolytic activity during cross-clamping.
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Chapter 6




There have been no detailed studies of the haemostatic system in patients with
ruptured aortic aneurysms. Some information is available from clinical studies
which have described relatively unsophisticated markers of disruption of the
haemostatic system such as platelet count, fibrinogen levels, PTR, APPT and fibrin
s-Jr i -i /"o O/CQ
degradation products. ' ' There are some more sophisticated studies of
disseminated intravascular coagulation in which patients with DIC secondary to
ruptured aortic aneurysm were included but in these studies the timing of blood
sampling was not stated, several patient groups were combined and specific data on
^A/" A/*Q
those patients with ruptured aneurysms were not presented." ' In addition there
are no data concerning the changes which occur during operation.
The primary aims of this study were to determine the degree of activation of
thrombin, plasmin and platelets at the time of admission in patients with ruptured
abdominal aortic aneurysms and to determine the changes which occur in these
factors during operation. The secondary aims were to determine whether any of the




Twenty-two patients undergoing operation for ruptured aortic aneurysm in the Royal
Infirmary of Edinburgh between 1/4/93 - 1/8/94 were included in this study. In all
cases the diagnosis of ruptured aneurysm was confirmed at operation. The mean age
of patients was 70 years (range 56-84 years). The male:female ratio was 3.4:1.
Blood sampling
Blood samples were obtained from 22 patients. Blood samples were taken from an
indwelling cannula placed in the radial artery. The first 5ml was discarded.
Thereafter samples were prepared as described above for platelet count PTR, APPT
and assays of fibrinogen, FPA and B-TG. Samples were taken immediately prior to




The overall 30 day mortality rate was 55%. Five patients died "on-the-table" from
uncontrolled haemorrhage. Five patients survived operation but died within 48 hours
of operation due to multiple organ failure. Two patients subsequently died from
multiple organ failure at 10 and 12 days post-operatively. One patient who survived
developed acute renal failure which required prolonged dialysis. The remaining 9
patients had uncomplicated post-operative courses.
The patients can therefore be divided into three groups; those who died on-the-table,
those who died post-operatively from multi-organ failure and those who survived.
In the first group who died on-the-table, two patients with free intraperitoneal rupture
arrested at the start of operation and were not successfully resuscitated. Two patients,
one with extensive intraperitoneal adhesions from previous surgery and another with
a suprarenal aneurysm were never successfully cross-clamped and died from
exsanguination. None of these four patients had a coagulopathy at the start of
operation. The fifth patient had a severe coagulopathy and although a graft was
inserted there was continuing haemorrhage and the patient died from cardiac failure.
The cause of death in the group who died in the early post-operative period was
predominately multi-organ failure with varying degrees of respiratory, cardiac and
renal failure. Four of the seven patients had significant lower limb ischaemia with
two undergoing an embolectomy and one undergoing an above knee amputation.
There was only one significant complication in the group of patients who survived;
one patient developed acute renal failure requiring prolonged haemodialysis.
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The operative details of patients in each group are shown in Table 7. Patients who
survived had shorter operations, shorter cross-clamp times, lower blood loss and
lower red cell transfusion requirements than those patient who died in the early post¬
operative period. Fresh frozen plasma and platelet transfusion were administered to
4/7 patients whoi died post-operatively compared with 2/10 in those who survived.
There was no difference in core temperature at the end of the procedure.
The results of the coagulation test taken at admission and at the end of operation are
shown in Table 8 . The patients who died in the early post-operative period had
lower platelet count, lower fibrinogen levels, higher FPA and BTG and more
prolonged PTR and APPT on admission and on post-operative testing than the
patients who subsequently survived. These differences did not attain statistical
significance apart from the post-operative BTG which was lower in those who
survived - p > 0.05 by Mann-Whitney test. The patients who died on the table
showed no difference on coagulation screen on admission compared with the
survivors.
During operation there were significant changes in coagulation studies. There was a
drop on platelet count in all but 2 patients, a drop in fibrinogen in all but 2 patients
and a rise in levels of FPA in all patients and BTG in all but one patient
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Table 7 Operative details in patients with ruptured aneurysm Figures
median (range)
Survivors n = 10 Died post-op n = 7
Age 69.7 (62-83) years 69.3 (56-77) years
Length of 113 (70-180) mins 148 (60-255)mins
operation
Length of cross 55 (45-75) mins 92 (40-210) mins
clamp
Blood loss 1780 (490-3990) mis 5985 (550-18000) mis
Red cell 5.4 (0-11) units 11 (3-26) units
transfusion
Fresh frozen 2 patients given 2 units 2 patients given 2 units
plasma transfusion 2 patients given 4 units
Platelet transfusion 2 patients given 5 units 2 patients given 5 units
2 patients given 10 units
Temperature at end 35.5 (34-36.5) °C 35.2 (32-37) °C
of procedure
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Table 8 Results ofcoagulation testing on admission and immediately post¬
operatively in patients with ruptured aneurysms in each clinical
group. Figures are median (range)
Survivors Died post-op Died "on-the-table"
n = 10 n = 7 n = 5
On admission
Platelet count (xl09/l) 289(160-445) 138 (27-249) 238 (140-297)
Fibrinogen (g/1) 3.8(1.7-5.13) 2.9 (0.5-7.3) 3.8 (0.6-6.2)
PTR 1.06(1-1.3) 1.92(1.2-1.5) 1.5 ( 1-2.6)
APPT 1.1 (1-1.3) 2.15(1-5) 2.4(1-5)
FPA (ng/ml) 27(10.9-94) 67(21.4-121) 98(53.5-164)
BTG (u/1) 249(105-1000) 370(176-1375) 650 (136-925)
Post op
Platelet count (xl09/l) 185(107-481) 123 (92-167)
Fibrinogen (g/1) 3.1 (1.2-4.6) 2.6 (0.6-4.9)
PTR 1.26(1-1.5) 1.83 (1.2-2)
APPT 1.3 (1-1.8) 2.5(1-6)
FPA (ng/ml) 110 (54.3-146) 208 (89.5-555)
BTG (u/1) 270 (300-1950) 970 (280-2275)
- 139-
Figure 21 Platelet counts pre-operatively andpost-operatively in the three
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Figure 22 FPA levels pre-operatively andpost-operatively in the three clinical

























Died Died on table Survivors Died
Pre-op Pre-op Post-op Post-op
- 141 -
Figure 23 BTG levels pre-operatively and post-operatively in the three clinical
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Discussion
The clinical findings in this study are similar to those described elsewhere; patients
who died in the early post-operative period underwent longer operations with long
cross-clamp times, greater blood loss and transfusion requirements. 145 147'149,151,270
As previously described a low platelet count on admission was a predictor of death;
all of the patients with a platelet count less than 150 xl09/l at time of admission
i fsy 1
died. ' However a normal platelet count was not a good predictor of survival as
a significant number of patients with normal platelet counts died.
The level of BTG on admission was not a good predictor of outcome. It is notable
that levels of BTG were elevated in all patients at time of admission even those who
had a normal platelet count. Levels of BTG at time of admission were significantly
higher than found pre-operatively in patients undergoing elective aneurysm repair
suggesting that the elevated BTG was related to the rupture rather than due to the
presence of an aneurysm. Levels of BTG at the end of operation were greater than in
patients who had undergone an elective repair. This may be due in part to the fact
that operation for rupture was carried out without the administration of heparin,
although it seems more likely that it is due to a combination of active pre-operative
bleeding, hypovolemic shock and the greater intra-operative blood loss during
emergency repair.
FPA was a poor predictor of outcome with elevated levels being found in all patients
at the time of admission. Levels of FPA rose further at the end of operation and
attained levels much higher than in patients undergoing elective operations.
It is unfortunate that the numbers of patients in this study are so small. It may be that
with larger numbers some of the differences would have achieved statistical
significance, although this must not be assumed. Overall the most significant
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differences between the patients who survived and those who did not were in terms
of platelet number and markers of platelet activity.
In conclusion this study indicates that:
1. Patients presenting with ruptured aneurysms have elevated levels of FPA
and BTG at the time of admission
2. During operation levels of FPA and BTG rise and platelet count drops
3. Patients who survive have significantly lower levels of BTG at the end of
operation than those who die in the early post-operative period
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Chapter 7




Endothelial cells may play an important role in the pathogenesis of coagulopathy.
Recent animal studies of septic shock have shown that the activation of endothelial
cells is an important early event in the pathogenesis of the coagulopathy associated
271with septicaemia. It is well known that endothelial cell have wide-ranging and
complex interactions with platelets, leucocytes and the coagulation and fibrinolytic
systems as detailed above. It may be that endothelial cells, activated by hypoxia
secondary to hypovolemic shock, could play a similar role in the early pathogenesis
of coagulopathy associated with ruptured aortic aneurysm.
A well established method for the investigation of endothelial cell function in vivo
does not exist. The majority of previous research on endothelial cell function has
been carried out in cell culture models using immunohistochemical or flow
cytometric techniques. Some in vivo work has been carried out using soluble markers
of endothelial cell activation, such as von Willebrand factor and soluble E-selectin.
These techniques provide little information as to the site at which endothelial are
activated and what is happening at a cellular level.
A number of studies using immunohistochemistry have been carried out on tissue
biopsy specimens but the degree of magnification gives little indication as to whether
the antigens are present extracellularly, intracellularly, on the luminal membrane or
within the lumen of the vessel. Recent animal studies have suggested that
immunoelectron microscopy is a useful technique for this purpose.
Immunoelectron microscopy would be the ideal technique but this technique has not
previously been used for the examination of endothelial cells in biopsy material from
human subjects. It was therefore decided that the initial studies should be carried out
using plain transmission electron microscopy of biopsy material obtained at the start
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of operation.
The aims of these studies were to determine whether biopsy material obtained at the
start of operation from patients undergoing aortic surgery would yield sufficient
numbers of undamaged and well fixed endothelial cells and to establish whether this
would be a feasible method for further studies of endothelial cell function following
rupture. In addition it was hoped that these studies might reveal evidence of





The aims of this study were establish the best type of tissue and fixative for an
electron microscopic study of endothelial cells in patients with ruptured aneurysms.
The ideal tissue would:-
1. Be easily obtained very early during operation at no risk to the patient
2. Yield good numbers of small capillaries
3. Fix well and be easy to prepare for electron microscopy
4. Not be affected during the induction of anaesthesia
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Methods and materials
Tissue was obtained from patients undergoing elective aortic aneurysm surgery.
Tissue was taken during abdominal incision as this obviated the need for a second
skin incision. Three types of tissue were easily accessible within a few minutes of
incision: skin, adipose tissue and skeletal muscle. Three different fixatives were
used:-
1. Glutaraldehyde in phosphate buffer
2. Millonig's EM fixative - paraformaldehyde and glutaraldehyde in
phosphate buffer
3. 2.5% glutaraldehyde in cacodylate buffer
Tissue was cut into specimens of about 2mm cubed and immediately placed into
fixative. The specimens remained in fixative for 12-24 hours, then washed in 5%
sucrose and placed in 1% osmium tetroxide in cacodylate buffer, washed in 10%
ethanol, and dehydrated by immersion in absolute alcohol for 30 minutes, repeated
three times, then cleared by immersion in propylene oxide B.D.H. for 30 minutes.
The tissue was then embedded in Araldite mixture for 12-24 hours at room
temperature and then hardened in fresh Araldite placed in an oven at 60°C for 48
hours. Blocks were cut from the Araldite and mounted on a dowel rod with sealing
wax. Ultrathin sections were cut from this and mounted on Athene 483 grids without
a supporting membrane. The sections were stained by floating on lead citrate for 2
minutes, washed in 0.02 N NaOH for 20 seconds, washed in distilled water for 10
seconds, immersed in Uranyl acetate for 10 minutes and washed in 50% ethanol for
20 seconds. (Table 24)
The processed specimens were viewed on a Phillips 301 electron microscope.
Electron micrographs of capillaries were taken for later detailed examination.
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Skin could be obtained immediately at the start of operation and it fixed easily with
all three fixatives. However preparation for electron microscopy was difficult as the
epidermis became extremely hard during fixation and was difficult to cut. It was
more difficult to identify small capillaries than in other tissues, with often only one
or two vessels in a high power field.
Adipose tissue
Adipose tissue could be obtained immediately at the start of operation from the
subcutaneous layer of fat just as quickly as skin. It was difficult to fix, giving optimal
results with glutaraldehyde/cacodylate fixative. Processing for electron microscopy
was easy and large numbers of small capillaries were readily identifiable at the
junctions between cells. (Figures 25 & 26)
Skeletal muscle
Skeletal muscle was obtained from rectus abdominis. This could only be achieved a
few minutes after the start of the procedure. The tissue fixed well and was easy to
prepare for electron microscopy. Large numbers of small capillaries were easily
found. (Figure 27)
In all three tissues the endothelial cells examined appeared normal and intracellular
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detail was good when compared with textbook examples. Mitochondria were well
preserved and Weibel-Palade were present in endothelial cells of larger capillaries
and venules.
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Figure 25 Endothelial cell (EC) from adipose tissue fixed in phosphate buffer. A




Figure 26 Endothelial cell (EC) from adipose tissue fixed in
glutaraldehyde/cacodylate buffer. A red blood cell (RBC) is present
within the lumen. Scale bar indicates 5pm
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Figure 27 Endothelial cell (EC) from skeletal muscle (SM). Large numbers of
intracellular vesicles (V) are present. Scale bar indicates 5pm.
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Conclusions
Electron microscopy of biopsy material obtained at the start of operation appeared to
be a feasible technique for studying endothelial cells in patients undergoing aortic
surgery. Skeletal muscle was easy to prepare and provided the most abundant and
best fixed capillaries but there were some drawbacks. It could not be obtained until
some minutes after the start of operation and might therefore be affected by trauma
inflicted during incision. In addition suxamethonium is given at induction of
anaesthesia causing intense muscle contraction which may result in tissue injury.
Skin was difficult to work with and provided unreliable numbers of small capillaries.
In addition skin preparation for operation involves washing which cools the skin
possibly affecting blood flow.
Despite the fact that adipose tissue was difficult to fix, it could be obtained
immediately at the start of operation and was not likely to be affected by the
induction of anaesthesia and preparation for operation. There were other favourable
features. For example large samples of fat could reasonably be taken which would
be useful for future immunolabelling studies.
It was therefore decided that adipose tissue should be used for the initial study in
patients with ruptured aneurysms and that skeletal muscle should be examined in a
second study.
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Endothelial cell structure in adipose tissue capillaries
following ruptured aortic aneurysm
Methods and materials
Fat samples were taken from the anterior abdominal wall immediately after skin
incision at the start of operation in 5 patients undergoing operation for ruptured
abdominal aortic aneurysm and from 5 control patients undergoing elective surgery
for abdominal aortic aneurysm. The diagnosis of ruptured aneurysm was confirmed
in all cases at the time of operation. The fat samples were cut into 2mm cubes and
were immediately fixed in 2.5% glutaraldehyde / cacodylate fixative. The specimens
were then processed for electron microscopy as detailed above.
Two blocks of tissue were cut from each sample. Electron micrographs were taken of
all capillaries present in each section. The number of capillaries examined in each
patient ranged from 6-12, mean 8.9 capillaries.
All patients with rupture had suffered a period of hypotension and one patient had an
established coagulopathy at the start of operation. No patient had received any blood




Examples of a normal endothelial cells are shown in figures 26 & 28. The vessel
diameter ranged from 6-38 pm which is in the expected range for capillaries and
post-capillary venules. The cell may have numerous intracellular vesicles. The
luminal surface is smooth and regular. Endothelial cells are joined by tight
junctions. There is commonly a process on the luminal surface where two
endothelial cells join. The basal cell membrane is smooth with no gap between cell
membrane and basement membrane.
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Endothelial cells from patients with rupture
On examination of endothelial cells from the patients with rupture there were a
number of subjective differences compared with the endothelial cells from the
control group. Firstly the luminal surface appeared more convoluted and the there
appeared to be more frequent luminal processes (Figure 29) The cell membrane on
the tips of these processes was thicker than elsewhere on the cell surface and had a
fuzzy appearance. Intracellular vacuoles were seen frequently. These were lucent,
circular structures about 0.5 - 1 micron in diameter commonly found near the cell
nucleus. In some cells the basal membrane was irregular and convoluted.
The most striking abnormality found in endothelial cells from patients with rupture
was the presence of small spherical processes, about 0.1 pm in diameter, on or
adjacent to the luminal surface (Figure 30 & 31). These resemble the budding of
small membrane bound vesicles into the lumen of the vessel. However must be
remembered that the electron micrographs are two dimensional cross sections and it
may be that these process are thin cylindrical processes which have been cut in cross
section.
In order to quantify these differences, each photomicrograph was assessed by three
independent, blinded observers who graded each capillary in the presence or absence
of luminal processes, budding, intracellular vesicles, intracellular vacuoles and
irregularity of the basement membrane. The numbers of capillaries in the control
and study patients with each feature are shown in Table 9. Process formation on the
luminal surface was significantly more common in the patients who had suffered
rupture than in the control group. Budding of the luminal surface was found in 11/45
of the capillaries from patients with rupture but in none of the capillaries from
control patients p < 0.001. Budding was found in at least one capillary from all the
patients with rupture but in none of the control patients p < 0.05.
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The vessels in which these budding processes were seen were larger than those in
which no budding was found. The mean diameter of vessel with budding was 26pm
(range ll-68pm) compared with a mean diameter of 17 pm (range 7-37pm) in
vessels without budding. It may be that the vessels demonstrating budding are post¬
capillary venules rather than capillaries. In one vessel which demonstrated budding
a leucocyte can be seen adhering to the endothelial cell (Figure 32). This supports
the hypothesis that these vessels are post-capillary venules as leucocyte adhesion and
migration takes place at this site.
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Figure 28 Endothelial cell (EC) from control patient undergoing elective
operation. Scale bar indicates 5pm.
Figure 29 Endothelial cell from patient with rupture demonstrating processes
(P) on luminal surface. Scale bar indicates 5pm.
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Figure 30 Endothelial cell from adipose tissue in patient with rupture
demonstrating budding (B) on luminal surface. Scale bar indicates
5pm.
Figure 31 Endothelial cell from adipose tissue in patient with rupture
demonstrating budding (B) on luminal surface. Scale bar indicates
5p.m.
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Figure 32 Endothelial cell from adipose tissue in patient with rupture
demonstrating budding (B) and adhesion of leucocyte (L). Scale bar
indicates 10pm.
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Processes 37 26 p < 0.05
Irregularity of basal 12 11 NS
membrane
Budding 11 0 p< 0.001
Vacuoles 19 8 p < 0.02
Intra-cellular vesicles 9 15 NS
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Endothelial cell structure in skeletal muscle capillaries
following ruptured aortic aneurysm
Methods and materials
Skeletal muscle samples were taken from rectus abdominis at the earliest opportunity
during operation in 3 patients undergoing operation for ruptured abdominal aortic
aneurysm and in 2 control patients undergoing elective operation for aortic
aneurysm. The diagnosis of ruptured aneurysm was confirmed in all cases at the time
of operation. The muscle samples were cut into a 2mm cubes and were immediately
fixed in 2.5% glutaraldehyde / cacodylate fixative. The specimens were then
processed for electron microscopy as detailed above.
All patients with rupture had suffered a period of hypotension, no patient had a
coagulopathy at the start of operation and one patient developed a coagulopathy by
the end of operation. No patient had received any blood products prior to operation.
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Results
The appearances of endothelial cells in capillaries from control patients were similar
to those in the adipose tissue samples from control patients although intracellular
vesicles were more often found, being present in nearly all endothelial cells
including those from ruptures (Figure 33). Budding on the luminal surface of the
endothelial, similar to that found in adipose tissue, was found in endothelial cells in
2/3 patients with rupture (Figures 35 & 34). No endothelial cells demonstrated
budding in the control group. As with the adipose tissue samples the budding was
more commonly found in larger vessels with diameters in the range 22-45 pm.
Vacuoles were present in 4/9 endothelial cells of one patient with rupture but were
not seen in any of the other patients.
The number of capillaries demonstrating processes, budding, vacuoles and
intracellular vesicles are shown in Table 10.
- 168-












Vesicles 8 9 7 6 7
Vacuoles 0 0 0 0 4
Processes 3 2 5 2 5
Budding 0 0 0 2 3
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Figure 33 Endothelial cell from skeletal muscle in patient with rupture
demonstrating budding (B). Scale bar indicates 10p.m.
Figure 33b Enlargement of central area ofpicture showing budding in greater
detail.
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Figure 34 Endothelial cellfrom skeletal muscle in patient with rupture
demonstrating intracellular vacuoles (V).
Figure 34b Enlargement ofarea containing vacuole (V). Weibel-Palade (WP)
bodies are also shown.
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Discussion
This study has demonstrated that there are ultrastructural differences between
endothelial cells in patients undergoing operation for ruptured aortic aneurysm and
patients undergoing elective operation for aortic aneurysm. These changes were
found in two different types of tissue. This suggests that widespread endothelial cell
activation in small vessels is an early event following aortic aneurysm rupture.
The changes were less marked in skeletal muscle. The reason for this may be that
there are intrinsic differences between endothelial cells in these two tissues or it may
272
be that the stimulus which is causing these changes varies between the tissues.
For example in response to worsening hypovolaemic shock the blood supply to
adipose tissue may be reduced earlier than in skeletal muscle thereby rendering
adipose tissue hypoxic for a longer period of time.
The most marked structural difference was the presence of budding which was found
in at least one capillary from all patients with rupture but in none of the capillaries
from the patients in the control group. A less marked finding was the reduction in
intracellular vesicles in endothelial cells from patients with rupture.
The ultras tructural changes in endothelial cells that we found are similar to those
described in heart capillaries of dogs subjected to a period of hypoxia produced by
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ligation of a coronary artery. These studies describe loss of cytoplasmic
vesicles at an early stage, 10-30 minutes, and the production on "blebs" on the
luminal surface of the cell after more prolonged ischaemia 60-180 minutes. It must
be noted that the "blebs" described are of greater size than the budding which is
described here.
The endothelial cell budding has the appearance of shedding of membrane bound
27
vesicles. Shedding is the release of cell surface constituents either in soluble form
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or in association with plasma membrane, as opposed to secretion which is the release
of soluble proteins from secretory granules in the in the cytoplasm to the exterior of
the cell.
In cell culture studies of human umbilical vein endothelial cells a number of
agonists, such as complement protein C5b-9, have been shown to stimulate the
shedding of membrane bound vesicles of a similar size to those observed in the
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present studies. These membrane bound vesicles have been shown to be strongly
procoagulant, promoting the production of the prothrombinase complex. It is should
be noted that tissue factor, being an integral membrane glycoprotein, is expressed by
shedding of membrane bound vesicles and it may be that this is the cause of
increased prothrombinase activity. '
Intracellular vacuoles were found more often in endothelial cells from patients with
ruptured aneurysm. Such ultrastructural appearances have been described in animal
studies of endothelial cell injury but their origin is unknown.193'194 In those animal
studies endothelial injury was induced by helium-neon laser and the appearance of
vacuoles within the endothelial cell was found to be an early sign of cell injury.
Aggregation of platelets on the cell surface was found to be associated with the
development of vacuoles in the endothelial cell, indicating that this is an
ultrastructural change which is associated with procoagulant functional changes.
However no such studies have been carried out in humans.
The cause of the endothelial cell changes found in these patients has not been
indicated by these studies. Several stimuli are known to cause endothelial cell
activation: hypoxia, cytokines, endotoxin, activated leucocytes, thrombin and
histamine. As noted above in septic shock the trigger for endothelial cell activation
is TNF-a, but it seems unlikely that patients with ruptured aneurysm have
endotoxaemia at the time of admission. It seems more likely that in these patients
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the stimulus is direct endothelial cell hypoxia. All the patients studied were
hypotensive on admission. Hypovolaemic shock results in widespread tissue
hypoperfusion and hypoxia which should be most marked in tissues such as
subcutaneous fat. Such hypoxia has been shown to cause endothelial cell activation
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in cell culture and animal models in as little as 30 minutes. In addition the
ultrastructural changes in endothelial cells are similar to those expected to occur with
hypoxia, but it must be noted that endothelial cells have a limited variety of
structural changes in response to stimuli.
The functional significance of these structural changes is a matter for speculation.
As stated above it has been shown that hypoxia induces structural changes in
endothelial cells in canine models and in one study it was shown that such cells
^01
demonstrate abnormal function in terms of vasodilatory reserve. However no
human or animal studies have been carried out relating changes in endothelial cell
structure to changes in endothelial cell function in terms of modification in
interactions with the haemostatic system.
It has been shown in cell culture models that hypoxia can induce endothelial cells to
2&2-2R4-
produce procoagulant substances such as tissue factor. This has not yet been
shown to be of significance in clinical studies but it does demonstrate that a
mechanism exists whereby endothelial cells, activated by hypoxia, could stimulate
thrombin production and ultimately trigger DIC.
In addition endothelial cells play an important role in leucocyte activation, adhesion
and migration both directly via expression of adhesion molecules and indirectly via
cytokine expression. Thus endothelial cell activation secondary to hypoxia might
cause leucocyte adhesion and activation in hypoxic tissues. Subsequent reperfusion
would wash out these activated white cells and cytokines contributing to multiorgan
failure in the early post-operative period.
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In summary the structural changes that have been demonstrated in endothelial cells
from patients with rupture are known to be associated with alteration in function and
are compatible with the structural changes caused by hypoxia. The endothelial cell
budding looks identical to the process of shedding of membrane bound vesicles. It is
by this process that tissue factor is expressed and it is known from cell culture
studies that tissue factor is expressed by endothelial cells in response to hypoxia. It
may be speculated that the ultrastructural changes described above represent tissue
factor expression. If it is so then this may well be the mechanism which triggers DIC
in these patients. It must be emphasised that this is speculative and further, more
sophisticated studies looking at function in addition to structure, are required to test
this hypothesis.
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In conclusion these studies have demonstrated that:-
1. Electron microscopy of tissue biopsy at time of operation is a feasible
method for the examination of endothelial cells.
2. Ultrastructural changes are present in endothelial cells of small vessels in
patients with aortic aneurysm rupture.
3. These changes are present in adipose tissue and skeletal muscle
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Future studies
While the above studies have indicated that ultrastructural changes do occur in
endothelial cells at an early stage following rupture they do not provide information
concerning the function and activity of these cells. Immunogold electron
microscopy has been shown to be a valuable technique for investigating endothelial
cell function. However these techniques have previously only been described in
cell culture models and animal models which allow vascular perfusion with fixative
prior to biopsy. Light microscopy with immuno staining wuould be easier to
perform but in the samll vessels being studied there would be insufficient resolution
to determine whether the area being stained was in the lumen, on the surface of the
endothelial cell, within the cytoplasm of the cell or in the subendothelial layer. This
is important as some of the factors of interest, such as tissue factor and von
Willebrand factor, would be a normal finding in the subendothelium or within the
cell cytoplasm but would be abnormal if expressed on the cell surface.
Immunoelectron microcroscopy should provide this degree of resolution.
An example of immunoperoxidase staining of a capillary within adipose tissue
obtained from a patient with a ruptured aortic aneurysm is shown in Figure 36. In
this example the primary antibody used was anti-vWF. Staining can be seen within
the vessel lumen and on the endothelial cell surface. Immunoperoxidase staining is
easier to perform but produces inferior results to those which are expected from
immunogold staining. With immunoperoxidase it is less clear-cut where staining has
occurred as it merely shows up as a darker area and it is more difficult to carry out
quantatative analysis. This example of immunoperoxidase staining demostrates that
it is possible to immunologically stain fixed adipose tissue and subsequently to
examine these tissue by electron microscopy without loss of ultrastructural detail.
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Figure 35 Immunogold technique. The staining can be carried out on after
fixation, before embedding or after embedding ifan embedding agent
such as LR White is used rather than araldite. The gold microsphere
appears as a dark dot on electron microscopy.
Step one
Monoclonal antibody to
receptor of interest (usually
Step two
Secondary antibody. Monoclonal to
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Figure 36 Endothelial cell from adipose tissue stained by immunoperoxidase
with primary antibody against vWF
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Chapter 8
Fibrin Sealant as a Topical Haemostatic Agent in
Vascular Surgery: A Randomised Clinical Trial
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Current knowledge of fibrin based adhesives and sealants
Fibrin based glues have several theoretical advantages over other tissue adhesives:
tissue compatibility, biodegradability and the ability to adhere to wet surfaces.
Fibrin sealant may be expected to be biocompatible as it is a naturally occurring
human protein which is being employed at a site where it can normally be expected
to be present. It may even promote healing since the first stage in normal wound
healing is the production of a fibrin network into which fibroblasts and capillaries
migrate. These expectations have been bourne out in various experiments.
Fibrin sealant is readily biodegradable via the physiological mechanism of
fibrinolysis. Fibrin sealant injected subcutaneously in rats was partially lysed at 3
900
days and no traces of it could be found at 7 days. When examined at 3-6 months
following implantation there was no evidence of residual fibrin sealant in knitted
dacron grafts which had been sealed with fibrin sealant, in ovine and canine
OOQmodels. In comparison grafts sealed with cross-linked collagen all had residual
sealant at 3-6 months. Likewise animal models of PTFE graft anastomoses and
arteriotomies sealed with fibrin glue have shown that there is complete resorption
after 2-4 weeks.290'291
Fibrin sealant does not excite an inflammatory response and does not cause late
fibrosis. Pretreatment of Dacron arterial grafts with fibrin sealant does not reduce
9Q9
fibrous ingrowth and neovascularisation. Canine femoral arteries, in which a
suture line had been sealed with fibrin glue, revealed no fibrosis or foreign body
291reaction on examination after 3 weeks. Similarly in a canine model of PTFE graft
anastomoses sealed with fibrin glue, no inflammatory reaction was found when these
were examined at times ranging from 1 day to 3 months.290 Fibroblasts could be
seen migrating into the fibrin glue patch within 2-3 weeks of surgery. In this study
the use of oxidised cellulose gauze was often associated with the presence of
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multinucleated giant cells. The high degree of biocompatibility indicated by these
2RR 293-29S
studies is supported in a number of other publications. '
There is evidence from animal studies that not only does fibrin sealant not inhibit
wound healing but that it may in fact improve wound healing. In a study of skin
wounds in rats which were closed either by adhesive tape alone or by adhesive tape
and fibrin sealant it was found that when examined after 8 days the wounds sealed
with fibrin sealant were significantly stronger. Since at this stage all traces of the
fibrin sealant had disappeared, the improvement in wound strength must be due to
296
superior wound healing.
Further evidence of biocompatibility is provided by animal experiments which have
shown that the development of intra-abdominal adhesions is actually reduced by the
use of fibrin sealant.297"299
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Methods of Production
The fibrin sealant kit used in these studies was provided by the Scottish National
Blood Transfusion Service. Human fibrinogen was manufactured at the SNBTS
Protein Fractionation Centre from pooled donor plasma cryoprecipitate. Human
thrombin preparation was supplied by the Centre Regional de Transfusion Sanguine,
Lille (CRTS) France.
Many other methods of producing fibrin sealant have been described. These involve
the extraction of fibrinogen from various sources such as single units of fresh frozen
plasma,300'301 autologous blood302"304 and pericardial blood.305 These techniques
evolved as a result of a ban of commercially prepared fibrinogen in the United States
by the Food and Drug administration in 1978 which was introduced because of
concerns about the risk of transmission of hepatitis in fibrinogen produced from
pooled donor plasma. Unfortunately these methods are time-consuming and
cumbersome and the concentration of fibrinogen yielded is unpredictable and often
sub-optimal.296'307
In addition, these techniques do not solve all the perceived problems with donor
plasma derived fibrin sealant as a source of thrombin is still required. If human
thrombin is used then exposure to homologous blood products is not avoided and the
use of bovine thrombin is associated with its own complications and hazards.
Bovine thrombin is a foreign protein and has been shown to cause immunisation.
Such thrombin inhibitors cross react with human thrombin which may inhibit normal
309 311
coagulation and thus cause a bleeding problem.
It has been shown that the fibrinogen and thrombin content of the components is
important in the properties of the final clot. Increasing the concentration of
9Qf\ 307
fibrinogen and thrombin increase the tensile strength of the clot. ' However
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increasing the concentration beyond a certain level has detrimental effects. In vivo
studies in adult male Wistar rats demonstrated wound strength at 8 days was reduced
when glue was used that had very high concentrations of fibrinogen and
^Q/"
thrombin. The explanation for this effect is that fibrin clot produced using more
concentrated thrombin and fibrinogen inhibits macrophage and neutrophil migration
312 313
and may have similar effects on fibroblasts. ' It appears that the optimum level
of fibrinogen is 29 - 39g/l and thrombin is 200 - 500 iu/ml. The fibrin sealant




Concern has been expressed that viral transmission could occur as a result of fibrin
sealant use. Theoretically virus remaining in the preparation could be adsorbed and
retained by the patient. There are reports in the literature which implicate
cryoprecipitated fibrinogen, administered intravenously, as a mechanism for the
oa/- o i r
transmission of HIV-1 and Hepatitis C. • Therefore the method of production
has been designed and the plasma derived components are treated to minimise the
risk of viral transmission. To date, studies have failed to show evidence of viral
transmission in over one million patients treated throughout Europe with fibrin
^ 1 ft
sealant prepared by current methods.
All blood donations are screened for Hepatitis B surface antigen and antibody to
Hepatitis C, Human Immunodeficiency Virus 1 and 2. The plasma is treated by
terminal heat treatment at 80°C for 72 hours, sometimes called extreme or severe
heat treatment. This treatment has an excellent safety record with no reported cases
of viral transmission from Factor VIII or IX manufactured by this method.317"321
Virus inactivation studies have been carried out on human fibrinogen manufactured
by this method.314 Studies using plasma inoculated by vaccinia, HIV1, and Semliki
Forest virus (SLFV), which is a Togavirus belonging to the same family as Hepatitis
C virus. These studies showed viral inactivation levels of >1.4 loglO reduction in
vaccinia, >6.0 loglO reduction in HIV, and >5.2 loglO reduction in SLFV. This
level of viral inactivation is similar to that achieved in the manufacture of factor VIII
Z8 which has an excellent safety record.
Virus inactivation of the CRTS Human Thrombin is carried out by 6 hour incubation
in a solvent/detergent mixture as developed by the New York Blood Centre
^99
(NYBC). Virus inactivation studies of human thrombin manufactured by this
method showed viral inactivation levels of >5.6 log 10 with VSV and >4.8 loglO
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with SindBis virus. This level of viral inactivation is equivalent to that achieved in
the production of NYBC antihemophilic factor which has an excellent safety
record.323-324
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Clinical Experience of Fibrin Sealant
The first description of the use of modern fibrin sealant was in 1972 as a tissue
adhesive for nerve repairs.91 Since then it has been used in a wide variety of clinical
31^v 99Q 330
settings: otolaryngology, plastic surgery, neurosurgery, '' thoracic
994 993 331 334. 333 337 33R339
surgery, ' • hepatobiliary surgery, pancreatic surgery, '
surgery for abdominal trauma,340"342 colorectal surgery,343 paediatric surgery,344
gynaecology,345'346 urology,347 ophthalmology348 and cardiac surgery.293'349"354
One area in which it appears to be particularly valuable is in patients with defective
haemostatic mechanisms, either congenital or secondary to anticoagulant therapy,




The possibilities for using fibrin glue in cardiovascular surgery were recognised by
92
Spangler early on during its development. Borst (1982) further developed and
promoted the use of fibrin sealant in this field describing its use for sealing knitted
grafts, puncture holes and suture lines in vascular anastomoses.349'350 These studies
were not controlled trials but the authors concluded that fibrin sealant was a useful
agent even in the presence of coagulopathy and/or heparinisation and they reported
that it was most useful in sites difficult or impossible to approach, locations
dangerous to suture and in arresting diffuse haemorrhage.
A similar study describing the use of fibrin sealant in paediatric cardiac surgery
recommended its use for resealing Dacron conduits, complex reconstructions of
pulmonary arteries, complex and multiple suture lines, Gore-tex patches in high
pressure systems, bleeding near major coronary artery branches, bleeding from raw
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areas of the heart at operation and all bleeding points that are difficult to control by
conventional means.354
A randomised controlled trial of fibrin sealant in patients undergoing repeat cardiac
surgery showed that, compared with conventional haemostatic techniques, fibrin
sealant had a superior success rate in achieving haemostasis at the sternal edge
within 5 minutes, and patients treated with fibrin sealant had lower operative blood
3S1
loss and a decreased incidence of emergency resternotomy.
Fibrin glue was reported, in a non-controlled study, as being useful in operations for
acute aortic dissection, both for sealing the suture line of the anastomosis and for
sticking dissected layers of aorta together to produce a stronger wall which held
sutures more securely. This is further supported by a controlled trial of patients
with acute aortic dissection in which fibrin sealant was found to reduce peri-
3S3
operative blood loss and overall mortality. Some centres now use fibrin sealant
o/r 1
routinely during operation for aortic dissection.
Peripheral Vascular Surgery
There have been few studies of fibrin sealant in peripheral vascular surgery. In a
randomised trial, using a canine model of peripheral vascular surgery with PTFE
grafts, fibrin sealant was shown to be more effective than oxidised regenerated
cellulose in controlling anastomotic bleeding.290 Those cases treated with fibrin
sealant achieved haemostasis more quickly, had lower operative blood loss and a
lower incidence of groin haematomas. A similar controlled study using a canine
model demonstrated that in cases where the vascular anastomoses was reinforced
with fibrin sealant there was significantly less blood loss and that a higher pressure
291
was required to burst the anastomosis. The only clinical report of fibrin sealant
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use in peripheral vascular surgery is a report of two cases in which fibrin sealant was
used to reinforce the aortic stump during operation for aorto-duodenal fistula.362
There no other studies of fibrin sealant in peripheral vascular surgery in humans but





The fibrin sealant kit used in these studies was provided by the Scottish National
Blood Transfusion Service. Human fibrinogen was manufactured at the SNBTS
Protein Fractionation Centre from pooled donor plasma cryoprecipitate. Human
thrombin preparation was supplied by the Centre Regional de Transfusion Sanguine,
Lille (CRTS) France.
The kit comprised 4 x 1ml syringes, a dual syringe applicator device (Figures 35 &
36) and four vials:-
1. Lyophilised human fibrinogen, 200mg, with factor XIII, 50 iu and
fibrinectin
2. 7ml solution of 20 mmol/1 Tris containing aprotinin, 21,000 kallikrein
inactivator units. For reconstitution of fibrinogen
3. Lyophilised human thrombin, 1,000 NIH units
4. 10ml solution of 40 mmol/1 calcium chloride. For reconstitution of
thrombin.
The fibrin sealant was prepared at the start of operation. The fibrinogen was
reconstituted using 5ml of the Tris/aprotinin solution and the thrombin was
reconstituted using 5ml of calcium chloride solution. The syringes and dual syringe
applicator device were supplied in sterile packaging. This was opened in an aseptic
technique onto the sterile surgical field. The scrub nurse then drew up 1 ml of each
solution into separate 1ml syringes. The syringes were placed in the dual applicator
and a mixing devices was attached to the ends of the syringes. A blunt ended 18
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gauge needle was attached to the mixing device (Figure 37 & 38). The complete
system was kept in the sterile field at room temperature until required.
■
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L—1 Fibrinogen _p]hr1 i nromoin
Figure 38 Applying fibrin sealant to the suture line ofa PTFE patch in internal
carotid artery using dual syringe applicator
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Study design
The study was a prospective, randomised, non-blinded trial. An initial pilot study
involving 8 patients was carried out in order to familiarise surgeons and theatre staff
with the use of fibrin sealant prior to the commencement of the trial.
Patients were recruited from the vascular surgery unit of the Royal Infirmary of
Edinburgh. Three groups of patients were recruited:-
(1) Patients undergoing carotid endarterectomy with arteriotomy closure
using a polytetrafluoroethylene (PTFE) patch.
(2) Patients undergoing elective arterial bypass graft using a PTFE graft.
(3) Patients undergoing elective abdominal aortic aneurysm repair.
All patients gave informed written consent and the trial was approved by the local
ethical committee. Past medical history and drug use within the previous 14 days
was recorded. To allow assessment of the viral safety of the sealant patients who
were known to be seropositive for anti-HIV, who had a history of hepatitis or whose
liver function tests were outside the normal range were excluded. In addition,
patients with a history of severe reactions to blood products or concurrent disease
which might compromise their ability to be retained within the study were also
excluded. A venous blood sample was taken for haemoglobin, haematocrit, platelet
and white cell count, prothrombin time, activated partial thromboplastin time and
liver function tests. A serum sample was stored at -40° C for later viral studies if
required.
Following entry into the trial the patients were randomised in a computer generated
sequence to treatment or control. In the treatment group, following completion of
the vascular anastomosis, fibrin sealant was applied to the suture line using a dual
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syringe technique. The clamps were released two minutes after application was
complete. In the control group nothing was applied to the suture line. The time taken
to achieve haemostasis from release of the clamps was recorded. Surgical treatment
was otherwise identical in the two groups.
In both groups any further manoeuvres, such as application of pressure, haemostatic
gauze or reversal of heparin, required to aid haemostasis were recorded. The length
of operation, blood loss and blood product usage were recorded.
Patients were followed-up for 26 weeks. Blood was taken at 24 hours and 5 days for
haemoglobin, haematocrit, platelet count and white cell count, and at 6 weeks and 12
weeks for liver function tests and at 26 weeks for virology testing.
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Carotid endarterectomy
Patients and operative details
The mean age of patients was 64.5 years, range 48 - 75 years and there was no
difference in mean age between the patients in the treatment and control groups.
Fifteen patients were taking regular aspirin and both the patients not taking aspirin
were in the control group. No patients had any abnormality on pre-operative
coagulation screen.
Operation was carried out under general anaesthetic in all cases. Heparin 5,000 iu
was given by intravenous bolus before the carotid artery was clamped. The heparin
was not reversed. Arteriotomy closure was performed using a 0.5 mm PTFE patch
(WL Gore) and 7.0 goretex suture.
After seventeen patients had been randomised (8 treatment and 9 control), both the
surgeon and anaesthetist thought that there was a clinically significant reduction in
bleeding in patients treated with fibrin sealant and requested that an interim analysis
be performed with a view to stopping the trial. A statistical analysis was performed
on the available data which confirmed the clinical impression and the randomisation




The time taken to achieve haemostasis was significantly shorter in the treatment
group than the control group - p < 0.005 by Mann-Whitney test (Figure 39). There
was no significant difference in total operative time. Operative blood loss was lower
in the treatment group (median 420ml range 300-500ml) than in the control group
(median 550ml range 350-1200ml) but this difference was not statistically significant
(Figure 40).
In all patients (9/9) in the control group and in one patient (1/8) in the treatment
group oxidised cellulose gauze was used to aid haemostasis. No patients required any
blood products.
Complications
One patient in the control group suffered a perioperative cerebrovascular accident on
the ipsilateral side to operation. He made a good recovery from this and was left with
reduced co-ordination in the right hand but no loss of power. There was no evidence
of arterial embolism or thrombosis in any patient in the treatment group. There were
no wound complications in any patient in either group.
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Patients and operative details
Twenty patients undergoing bypass grafting using PTFE bypass graft were
randomised. The mean age of patients was 67.6 years, range 56 - 85 years and there
was no difference in mean age between the patients in the treatment and control
groups. Five patients in the control group and five in the treatment group were
taking aspirin prior to operation. No patients had any abnormality on pre-operative
coagulation screen. In all cases the anastomosis at the inflow end of the graft was
observed. These were all performed as end-to-side anastomoses.
Heparin 5,000 iu was given by intravenous bolus before the artery was cross-
clamped. The heparin was not reversed. 8mm and 10mm externally reinforced PTFE




The times to achieve haemostasis in the control and treatment groups are shown in
Figure 41. The median time taken to achieve haemostasis in the fibrin sealant group
was 2 minutes compared with 9.5 minutes in the control group. This difference was
statistically significant - p = 0.012 by Mann-Whitney. Haemostasis was achieved
immediately on release of the clamps in 4/10 patients in the treatment group
compared with 0/10 in the control group - p = 0.14 by Fisher exact test. There was
no difference in overall operating time, blood loss or blood product requirement.
There were no embolic events in any patient but one patient in the control group
suffered an early graft occlusion.
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Patients and operative details
Twenty patients were randomised. The mean age of patients was 67.6 years, range
56 - 85 years and there was no difference in mean age between the patients in the
treatment and control groups. Three patients in the control group and three in the
treatment group were taking aspirin prior to operation. No patients had any
abnormality on pre-operative coagulation screen.
Operation was carried out under general anaesthetic with thoracic epidural. Heparin
5,000 iu was given by intravenous bolus before the aorta was cross-clamped. The
heparin was not reversed. Woven dacron aortic grafts (Vascutek) were used, and the
anastomosis was performed with 5.0 Prolene sutures (Ethicon).
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Results
The times to achieve haemostasis in the control and treatment groups are shown in
Figure 42. The time taken to achieve haemostasis in the fibrin sealant group was
shorter but this difference did not reach statistical significance - p = 0.08 by Mann-
Whitney. Haemostasis was achieved immediately on release of the clamps in 8/10
patients in the treatment group compared with 4/10 in the control group - p = 0.08 by
Fisher exact test. There was no difference in overall operating time, blood loss or
blood product requirement.
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There were three major complications:-
The first patient was in the treatment group. He developed a coagulopathy post
operatively and required laparotomy in the early post-operative period for control of
haemorrhage. At laparotomy there was bleeding from multiple sites including both
the treated proximal anastomosis and the untreated distal anastomosis. He made a
good recovery from this and was almost ready for discharge when he suffered a
severe cerebrovascular accident 10 days post-operatively. He made no recovery and
died 24 hours later.
The second case was a patient in the treatment group. He underwent an
uncomplicated aortic aneurysm repair but was found to be paraplegic on awaking
from the anaesthetic. This is a well recognised but uncommon and unpredictable
complication of aortic surgery thought to be due to an abnormal pattern of arterial
supply to the spinal cord which is disrupted during operation. ' J0-50D/
The third patient was in the control group. This patient underwent uncomplicated
aneurysm repair and was making good recovery when he suffered a fatal myocardial
infarction 48 hours after operation.
No other patient suffered from any thrombo-embolic complication or wound
infection.
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Results of virology tests
Follow-up was completed on 43 patients, 24 in the treatment group and 21 in the
control group. At time of entry to the trial 39/43 patients had antibodies to Hepatitis
A, 2/43 to Hepatitis B core antigen, 2/43 to Hepatitis B surface antigen, 18/43 to
parvovirus B19 and none had antibodies to Hepatitis C virus. No patient had
Hepatitis B surface antigen present at any time. Only one seroconversion occurred; a
patient in the treatment group developed antibodies to parvovirus B19 at 26 weeks.




Fibrin sealant is not a new compound. It has been available for almost 20 years and
there are over 1,000 publications on the Medline database concerning its clinical
use.368 However nearly all of these publications are anecdotal or small non-
controlled studies. There are only three previous randomised controlled trials: one
concerning its use in operation for aortic dissection, another regarding it use in
reducing bleeding from the sternal edge in patients undergoing sternotomy during re-
or 1 QO/"
do cardiac surgery and the third concerning its use in hepatic resection.
The present studies are significant for a number of reasons: They are the first studies
of its clinical use in peripheral vascular surgery, they are randomised controlled
trials, unlike nearly all other publications on this subject, and the patients were
followed up for six months to determine viral safety.
These trials indicate that fibrin sealant is effective as a topical haemostatic agent in
vascular surgery. This was shown in three different types of vascular anastomoses:
PTFE patch closure, end-to-side anastomosis with PTFE bypass graft and end-to-end
anastomosis from aorta to woven dacron graft. The benefit was greatest in the group
of patients undergoing carotid endarterectomy with PTFE patch, not because fibrin
sealant was more effective in this situation but rather because these patients have
more prolonged bleeding than those undergoing aneurysm repair or bypass grafting
and thus the benefit was greater.
The only statistically significant difference was in the shortening of the time taken to
achieve haemostasis. The overall operating times were not significantly shorter.
This is partly due to the fact that the bleeding time is relatively short in terms of
overall operating time and therefore a significant reduction in time to achieve
haemostasis does not result in a significant difference in overall operating time. In
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addition while waiting for bleeding to stop at one site the surgeon can be proceeding
with the operation at another site. For example during bypass grafting the surgeon
may be performing the lower anastomosis while waiting for the upper anastomosis to
stop bleeding.
The blood loss in the patients undergoing carotid endarterectomy was lower in the
treatment group than in the control group but this was not statistically significant. It
may be that if the trial had not been stopped this difference might have reached
statistical significance. In the other two arms of the trial there was no difference in
the overall blood loss which was as expected. The amount of blood lost from
anastomotic bleeding in aortic aneurysm repair and bypass grafting is small
compared to the overall blood loss.
An important concern about using fibrin sealant at vascular anastomoses is that it
might promote intravascular thrombosis leading to early graft occlusion or
embolism. No evidence of this has been found in this study. In fact the only
intraoperative thromboembolic event and the only early graft occlusion were in
patients in the control group.
-y /^o
Another common concern is that fibrin sealant may cause transmission of viruses."
In vitro studies have shown that the method of production of fibrin sealant is
effective in killing viruses present in the collected plasma. Other blood products
317-321 373
produced using these methods have been found not to transmit viruses. ' '
324-
The follow-up studies in these patients did not show any evidence of viral
transmission. Only one seroconversion occurred and that was to parvovirus B19.
This virus is usually transmitted by means other than by transfusion of blood
products. It is a common pathogen as shown by the fact that half the patients in this
study had been infected at some time. Therefore this single seroconversion does not
provide definite evidence of viral transmission.
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The significant question which arises is whether the routine use of fibrin sealant
should be recommended for peripheral vascular surgery. There was a clear benefit in
terms of reducing anastomotic bleeding in carotid endarterectomy with PTFE patch.
Prolonged bleeding is common during this procedure and the routine use of fibrin
sealant is justified. However prolonged anastomotic bleeding is relatively uncommon
in aortic aneurysm repair and PTFE bypass grafting and, although fibrin sealant is
effective in reducing anastomotic bleeding in these procedures, its routine use cannot
be justified.
-209-
In conclusion these studies indicate that:-
1. Fibrin sealant shortens the time required to achieve haemostasis at
vascular anastomoses.
2. Fibrin sealant reduced operative blood loss during carotid endarterectomy
but this was not statistically significant.
3. The use of fibrin sealant at vascular anastomoses is not complicated by
intravascular thrombosis




Future developments with fibrin sealant extend in two directions. The first is to use it
in different clinical settings. The second is to develop new formulations and new
methods of application in order to improve its efficacy and ease of use in established
clinical settings.
Clinical situations in which fibrin sealant might be expected to be useful are those
where there is commonly prolonged bleeding which is not easily controlled by
conventional means. For example during aortic aneurysm surgery for rupture there is
often prolonged bleeding from vascular anastomoses especially when a coagulopathy
is present. Fibrin sealant might be expected to be effective in this situation as it has
been shown to be effective in the presence of a coagulopathy, either congenital or
-5 r/r o ro
secondary to warfarin therapy, ' and we have shown above that it reduces the
time taken to achieve haemostasis at end to end aorto-dacron graft anastomoses.
Unfortunately it would be difficult to conduct prospective randomised trials in these
patients because of the emergency nature of the surgery and the difficulty in
obtaining informed consent. Studies of fibrin sealant in this situations would
probably have to be non-controlled.
The current formulation and method of application of fibrin sealant has several
disadvantages. It takes 10-15 minutes to dissolve the fibrinogen and thus the sealant
needs to be prepared in advance. This is not a problem in clinical trials as it is
known before the start of operation whether fibrin sealant is to be used. However in
normal clinical practice topical haemostatic agents are not commonly used on a
routine basis as prolonged haemorrhage is uncommon. Topical haemostatic agents
are more commonly used only after a bleeding problem arises and are therefore
required immediately. A formulation in which fibrin sealant could be stored ready
for immediate use would be a major improvement. Unfortunately in its current
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formulation the fibrinogen component gels at room temperature, needing to be
heated to above 37°C to return to solution, and it therefore could not easily be stored
ready-made.
If a ready to use formulation were available then the indications for fibrin sealant in
vascular surgery could be extended. For example, as stated above, prolonged
anastomotic bleeding during bypass grafting is an uncommon occurrence and thus
the routine use of fibrin sealant for all cases is not justified. When it does occur the
currently available fibrin sealant is of little use as it takes at least 15 minutes to
prepare, by which time the bleeding would have almost stopped. A fibrin sealant
available in the operating theatre, ready for use, would be very useful for these
situations.
A second disadvantage with the current formulation of fibrin sealant is that on
release of the clamps there is a tendency for the fibrin sealant to be "blown off" the
patch by the pressure of blood within the lumen. Combining the sealant with
something to hold it in place might be useful. The use of collagen fleece in
combination with fibrin sealant has been reported in cardiac surgery.354 Since
completing the carotid endarterectomy arm of the trial we have used fibrin sealant in
combination with collagen fleece for carotid endarterectomy on four occasions. This
limited experience has suggested that fibrin sealant in this formulation is more
effective but a clinical trial would be required to prove this.
Another advantage of combination with collagen fleece is that by holding this fibrin
sealant in place it is more likely to be effective in situations where there is active
bleeding. The use of fibrin sealant at vascular anastomoses, in comparison with its
use other sites, is easier because bleeding at the anastomosis can be stopped by
clamping the relevant vessels while the sealant is setting. Where there is active
bleeding the components of the sealant may be washed away before a strong fibrin
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network is formed.
The development of a fibrinogen impregnated collagen fleece with a long shelf-life
might solve both problems. The main problems to be overcome are the development
of a formulation of fibrinogen which stays in solution at room temperature with a
useful shelf-life and a means by which to sterilise fibrinogen in solution without
degrading it. Any new formulation would require a randomised clinical trial to
determine how well it performed in relation to current fibrin sealant and, as shown
by the above studies, patients undergoing peripheral vascular surgery would be
suitable for this purpose.
A further possible application for fibrin sealant is in the treatment of prosthetic graft
infections. In current practice graft infection requires the removal of the graft which
is commonly followed by amputation. Antibiotic treatment is unable to fully
eradicate infection in the presence of a foreign body and replacement of the graft
invariably results in recurrent infection. In animal studies a fibrin glue - antibiotic
suspension has been shown to be effective in the prevention of graft infection in a
O/TQ
contaminated field. This model does not exactly mirror the clinical situation as
there was no initial infected graft to be removed, micro-organisms were added at the
time of graft insertion and thus the graft was not inserted into a site with established
infection. Furthermore the animals were sacrificed at day 17 post-operatively at
which time there was evidence of continued infection on tissue culture although
there was no gross infection. It may be that if this experiment was continued the
animals would eventually develop graft infection. Despite these reservations fibrin
glue - antibiotic suspension might be effective in the situation of graft infection.






Disturbance of the haemostatic system may be of paramount importance in the
pathogenesis of many of the complications of aortic aneurysm surgery. The first and
most obvious of these is the excessive bleeding often encountered during operations
for ruptured aneurysm which is due to disseminated intravascular coagulation. As
shown above post-operative haemorrhage is strongly associated with this
coagulopathy and is found not only in patients undergoing operation for rupture but
also in patients undergoing elective operations.
Excessive and inappropriate thrombosis may be as important as the bleeding
tendency. In patients with ruptured aneurysms there is a significant morbidity and
mortality associated with intraoperative lower limb arterial thrombosis. It seems
likely that as well as the clinically apparent thrombosis in the lower limbs there is
also occult thrombosis in various vital organs, such as kidney, lung and heart, which
may lead to multiorgan failure and thus fatally complicate an otherwise technically
370
successful operation. There was an unexpectedly high incidence of thrombotic
events such as myocardial infarction and stroke in the patients requiring re-operation
for control of haemorrhage. It may be the case that these patients develop a pro-
thrombotic tendency in the early post-operative period which is responsible for the
high incidence of thrombotic events. Other authors have also reported a high
incidence of thrombotic events in the early period following repair of a ruptured
aortic aneurysm.163'371'372
Re-examining the hypothesis presented above in light of the findings presented in
this thesis it is apparent that some refinements can be made. Contrary to earlier
reports, there was little evidence of systemic activation of the soluble coagulation
and fibrinolytic systems in patients with asymptomatic infrarenal aortic aneurysms.
Levels of fibrinogen were at the upper end of the normal range although this might
be expected in a group of patients with a high prevalence of atherosclerosis. In no
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patient was there significant prolongation of either the PTR or APTT. It does not
appear that there are significant pre-existing defects in the soluble coagulation
system that might account for the high incidence of coagulopathy in patients
undergoing elective aneurysm repair or suffering aneurysm rupture.
However, the presence of an aortic aneurysm appears to have a marked effect on
platelets. Platelet counts in patients with aneurysms were low, although usually
within the normal range. Levels of soluble glycocalicin were elevated suggesting
either increased turnover of platelets or a chronic low level of activation or both.
The fact that patients with carotid artery disease had high platelet counts and normal
levels of glycocalicin suggests that the effect on platelets is related to the presence of
an aneurysm rather than atherosclerosis.
The elevated levels of glycocalicin may represent activation of circulating platelets.
It has been demonstrated in vitro that activation of platelets can lead to the
generation of a protease which cleaves glycoprotein lb (GPlb) close to the site of its
insertion onto the platelet membrane. The soluble degradation product thus released
Q'7'2
is glycocalicin. GPlb is central to the process of platelet adhesion at the site of
vessel wall injury and thus vital for clot formation and haemostasis. It is therefore
easy to envisage that platelets deficient in GPlb would be dysfunctional. Such loss
of GPlb occurs during platelet storage in blood banks and has been proposed as the
373
reason for the decreased functional ability of stored platelets. Thus in these
patients there may be a combination of dysfunctional platelets and a mild degree of
thrombocytopenia which could significantly compromise the coagulation system.
Haemostatic function in the resting state might be near normal but the threshold at
which clinical bleeding problems occur would be much lower and there would be
little reserve in the face of a major challenge to the haemostatic system such as
aneurysm rupture or aortic operation.
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There were elevated levels of markers of thrombin and platelet activation at time of
admission in patients with ruptured aortic aneurysm. This was found in nearly all
patients even those who were not hypotensive on admission and who did not develop
a clinical bleeding problem. The more sophisticated markers of activation of
platelets and the coagulation system did not predict outcome any better than the
simple platelet count. It may be that the platelet count is a sensitive measure of the
overall insult to the coagulation system and the patient in general.
There was a marked rise in markers of thrombin, plasmin and platelet activation, and
a significant drop in platelet numbers by the end of operation. The relative
contributions of overall duration of operation, duration of cross-clamping and
reperfusion cannot be determined from these studies. It would be useful to examine
the changes which occur in the haemostatic system during operation for rupture in
isolation without the confusing effects of a variable degree of hypoxic shock prior to
operation.
Unfortunately the studies of changes in the haemostatic system which occur during
elective aortic repair, although interesting in their own right, were found to be a poor
model for the events which occur during operation for rupture. For example, there
was a marked rise in FPA and BTG during operation for ruptured aneurysm which
was not found in patients undergoing elective operations. This difference may be
attributable to the effect of systemic heparin. It was not anticipated during the design
of these studies that heparin would have such a markeds effect.
However the time-dependent activation of platelets, thrombin and plasmin which
occurred during the phase of initial dissection in elective operations was striking. It
seems likely that this would have continued if heparin was not given and indeed this
was seen in the patient with the contained rupture. The data from the patient with
contained rupture indicated that there was steadily increasing activation of platelets
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and thrombin throughout operation. In the elective patients there was evidence of
platelet activation following reperfusion and this seemed to be related to the duration
of cross-clamping. These findings support the hypothesis that the trauma of surgery,
the hypoperfusion associated with cross-clamping and the effect of reperfusion of
ischaemic tissue cause activation of the coagulation system which may contribute to
the process leading to DIC.
As stated above the findings in patients undergoing elective aortic repair are
interesting in their own right. If disturbance of the haemostatic system is important
in much of the morbidity and mortality associated with aortic surgery then greater
understanding of these events might quite quickly lead to new therapeutic strategies
to improve the prognosis of patients undergoing aortic surgery. There are already a
number of potent drugs available by which the haemostatic system can be
manipulated but their use has developed empirically. For example, systemic heparin
is given during elective aortic surgery in order to prevent arterial thrombosis during
cross-clamping and it was thought that it increased bleeding problems. However a
randomised study has shown that it has no effect on the rate of thrombotic episodes
or operative blood loss but it did show that heparin reduced the rate of perioperative
myocardial infarction." The most significant conclusion from this study is that
intraoperative manipulation of the haemostatic system can prevent complication in
the early post-operative period and improve outcome. Greater understanding of the
pathogenic mechanism of post-operative MI and its relationship to the haemostatic
system might lead to the development of more effective means of manipulating the
haemostatic system.
The means by which severe shock causes activation of the haemostatic system are
unknown. Current knowledge obtained from cell culture models of the effects of
hypoxia on endothelial cells indicates that there is a pathway by which hypoxic
activation of endothelial cells could lead to DIC. However, there have been no
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previous clinical studies of endothelial cells. The electron microscopic studies of
endothelial cell are significant in that for the first time it has been shown that there
are changes in endothelial cells of shocked patients. These ultrastructural changes
are similar to those that have been shown to occur in animal models in response to
shock. These responses are known to be associated with increased procoagulant
activity.
These data supports the hypothesis that events in tissues rendered hypoxic secondary
to hypovolemic shock are responsible for triggering DIC but it is still a long way
from providing proof and does provide details of the pathogenic pathway which
leads to DIC. It is important to determine the functional changes in endothelial cell
which might be done by immunoelectron microscopy but this will still fall short of
proving the link. Definitive proof will require an animal model in which various
steps of the hypothesis can be blocked to determine their significance and these
findings would have to be confirmed by observational studies in humans.
Finally what significance do these findings have for the management of the
individual patient ? The management of hypovolemic shock is a difficult issue. The
simple reversal of hypovolaemia at an early stage using intravenous colloid,
crystalloid, red cell concentrate and blood components does not seem to be the
answer. Many authors believe that the maintenance of a relatively hypovolaemic
state until surgical control of haemorrhage is achieved improves outcome, not only in
'YlA'X'lfy
ruptured aneurysm but also in trauma. A randomised study of patients
admitted with bleeding peptic ulcers indicated that aggressive early resuscitation
377with blood transfusion was associated with worse outcome. Some of these
authors have proposed that hypovolaemic shock may in some way enhance
haemostasis, either by direct haemodynamic effects or by effects on the haemostatic
systems. These mechanisms are poorly understood. It is clear that at some stage
hypovolaemic shock no longer enhances haemostasis but sets in train the events that
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lead to disseminated intravascular coagulation with disastrous results. The early
identification of these patients and the process which leads to DIC may be vital to
improving their outcome. It seems likely that the same processes which in the early
stages of hypovolaemic shock improve haemostasis may lead to DIC when the state
of shock is sustained beyond a certain point. For example there were ultrastructural
changes in endothelial cells and elevated levels of markers of platelet and thrombin
activity at the time of admission in patients who underwent successful repair of
ruptured aneurysm and who did not develop a clinical coagulopathy. There were
similar changes in patients who developed a coagulopathy and died.
Manipulation of the haemostatic system by pharmacological means using drugs such
as heparin, aprotinin, anti-thrombin III or hirudin has theoretical drawbacks. It may
disturb physiological processes which are advantageous in some patients and may
not even be efficacious in those patients who develop or are destined to develop a
coagulopathy. A recent case report highlights the dangers of meddling with the
haemostatic system in these patients (see appendix 1) 380
One therapeutic modality which has few theoretical drawbacks and several attractive
features is early platelet transfusion. It may be that patients with aneurysms have
dysfunctional platelets prior to rupture and there is certainly evidence of platelet
activation at an early stage following rupture. Furthermore thrombocytopenia
appears to be one of the strongest predictors of poor outcome. A recent paper
reporting improved results in the repair of thoracoabdominal aortic aneurysms
apportioned much of the improvement to a policy of early transfusion of platelets
preventing the onset of clinical coagulopathy.378 A randomised trial of immediate
platelet transfusion in patients admitted with ruptured aortic aneurysm could be
justified.
Fibrin sealant may well prove to be useful as a haemostatic agent in patients
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undergoing aortic surgery who develop a coagulopathy. It would be difficult to
conduct randomised trials in this setting due to problems in getting informed consent.
The randomised studies of its use in elective surgery indicate that it is an effective
haemostatic agent at suture lines in dacron aortic grafts. It has been shown to be safe
in that it does not produce thromboembolic events and that does not transmit viral
infection. In elective surgery suture line bleeding is not commonly a problem and it
is thus of limited use but in surgery for rupture suture line bleeding is a significant
problem especially when a coagulopathy is present. Fibrin sealant has been shown
o rzr ro
in other studies to be effective in the presence of a coagulopathy. ' The major
problem with the current fibrin sealant is the time taken in preparation, in particular
the reconstitution of the fibrinogen component. A ready to use fibrin sealant
available in theatre would be very useful although the impact on overall mortality is
likely to be quite small.
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Introduction
Patients bleed at surgery. In most patients a combination
of good surgical technique and physiological haemo¬
static mechanisms results in cessation of bleeding or
in acceptable levels of haemostatic control. In some
patients bleeding does not stop. These patients have one
of two things: inadequate surgical haemostasis, or failure
of physiological mechanisms. The distinction between
these two should be emphasised. Surgical bleeding
occurs when there is a large defect in a vessel wall that
cannot be sealed by the haemostatic process but than can
be corrected surgically. Vessel constriction may result in
the apparent cessation of bleeding for a while but bleed¬
ing will resume when vasospasm ceases. The treatment
of this bleeding is surgical: the placement of a ligature,
under-running or electrocautery. In microvascular bleed¬
ing, due to failure of physiological haemostatic mecha¬
nisms, there is bleeding from a multitude of very small
vessels. A previously dry operating field may start to
ooze blood over a large area. The treatment of this sort
of bleeding is to correct the underlying coagulopathy;
re-operation may be disastrous. Identification of the cause
of the coagulopathy and determining the best treatment
can be difficult. Patients may have a combination of
problems that include pre-existing compromised coagu¬
lation due to liver disease or aspirin therapy, dilutional
coagulopathy due to massive blood loss, or disseminated
intravascular coagulation due to head injury, sepsis or
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hypovolemic shock. During a bleeding episode new
factors may come into play and the relative contribution
of established factors may alter. These complex surgical
coagulopathies require a rational and pragmatic approach
to diagnosis and management. Traditionally, abnormal
results of routine laboratory tests such as low platelet
count or prolonged clotting times have been seen as
necessary to confirm the presence of a bleeding disorder.
In surgical patients this can be inappropriate. A normal
clotting screen does not contradict a clinical diagnosis of
abnormal bleeding, and abnormal screening tests do not
necessarily indicate the primary lesion in the haemostatic
system.
The formation of the haemostatic plug
Coagulation begins with the release of tissue factor from
damaged cells and with the simultaneous exposure of
subendothelial collagen to the plasma. Three interactive
steps ensue: 1) Activation of platelets; 2) Generation
of the enzyme thrombin; 3) Generation of the enzyme
plasmin.
Activation ofplatelets
Once the endothelial lining of a vessel is disturbed plate¬
lets enter the breach. Dynamic flow characteristics of the
moving stream of blood are important in this initial con¬
centration of platelets into the endothelial gap. In par¬
ticular the presence of an adequate concentration of red
blood cells is necessary to promote localisation of plate¬
lets at the periphery of the blood flow.1 At the injury site
several biochemical mechanisms may operate to bind
and activate the pjatelets (Fig. 1). Important among these
mechanisms is the binding of platelets to von Willebrand
factor (vWf). VWf is a soluble plasma protein that binds
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Fig. 1
in its native form to exposed collagen in the wound. This
results in a conformational change in the vWf molecule,
so that it now exposes previously hidden binding sites
for platelets. Platelets entering the wound bind to the
vWf molecule through an important receptor on the
platelet membrane, glycoprotein (GP) lb. This activates
the platelets.2 Activated platelets bind to collagen, and
to each other, and promote the formation of a stable clot
through activation of the clotting cascades. The initial
localisation and activation of platelets can fail and a
coagulopathy ensue if: 1) the collagen is abnormal
(scurvy, Ehlers-Danlos syndrome); 2) the von Willebrand
factor is absent or abnormal (von Willebrand's disease);
3) the platelets are reduced in number or function
(thrombocytopenia from any cause, renal disease, aspirin
therapy, other acquired or congenital platelet function
defects including Dextran therapy and congenital absence
of the GPIb receptor); 4) the haematocrit is critically
reduced (below 20%).'
Laboratory testing ofactivation ofplatelets. There is no
foolproof test of this extremely important step in the
coagulation process, and routine clotting screens can miss
serious defects. The bleeding time will usually, but not
invariably be prolonged, and a platelet count will detect
thrombocytopenia if it is present. The prothrombin time
and activated partial thromboplastin time (APTT) are not
affected by platelet function and may be entirely normal.
However, in von Willebrand's disease there is an associ¬
ated deficiency of factor VIII, which causes a prolonged
APTT. Extended testing of platelet function may be
necessary to identify the cause of a coagulopathy.
Generation of the enzyme thrombin
On the surface of the immobilised and activated platelets
at the site of injury a series of self-amplifying steps takes
place that results in the local generation of the serine
protease thrombin. In addition to activated platelets and
tissue factor from damaged cells, this cascade requires a
series of circulating proenzymes (factors VII, X, XI, IX)
to be activated sequentially and amplified, along with
their necessary plasma cofactors (VIII & V). Deficien¬
cies of these factors occur: they are well characterised
but very uncommon, and unlikely to present de novo to
the surgeon. Thrombin is pivotal in the clotting process:
it amplifies its own formation from precursors, acts as a
potent platelet activator, and generates insoluble fibrin
from circulating fibrinogen.
Fibrin and fibrinogen. Fibrinogen is present in massive
amounts in plasma. After albumin and the immuno¬
globulins, it is the most plentiful plasma protein. It has
two major functions: in its soluble form it is the ligand
through which platelets bind together; after proteolysis
by thrombin it forms a dense and insoluble fibrin mesh
on the platelet plug.
Laboratory testing ofgeneration of thrombin. The path¬
ways involved in the generation of the enzyme from its
plasma precursors are tested in vitro by a combinauon
of 3 or 4 tests: a prothrombin time which to be normal
requires physiological amounts of factors VII, X, V and
prothrombin; an activated partial thromboplastin time
which requires physiological amounts of prothrombin,
factors V, VIII, IX, X and XI, and the contact acdvating
factors, and either a thrombin time or a plasma fibrino¬
gen level to assess the amount of fibrinogen available. It
has been customary to conceptualise the clotting process
in terms of these, tests: if the tests are normal then hae-
mostasis must be intact, if the tests are abnormal then
haemostasis must be abnormal. However, these tests are
an artificial simulation of the clotting process: they use
artificial substitutes for several factors that are essential
for in vivo haemostasis such as activated platelets, von
Willebrand factor, and collagen; they require an intact
contact activation system to work in vitro, which humans
do not. These tests should appropriately be used as a
necessary aid to the formation of a diagnosis along with
the rest of the clinical picture.
Generation of the enzyme plasmin
Plasmin is formed in the clot by the action of an enzyme
(tissue plasminogen activator, released from damaged
tissue) on a precursor in the plasma — plasminogen.
Plasminogen is preferentially concentrated from the
plasma into the forming clot, where after activation by
tissue plasminogen activator it can cause maximum
breakdown of formed fibrin while at the same time it is
protected from the potent inhibitor in the plasma, alpha
2-antiplasmin. The plasmin mechanism serves to limit
clot formation to the site of injury, where clotting activa¬
tion is strong enough to overcome plasmin-induced clot
breakdown.
Laboratory testing for plasmin generation. It is not usual
to need to test for an intact fibrinolytic system, except in
the investigation of a thrombotic tendency. Evidence
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of plasmin activation is a useful diagnostic test for dis¬
seminated intravascular coagulation (DIC). Breakdown
products of fibrin caused by excessive plasmin activa¬
tion in DIC can be detected in the plasma. One of 2 tests,
D-dimers or fibrin degradation products can be measured.
D-dimers are more specific for DIC.
Diagnosis and management of coagulopathies
From a clinical viewpoint, coagulopathies fall into two
main categories: those diagnosed surgery, and those pre¬
senting at or after surgery.
Preoperative diagnosis of coagulopathy
Diagnosis. In common with other clinical conditions,
coagulopathy should be diagnosed by a sequence of
history, physical examination and laboratory analysis. If
conscious the patient should be asked specific questions.
Does the patient bleed or bruise abnormally?
Is there a family history of abnormal bleeding?
Has the patient taken aspirin within the previous
week?
Has the patient had warfarin therapy?
Specific question should inquire about bleeding at previ¬
ous surgery, or after dental extraction.
Physical signs of liver disease or of skin bleeding
other than senile purpura will predict for abnormal
haemostasis. The presence of hypotensive shock, sepsis,
or obstetric complications suggests that an acquired
coagulopathy may already be established.
Laboratory analysis for bleeding problems includes an
assessment of liver and renal function, as well as a clot¬
ting screen, consisting of a platelet count, an activated
partial thromboplastin time (APTT) and a prothrombin
time (PT). If an abnormal finding is made on the clinical
or laboratory assessment a haematological consultation
should be obtained. (In the absence of predictive indica¬
tors, a bleeding time to assess the risk of excessive bleed¬
ing at surgery due to abnormal platelet function or von
Willebrand's disease has such poor positive and negative
predictive values as to be of little use as a screening test.3)
Appropriate management will depend on the cause of
the coagulopathy and on the time available for therapeutic
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intervention. Management in specific clinical conditions
is discussed in later sections.
Diagnosis and management of coagulopathy presenting
during surgery
A pragmatic and stepwise approach is outlined.
Step I. When unexpected diffuse microvascular bleeding
develops during surgery contributing clinical causes
should be identified from the available history (Table 1).
Several factors may be present at the same time.
Step 2. A clotting screen is sent to the laboratory imme¬
diately. Laboratory testing is performed to guide therapy
by helping to identify the pathological mechanisms oper¬
ating in an established coagulopathy. It is not intended to
confirm the presence of one.
Step 3. If there is not time to wait for the clotting screen
result haemostatic therapy is given on the basis of
the presumed clinical causes identified by history and
examination.
Step 4. If the clotting screen result agrees with the clini¬
cal diagnosis appropriate therapy is given as discussed in
the next section and the effects checked clinically and by
repeat laboratory testing.
If the clotting screen result is not in agreement with
the clinical diagnosis, both the presumed clinical cause
and any identified laboratory abnormality should usually
be corrected. For example in a patient bleeding following
cardio-pulmonary bypass who has a normal platelet
count and a prolonged prothrombin time, it can be
assumed on clinical grounds that a platelet function
defect is present as well as the clotting factor abnormality
detected by the prolonged prothrombin. Both should be
treated.
Clinical conditions associated with coagulation
defects
Congenital defects of coagulation
Congenital defects in coagulation are rare. The most
common conditions, haemophilia A, Christmas disease
(haemophilia B) and von Willebrand's disease have
incidences of 1-5 per 100 000. Rarer conditions include
deficiencies of other clotting factors and platelet func¬
tion defects. Surgery in patients with known congenital
clotting disorders must be carried out with the close co¬
operation of a haematologist who has a special interest
in this area. Adequate amounts of appropriate replace¬
ment therapy must be available before elective surgery is
performed.
Haemophilia A (deficiency of factor VIII) and haemo¬
philia B (Christmas disease; deficiency of factor IX) are
clinically similar. Both are inherited as X-linked reces¬
sive disorders. Patients present with a mild, moderate or
severe bleeding Tendency, depending on their factor
levels. Patients with severe disease tend to bleed into
muscles and joints with minimal trauma. They may pre-
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sent with other serious haemorrhage such as acute upper
GI bleeds or intracranial haemorrhage. Patients with mild
disease may have only a very slight bleeding tendency,
but manifest as serious bleeding at surgery.
Von Willebrand's disease, deficiency of von
Willebrand factor, is an autosomal dominant condition
with an incidence of 2.5 per 100 000. Mucocutaneous
bleeding and profuse haemorrhage following dental
extraction or minor surgery are common. Unexpected
bleeding following surgical challenge may be the
presenting feature, even in adulthood.
Liver disease
Liver failure is commonly associated with coagulation
problems. Patients with liver failure have several reasons
for developing clotting abnormalities. There is reduced
absorption of vitamin K, reduced synthesis ofmany clot¬
ting factors (including II, VII, IX and X, and fibrinogen),
thrombocytopenia caused by hypersplenism, and low
grade DIC due to impaired synthesis of inactivators in
the liver and failure to clear activated clotting factors.
Abnormal coagulation studies can be shown in 85% of
patient with liver disease although only 15% have clinical
bleeding problems.4 Abnormal clotting tests and throm¬
bocytopenia are commonly found in patients undergoing
liver biopsy. However, these do not correlate well with
bleeding problems.3 It is advisable to raise the platelet
count above 100 x 109 per litre by platelet transfusion
and to correct the prothrombin time to less than 1.7, if
possible, with vitamin K and fresh plasma before liver
biopsy is performed.6
Renal failure
Chronic uraemia is associated a mild bleeding tendency
mainly ascribed to impaired platelet function,7-3 although
a low haematocrit9-10 and abnormal endothelial cell func¬
tion" also contribute. In these patients, the presence of
haemostatic impairment can be identified and quantified
by the bleeding time. Correction of a prolonged bleeding
time can be achieved by raising the haematocrit to about
30%, and by dialysis. Additional effective measures are
desmopressin infusion, cryoprecipitate infusion, or plate¬
let transfusion. The use of blood products should be
avoided unless lack of time in an actively bleeding patient
compromises the use of pharmacological alternatives.
Acute renal failure can complicate a complex coagu¬
lopathy but is unlikely to contribute significantly to
the bleeding tendency. Extended ultra-filtration can cause
a consumptive thrombocytopenia, and systemic anti¬
coagulation will worsen the impairment of haemostasis.
In addition, chronic renal failure and nephrotic
syndrome are associated with a thrombotic tendency,
caused by low levels of the antithrombotic proteins, anti-
thrombin HI and protein C and by impaired release of
tissue plasminogen activator.3
Drug therapy
Many drugs interfere with normal coagulation and can
cause bleeding problems both in emergency and elective
settings.
Heparin. Heparin directly impairs thrombin generation
and activity by active site enzyme inhibition. It is given
in a low dose regime for prevention of deep venous
thrombosis (DVT) or in a higher, therapeutic dose, for
treatment of acute thromboembolic disease or to prevent
clotting of extracorporeal systems. Low dose heparin is
associated with a small increase (2%) in the incidence of
minor bleeding and wound haematomas but no increase
in the incidence of serious bleeding.12 In patients treated
with therapeutic heparin the reported incidence of clini¬
cally significant bleeding varies from 1-15%.13 Heparin
has an in vivo half life of a few hours. Its effect on hae¬
mostasis can be rapidly reversed by infusion of protamine
sulphate. It is not reversed by plasma therapy.
Heparin can cause several serious complications in
patients other than a bleeding tendency from its pharma¬
cological activity. Up to 7% of patients treated with
prophylactic heparin will develop an immune thrombo¬
cytopenia.14 This usually takes approximately 10 days
of treatment to develop on first exposure to the drug,
though on subsequent exposure the onset may be much
quicker. Though usually mild, severity of the thrombo¬
cytopenia can be profound, with the platelet count less
than 10 x 109 per litre. Other complications related to
heparin associated thrombocytopenia are thrombosis,
either venous or arterial, and acute skin necrosis at the
site of subcutaneous injections.13 These effects can be
induced by very small amounts of heparin, even by
heparin flushes of indwelling lines. Management of a
patient with heparin-associated thrombocytopenia
depends on the clinical situation, the certainty of the
diagnosis, and the risks involved in ignoring it. In general
a thrombocytopenic patient on heparin therapy should
have the heparin stopped. This includes line flushes
and subcutaneous low dose therapy. Anticoagulation can
be continued according to the clinical situation with
warfarin, aspirin, prostacyclin, ancrod, or a specific non-
cross-reactive low molecular weight heparin, of which
Orgaran™ is the only one available at the time of
writing.13 Laboratory confirmation of the diagnosis is
possible in a few centres, although more generally appli¬
cable tests have recently been developed.16 Bleeding
thrombocytopenic patients should be treated by reversal
of heparin with protamine, and platelet transfusion com¬
bined with intravenous immunoglobulin. Non-heparin
anticoagulation can be re-established about 24 h after
bleeding has stopped. Patients with extending venous
thrombosis or with arterial thrombosis in association
with heparin associated thrombocytopenia should be
treated by fibrinolytic therapy or surgical clot removal,
followed by alternative systemic anticoagulation.
Aspirin. Aspirin invariably and irreversibly causes
impairment of platelet function. After a single oral dose
impairment oT platelet function may persist for up to
a week. This may contribute to clinical haemostatic
impairment in surgical patients. This effect is more
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likely to be clinically significant when other factors are
contributing to a bleeding tendency. For example', recent
prospective trials in patients undergoing coronary artery
bypass grafting have failed to show a difference in
bleeding in patients taking a single preoperative aspirin
dose compared to controls.17 However, aspirin in combi¬
nation with low dose heparin has been reported to cause
an increase in serious bleeding in surgical patients.18
Clinical bleeding in patients who have ingested aspirin
within the previous week may need to be treated with
platelet transfusions. Other factors will probably be con¬
tributing to the haemostatic failure and will need to be
treated also.
Warfarin. Warfarin exerts its anticoagulant effect by
interfering with the terminal steps in the synthesis of the
vitamin K dependent clotting factors II, VII, EX and X,
all of which are terminally gamma-carboxylated serine
proteases. The failure to achieve terminal gamma carbo-
xylation prevents these proteins forming enzyme-substrate
complexes on the surface of activated platelets.
Warfarin is clearly associated with an increased
incidence of bleeding.19-21 There is a good correlation
between degree of anticoagulation and incidence of
bleeding. In combination with low dose heparin, warfarin
causes a marked increase in serious bleeding complica¬
tions and this combination should be avoided.22 Patients
on warfarin therapy are at increased risk of both bleeding
and thromboembolic episodes in the perioperative
period. In general warfarin therapy can be stopped prior
to operation. Anticoagulation can be maintained with
heparin during the immediate perioperative period
and warfarin can be restarted as soon as the patient can
swallow.
Patients who develop serious bleeding on warfarin at
any level of anticoagulation should have the warfarin
effect reversed by combination therapy using clotting
factor concentrate of II, IX and X, and either factor VII
concentrate (if available) or fresh frozen plasma (FFP).6
In combination with factor concentrate, about 300 ml of
FFP will provide enough factor VII.23 The half life of
factor VII in vivo is less than 2 h, and repeated testing
and infusion may be necessary. The patient should also
receive vitamin K 10 mg by injection.
Thrombolytic therapy. Patients may require surgery
shortly after receiving thrombolytic therapy for one of
several reasons including emergency bypass grafting,
persistent bleeding after arterial catheterisation, and in¬
tracranial haemorrhage. Thrombolytic therapy results in
depletion of fibrinogen by direct enzymatic digestion by
plasmin. Levels of factors V and VIII in the plasma are
also reduced by plasmin digestion. In addition, plasmin
causes a platelet functional defect. Often the patients
will also have been started on heparin. Patients under¬
going cardiac surgery have a considerable increase in
bleeding after failed thrombolytic therapy.24 Management
of these patients involves stopping the infusion of the
thrombolytic agent, and of heparin if used. If the patient
is not actively bleeding, results of a clotting screen can
be awaited. If there is active bleeding, or if the fibrino¬
gen level is less than 1 g per litre, cryoprecipitate is
given: 10 units, given as a single pool, will raise the
plasma level by approximately 0.7 g per litre in an aver¬
age adult. Cryoprecipitate also contains factors V and
VIII, and this dose will probably be adequate to correct
the deficiencies. Heparin should be reversed with pro¬
tamine sulphate. If these measures fail platelets should
be transfused. If the bleeding is immediately life-threat¬
ening antifibrinolytic agents, tranexamic acid or epsilon
aminocaproic acid, should be given.25 The fibrinogen
levels should be checked repeatedly after treatment, since
fibrinolysis may persist after infusion of cryoprecipitate.
Massive blood loss
Massive blood loss rarely occurs in isolation. Usually
there is a degree of shock and there is often associated
major trauma. Degree and length of shock and the
number of units of red cell concentrate (RCC) transfused
are strong indicators of overall outcome in these
patients.26,27 Despite this there have been several well
designed studies that have managed to isolate and iden¬
tify the problems occurring with blood loss alone. Sig¬
nificant coagulation defects tend to occur after about 20
units of RCC have been transfused.28-29 It should be em¬
phasised that patients can receive very large transfusions
and still exhibit normal clotting. Of those who develop
abnormality on laboratory testing most do not have clini¬
cal bleeding problems. In one study only 29% of patients
transfused 20—30 units of RCC developed abnormal
clotting.28 The difficulty in predicting the patients who
will develop clotting problems and at what stage this
will occur, means that rigid protocols of platelet and FFP
administration in conjunction with massive transfusions
are inappropriate. Initial resuscitation is usually carried
out with crystalloid with or without colloid, followed by
RCC when available. After massive transfusion with
RCC, which lack platelets and other clotting factors, a
dilutional coagulopathy develops: a platelet count of less
than 100 x 109 per litre is most clearly associated with
bleeding problems. Reduction of clotting factors, in
particular V and VHI, associated with a mild prolongation
of clotting test times, is common but does not correlate to
the risk of developing microvascular bleeding. Marked
prolongation of the clotting times, however, is usually
associated with a drop to less than 20% of normal
plasma levels of factors V and VIII with hypofibrinoge-
naemia and suggests the onset of a consumptive
coagulopathy. A patient who develops microvascular
bleeding during the course of resuscitation after blood
loss should be treated with platelet and fresh frozen
plasma transfusion. If the clotting screen reveals fibrino¬
gen levels of less than 1 g per litre, cryoprecipitate (a
pool of 10 units in an adult) should also be given.
Disseminated intravascular coagulation
Disseminated intravascular coagulation (DIC) occurs
when coagulation is triggered by some abnormal stimulus
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to take place in the general circulation, and is not confined
to a region of damaged tissue. Many disease processes
can cause DIC (Table 1). The factors that trigger DIC
may differ.30 Brain is a rich source of tissue thrombo¬
plastin: the high incidence of DIC in patients with head
injury, especially when brain tissue itself is injured is
most likely due to tissue thromboplastin release, causing
direct intravascular activation of tissue factor and subse¬
quent thrombin activation. In septic shock DIC can be
precipitated by endotoxin, and perhaps by direct activa¬
tion by the bacterial cell wall. Direct endothelial hypoxia
may precipitate DIC in hypotensive shock.
The clinical picture in DIC can be diverse. Some
patients have a primarily thrombotic disease process
with multiple infarcts and organ failure; others have a
mainly haemorrhagic disorder. DIC can be acute and
• overwhelming with complete defibrination, profound
thrombocytopenia and uncontrollable haemorrhage; it
can also present as a sub-clinical disorder detected only
on coagulation studies. Coagulation studies typically
show thrombocytopenia, prolongation of clotting times,
hypofibrinogenaemia, and the presence of circulating
fibrin degradation products. It has not proved possible to
complete good laboratory or clinical studies of DIC until
recently. The use of primate models of endotoxic shock
have elucidated the mechanisms of DIC in this setting.
Coagulation is activated by endotoxin through tumour
necrosis factor (TNF), probably via interleukin 6, causing
expression of tissue factor in monocytes and endothelial
cells.31 Exogenous tissue factor pathway inhibitor, a
naturally occurring anticoagulant in human plasma, pre¬
vented the onset of DIC and improved survival in these
studies. Other possible therapeutic agents that may
emerge in the future for treatment of DIC include anti-
thrombin III (ATIH) and activated Protein C, both of
which are naturally occurring thrombin inhibitors. Clini¬
cal trials to date of ATHI have been inconclusive32 or
disappointing.33-34 It is likely that in established DIC no
single agent will be sufficient, but that a combination of
inhibitors of cytokines and antithrombins will be neces-
saiy. At present standard management of DIC involves
removal of the cause if possible, and replacement of the
consumed clotting factors, especially fibrinogen, factors
VIII and V, and platelets, with transfusions of cryopre-
cipitate, fresh frozen plasma and platelet concentrates.
There is no evidence to support the use of heparin in DIC.
Cardiopulmonary bypass
Following cardiopulmonary bypass (CPB) 10-20% of
patients may develop a degree of haemostatic failure,
more commonly after repeat procedures. CPB has wide
ranging effects on coagulation: platelets, the comple¬
ment system, leucocytes and coagulation factors are all
affected.35-41 Thrombocytopenia and platelet dysfunction
are probably the most significant abnormalities resulting
from CPB. Platelets are activated during the procedure.
These activated platelets form circulating aggregates,
secrete granule contents and may inappropriately acti¬
vate coagulation. Platelets may be directly activated by
contact with the CPB circuit or the effect may be medi¬
ated by thrombin, plasmin, or leucocytes. CPB activates
leucocytes and production and granulocyte elastase and
oxygen free radicals can be shown.39 Leucocyte activa¬
tion is probably mediated by the complement system:
increased levels of C3a and C5a are found early after the
commencement of CPB.40 Elastase from activated
leucocytes is a direct platelet agonist.42 Plasmin levels
rise during CPB: tPA release from ischaemic tissue may
contribute to this phenomenon. Plasmin is also a platelet-
activating enzyme.
Other effects of CPB include a reduction of plasma
levels of clotting factors II, V, VII, VIII, EX and X,
elevation of factor XII and activation of fibrinolysis. The
significance of these effects is uncertain. It has become
apparent that aprotinin, a broad spectrum inhibitor of
serine proteases, including kallikrein, plasmin and elastase
reduces or completely prevents the coagulopathy in¬
duced by cardiopulmonary bypass.43 The mechanism for
this effect is unclear but prevention of activation platelet
is probably involved.44
Patients undergoing cardiopulmonary bypass may
have additional causes of coagulopathy such as aspirin
ingestion, incomplete warfarin reversal, sepsis associated
with endocarditis, or recent fibrinolytic therapy. Re-
operated patients, those with recent aspirin ingestion,
and patients with septic endocarditis are likely to benefit
from aprotinin infusion.45 Patients presenting with ex¬
cessive microvascular bleeding after heparin reversal at
the end of bypass can be treated with platelet transfu¬
sion, and by correcting of any residual prolongation of
the clotting times _ with fresh frozen plasma. However,
the platelet function defect induced by cardiopulmonary
bypass is usually self limiting, and reverses naturally
within 2 h. The patient should be spared the hazards of
exposure to blood products for minor levels of micro¬
vascular bleeding.
Liver transplant
Patients undergoing liver transplant have a complex
coagulopathy that arises from the pre-existing coagulo¬
pathy of end-stage liver failure complicated by the effects
of the operation itself, particularly during the anhepatic
phase. There is increased fibrinolysis caused by increased
levels of plasmin from a combination of increased release
of tPA from injured endothelium, reduced clearance of
tPA and a lack of hepatic synthesis of alpha-1 anti-
plasmin.46-47 These abnormalities resolve at varying rates
following reperfusion of the transplanted liver. Aprotinin
has been reported to. reduce bleeding in liver transplanta¬
tion, though this is disputed.48-50 The most significant
action is probably inhibition of free plasmin.
The fast-moving changes in coagulation during liver
transplantation require monitoring that is more immediate
than the 20-30 min required for a conventional coagula¬
tion screen. Some centres report useful results from
thromboelastastography. This is a device which can be
used in the operating theatre to give an assessment of
overall function of the haemostatic system, including
COMPLEX SURGICAL COAGULOPATHIES 127
platelet function from a single sample.49'31 However the
technique does not give immediate results, and no objec¬
tive studies are available showing benefit from its use.
Much of the immediate treatment of excessive blood loss
during transplant remains the empirical use of platelet,
plasma, and cryoprecipitate infusions.
Ruptured aortic aneurysm
Emergency surgery for ruptured abdominal aortic aneu¬
rysm still carries a mortality rate of about 50%.32-33
Several factors are associated with poor prognosis: low
systolic blood pressure at presentation, advanced age,
excessive operative blood loss and coagulopathy. Coag¬
ulopathy has been shown to cany a particularly poor
prognosis.36-37,38 Patients with a poor prognosis associ¬
ated with coagulopathy can be identified by means of
routine haematological investigation at time of admis¬
sion. In a recent study patients with a platelet count
>100 had a mortality of 7.4%. Patients who had a plate¬
let count of < 100 had a mortality of 82%,37 presumably
due to established tissue hypoxic damage and associated
consumptive coagulopathy before resuscitation and sur¬
gery. Future studies directed towards pharmacological
intervention in this poor prognosis group may improve
the outcome in patients with ruptured aneurysms who
survive to reach hospital.
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Postoperative Haemorrhage Following Aortic Aneurysm Repair
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Between 1988 and 1993, 17 (3%) out of a total 654 patients underwent reoperation for control of haemorrhage following
repair of abdominal aortic aneurysm in a vascular surgery unit. The first operation was performed for rupture in 12 cases
and electively in five. The incidence of reoperation for postoperative bleeding was 1.7% following elective operation and
3.3% following emergency operation. Case-controls, matched for sex and primary operation, were identified. The mortality
rate in those requiring reoperation was 58% compared with 23% in the control group (p = 0.037). Seven patients suffered
progressive deterioration and died in the early postoperative period. Of the remaining ten patients, four suffered unexpected
serious complications; two a fatal cerebro-vascular accident (CVA), one a fatal myocardial infarction (MI) and the fourth
a non-fatal CVA. The patients requiring reoperation had greater blood loss (p < 0.05), greater transfusion requirements
and lower core temperatures (p < 0.05) at the end of their first operation than the control group. All except one of the
patients who bled had evidence of coagulopathy and had lower platelet counts than the control group both before and after
the first operation. At reoperation there were multiple minor bleeding points in 11 patients, no active bleeding points in two
patients and a discrete bleeding point in four patients. In conclusion, re-operation for control of postoperative haemorrhage
is an uncommon complication which is strongly associated with coagulopathy, may predispose to "rebound" postoperative
thrombotic episodes, and carries a poor prognosis.
Introduction
Abdominal aortic aneurysm is a common condition
and the number of operations being performed is
steadily rising.1"4 This increase is due to a combination
of increasing awareness of the condition, greater ease
of diagnosis due to the wide availability of ultra¬
sound, a greater willingness to perform operations in
older and less fit patients 5 and a true increase in the
incidence of the condition.6 The incidence of haemor¬
rhage both during and after operation, which formerly
accounted for the majority of deaths after aneurysm
repair, was much reduced by the introduction of the
"inlay" technique which avoids the need for extensive
dissection.7 Despite this and other technological
improvements, haemorrhage remains one of the more
common complications of aneurysm repair.3,8"10 The
purpose of this study was to determine the incidence,
nature and outcome of postoperative haemorrhage as
a preliminary to examining ways of avoiding this
complication.
Please address all correspondence to: A. A. Milne, Vascular Research
Office, Royal Infirmary of Edinburgh, Lauriston PI, Edinburgh,
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Methods and Materials
The case records of all patients undergoing lapar¬
otomy for control of haemorrhage following aortic
aneurysm repair, during the period 31 July
1988-1 August 1993 in the Vascular Surgery Unit of
the Royal Infirmary of Edinburgh, were identified by
means of the Vascular Audit system. Seventeen
patients were identified, 10 male and 7 female, with a
mean age of 73 ± 5 years. In five the first operation had
been elective and in 12 the operation had been
performed for rupture. During this period 291 elective
operations and 363 emergency operations were car¬
ried out for abdominal aortic aneurysm in the Vas¬
cular Unit giving an incidence of operation for
postoperative bleeding of 1.7% after elective opera¬
tions and 3.3% after emergency operations. Case-
controls, matched for sex and indication for operation,
were selected from operation records during the same
period by the following method. For each study
patient the next patient of the same sex undergoing
operation for the same indication was selected. The
mean age of the control group was 71 ± 8 years.
Operations were carried out either by a consult¬
ant vascular surgeon or by a senior registrar with
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Preoperative platelet count (X109/1) 103 81-385 253 244-336 NS
Platelet count after first operation (X109/1) 92 40-140 112 64-175 NS
Fibrinogen after first operation (g/1) 1.12 0.6-2.9 1.30 0.6-3.8 NS
Prothrombin ratio after first operation 1.6 1.1-3.3 1.4 1.0-2.2 NS
Temperature at the end of operation (°C) 34 31.6-36 35 32.5-37 p < 0.05
Operation length (mins) 180 85-320 112 80-300 NS
Cross-clamp time (mins) 65 44-100 45 40-70 NS
Blood loss (ml) 5150 2000-12500 2035 840-10700 p < 0.05
Transfusion RCC (units) during first operation 12 6-18 6 1-16 NS
considerable experience in vascular surgery. All
patients undergoing elective operation were given
systemic heparin (5000 iu) prior to cross-clamping.
Those undergoing operation for rupture were not
given systemic heparin but heparinised saline (5 000
iu/500 ml 0.9% saline) was used for irrigation and
flushing.
Statistical analysis was carried out using Systat
for windows v5.0®. Mann-Whitney U-test, y2 and
Fisher's exact test were used where appropriate. Data




Mean operating time, cross clamp time, blood loss and
transfusion requirements were all greater in patients
who bled postoperatively than in the controls,
although these differences were not statistically sig¬
nificant except for blood loss, p < 0.05, Mann-Whitney
(see Table 1). The study group had a lower mean
temperature at the end of operation (p < 0.05, Mann-
Whitney). These data suggest that patients who bled
post-operatively had more complicated primary
operations.
At re-exploration a single bleeding point was
found in only four patients. Of these two were
bleeding from the proximal anastomosis, one from a
lumbar artery and one from the median sacral artery.
In two patients no active bleeding point was found
although there was a considerable volume of blood in
the peritoneal cavity. In the remaining 11 multiple
minor bleeding points and/or diffuse oozing were
found.
Clinical outcome
In total there were 10 deaths (58%) within 30 days in
the study group compared with four deaths (23%) in
the control group (p < 0.05, Pearson y2) (see Table 3)
The mortality rate for the patients who had undergone
an elective primary operation (4/5) was greater than
for those who had undergone operation for rupture
(6/12).
Seven of those who died in the study group
followed a clinical course of progressive deterioration
and death from continuing haemorrhage and multi-
organ failure. Ten patients made a good initial
recovery and were discharged from the intensive care
unit back to the general ward. In this group there were
three late deaths; two from cerebro-vascular accident
(CVA), both at ten days postoperatively and one from
cardiac arrest on the fourteenth postoperative day,
subsequent to a myocardial infarction diagnosed on
electrocardiogram findings earlier that day. In addi¬
tion to these deaths a further patient suffered a non¬
fatal CVA 19 days after operation. In two of the three
CVA cases the diagnosis was made on clinical grounds
and in the other the diagnosis was confirmed by CT
scanning. There were no late deaths in the control
group but one patient suffered a non-fatal MI on the
second postoperative day.
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Preoperative platelet count (Xl09/1) 163 120-271 260 124-395 NS
Platelet count after first operation (X109/l) 81 63-177 187 93-220 NS
Fibrinogen after first operation (g/1) 1.80 1.1-2.2 2.05 1.7-2.4 NS
Prothrombin ratio after first operation 1.6 1.0-1.8 1.2 1.0-1.4 NS
Temperature at the end of operation (°C) 35.5 35-36.1 36.5 36.5-37 NS
Operation length (mins) 170 160-240 125 110-220 NS
Cross-clamp time (mins) 75 4^100 45 40-70 NS
Blood loss (ml) 1960 390-3665 1500 935-2000 NS
Transfusion RCC (units) during first operation 2.5 0-6 2.0 0-3 NS
Table 3. Outcome and site of bleeding in patients who required
re-operation for control of haemorrhage
Type Outcome Operative findings
1 Elective Died Early death Proximal anastomosis
2 Elective Died MI day 12 Diffuse bleeding
3 Elective Survived Lumbar artery
4 Elective Died Early death Diffuse bleeding
5 Elective Died CVA day 10 Proximal anastomosis
6 Rupture Died CVA day 10 Diffuse bleeding
7 Rupture Survived Renal failure Diffuse bleeding
8 Rupture Survived Median sacral artery
9 Rupture Died Early death Diffuse bleeding
10 Rupture Died Early death Diffuse bleeding
11 Rupture Survived Renal failure Diffuse bleeding
12 Rupture Survived Diffuse bleeding
13 Rupture Survived CVA day 19 Diffuse bleeding
14 Rupture Survived Diffuse bleeding
15 Rupture Died Early death No active bleeding
16 Rupture Died Renal failure and MI No active bleeding
17 Rupture Died Early death Diffuse bleeding
Coagulation results
All but one patient who required re-operation had
abnormal results on coagulation screening following
the first operation (see Tables 1 and 2). The only
patient who did not have a coagulopathy had bled
because of a technical error — failure to under-run a
lumbar artery. Of the five elective patients who
required re-laparotomy for haemorrhage, three had
platelet counts of less than 100 X 109/1 and one had a
platelet count less than 150 X 109/1 following the first
operation (normal range 150-450 X 109/1). Only one of
the elective patients in the group developed post¬
operative thrombocytopenia with a platelet count of
93 X 109/1.
Discussion
This study confirms that operation for control of
haemorrhage after aortic aneurysm repair is an
uncommon but serious complication which is nearly
always associated with a coagulopathy and thrombo¬
cytopenia (Tables 1 and 2). The importance of coagu-
lopthy has not been emphasised in previous reviews
on this subject.11 From the data available in this study
it is impossible to determine whether the coagulo¬
pathy is the cause of the haemorrhage or vice versa.
However, the fact that patients who bled had lower
platelet counts prior to the first operation (Tables 1
and 2) and that very often no significant bleeding
point could be found suggests that coagulopathy is an
important causal factor in most patients. It should also
be noted that many of the patients with ruptured
aneurysms received platelet transfusions (median 5
units, range 0-20 units) and it may be that without
them the severity of postoperative thrombocytopenia
would have been greater.
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The role of coagulopathy as a causal factor of
haemorrhage is easily understood in patients with
ruptured aneurysms, as it is well established that
many of them have coagulopathy on admission,12 and
it may be that coagulopathy is a causal factor in
elective patients as well. Coagulopathy is an estab¬
lished complication of elective aortic aneurysm repair.
It was first reported in 195513 and subsequent studies
have revealed that laboratory evidence of abnormal
coagulation following aortic surgery is common. 14-16
In this study four out of five patients who required re¬
operation after elective operations had thrombocyto¬
penia following the primary operation. Examination
of the records of 20 consecutive patients undergoing
elective aneurysm repair revealed that only one had
postoperative thrombocytopenia. This is a signifi¬
cantly lower incidence of postoperative thrombocyto¬
penia than in the study group, p = 0.016 by Fisher's
exact test.
It is interesting to note that many patients were
hypothermic at the end of operation. It may be
advisable that greater efforts are made to avoid heat
loss in these patients although all normal precautions,
such as heated water blankets, polythene bags around
the lower legs, the use of a blood warmer and placing
the small intestine in a "gut-bag", were undertaken
routinely. The hypothermia in the patients who bled
may simply reflect the fact that they had undergone
longer and more complicated operations but it should
be noted that hypothermia potentiates the activation
of platelets by plasmin and may thus contribute
directly to the generation of a coagulopathy.17
The reason for the high incidence of stroke in this
study is a matter for conjecture. In one case it is known
that the stroke was thrombo-embolic in nature rather
than haemorrhagic but in the other two cases this
information is not available. If one assumes that these
events were thrombotic and also that the post¬
operative MI was also a thrombotic episode then it
may be that these patients develop a "rebound"
prothrombotic state. This is supported by the fact that
at the time of these events the platelet count was
rising; in two cases the platelet count had more than
doubled in the preceding 48 hours. The presence of a
prothrombotic state after ruptured aneurysm has been
suggested in a recent publication.18 An association
between coagulopathy and postoperative thrombotic
events is also suggested by data published in another
study of ruptured aortic aneurysms. Davies et al.
reported that in a group of 12 patients who developed
a coagulopathy in association with a ruptured aneu¬
rysm there were three postoperative deaths which
might be attributed to thrombotic events; two from MI
on days 1 and 9 and one from stroke on day 14. In
contrast, in the group of 23 patients who had no
evidence of coagulopathy there were no deaths from
MI or stroke (p = 0.05 by Fisher's exact test).12 The
presence of a prothrombotic state may account for the
high incidence of MI in the early postoperative period
found in most published series of aneurysm repairs.
Further studies are required to investigate this
hypothesis.
The findings at second operation indicate that in
most cases defective operative technique was not the
cause of bleeding. The evidence suggests that the
development of a coagulopathy was responsible.
Greater understanding of the pathological process
which leads to coagulopathy in these patients is
required, in order to develop more effective ther¬
apeutic strategies and thus reduce the mortality
associated with aortic surgery.
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Disseminated intravascular coagulation after
aortic aneurysm repair, intraoperative salvage
autotransfusion, and aprotinin
Sir—Intraoperative salvage autotransfusion and high-dose
aprotinin have each been reported to reduce homologous
blood transfusion in patients undergoing aortic aneurysm
repair and each modality appears to be safe is isolation.1"3 We
describe a case of disseminated intravascular coagulation
(DIC) with a fatal outcome after an elective aortic aneurysm
repair during which intraoperative autotransfusion and
aprotinin were used.
A 60-year-old male Jehovah's Witness was admitted for
elective repair of an abdominal aortic aneurysm. He had
type II hyperlipidaemia with widespread vascular disease.
Coronary angiography one year previously had shown a
severe stenosis in the left anterior descending coronary artery
and an occluded right coronary artery. Preoperative
haemoglobin was 140 g/L, platelet count 197xlO®/L,
coagulation screen normal, urea 7-3 mmol/L, sodium 132
mmol/L, potassium 4-2 mmol/L, creatinine 126 jtmol/L,
normal chest radiograph, and a left ventricular ejection
fraction of 47% by isotope scanning. An electrocardiogram
showed inferolateral ischaemia.
Aprotinin 500 000 IU was given intravenously at
induction and a further 1500 000 units were given during
the operation. Heparin 5000 IU was given intravenously
before aortic cross-clamping. Autotransfusion was carried
out using a Solcotrans system after heparin had been given.
The operative blood loss was 2100 mL of which 1400 mL
was salvaged by autotransfusion. Immediately
postoperatively all four limbs were extensively mottled. The
patient subsequently developed diarrhoea and
haemoglobinuria. Investigations 5 hours after the end of
operation revealed platelet count 75xl0"/L, prothrombin
ratio 1-25, activated partial thromboplastin ratio 1-4,
fibrinogen 1-8 g/L, and D-dimers 1-2 (normal range <0-25).
Urine output decreased overnight despite a central venous
pressure of 5-10 cm H20. The next day the patient suddenly
developed tachypnoea and tachycardia with evidence of
anterolateral ischaemia. Cardiac arrest followed and, despite
attempts at resuscitation, he died. At necropsy there were
new areas of myocardial infarction around an old posterior
infarct. The left ventricle was dilated and pulmonary
oedema was present. The right kidney was infarcted;
histology showed foci of cortical infarction with multiple
fibrin microthrombi in small arteries, arterioles, and
glomerular tufts. Microthrombi were also found in the liver
and heart.
Intraoperative autotransfusion and aprotinin used alone
are apparently safe, but there are no published data on their
combined use. Activation of the clotting system occurs in the
Solcotrans reservoir, presumably via the contact pathway,
with associated fibrinolysis and generation of D-dimers.3
The plasma concentration of aprotinin in this patient is
unlikely to have inhibited D-dimer formation. However,
systemic antifibrinolytic therapy may accentuate the clinical
features of severe DIC and, although reinfusion of reservoir
blood usually causes no systemic adverse effects, in this
patient aprotinin could have contributed to deposition of
fibrin microthrombi from the reinfused blood in the
microvasculature and subsequent failure to clear such
microthrombi by fibrinolysis. Although additional causes,
such as mild perioperative hypotension and a pre-existing
subclinical prothrombic state from clotting activation in the
aneurysm sac, may have contributed to the clinical picture,
fatal DIC following elective aneurysm repair is rare.' We
suggest that caution should be exercised when considering
the use of Solcotrans and aprotinin for blood saving at
surgery.
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Endothelial cell ultrastructure after aortic aneurysm rupture: an
electron microscopy study
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Endothelial cell activation as an early response to
hypovolaemic shock may be important in the pathogenesis
of coagulopathy and multiple organ failure after aortic
aneurysm rupture. The aim of this study was to determine
whether any evidence could be found of changes in
endothelial cell ultrastructure in patients undergoing
operation for ruptured aneurysm and to establish a model
for future studies of endothelial cells in these patients. At
the start of operation, fat samples from the anterior
abdominal wall were taken from five patients with
ruptured abdominal aortic aneurysms and in an identical
fashion from five control patients undergoing elective
surgery. Endothelial cells lining capillaries were examined
by transmission electron microscopy. Photomicrographs
were taken of all capillaries present and these were
assessed blindly by three independent observers. When
compared with controls it was found that the luminal
surface of the endothelial cells in patients with aneurysm
rupture was more convoluted, with more frequent
processes projecting into the lumen of the capillary.
Budding of the luminal surface of the endothelial cell was
seen in 11 of 45 capillaries in the rupture group and in
none of 44 capillaries in the control group (P< 0-005).
Budding was seen in at least one capillary of all five
patients presenting with rupture but in none of the
control group (P<0-05). In conclusion, at the
ultrastructural level there are changes within endothelial
cells in capillaries at an early stage after ruptured
abdominal aortic aneurysm.
The development of coagulopathy is a well recognized
complication of ruptured abdominal aortic aneurysm
which carries a very poor prognosis1. The coagulopathy
may be present at the time of admission or may develop
during the operation2. This condition has not been
extensively investigated and the pathogenesis is as yet
poorly understood. Although the pathogenesis of
coagulopathy in this clinical situation remains obscure,
there has been a considerable increase in understanding
of the physiology and pathology of haemostatic systems in
recent years. Disseminated intravascular coagulation
associated with septicaemia is one of the few acquired
coagulopathies which is well understood; it appears that
endothelial cells, activated by endotoxin via tumour
necrosis factor a (TNF-a), play a pivotal role in its
pathogenesis3. It may be that endothelial cells, activated
by hypoxia secondary to hypovolaemic shock, could play a
similar role in the early pathogenesis of coagulopathy
associated with ruptured aortic aneurysm.
This study was performed to determine whether there
were morphological changes in endothelial cell ultra-
structure at an early stage following ruptured aneurysm
that could be associated with endothelial cell injury, and
to establish a model for further studies of endothelial cell
morphology and function after ruptured aneurysm or
other causes of severe hypovolaemic shock.
Materials and methods
Fat samples were taken from the anterior abdominal wall
immediately after skin incision at the start of operation in five
patients undergoing operation for ruptured abdominal aortic
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aneurysm and from five control patients undergoing elective
surgery for abdominal aortic aneurysm. The diagnosis of
ruptured aneurysm was confirmed in all cases at the time of
operation. The fat samples were cut into small blocks and
immediately fixed in 2-5 per cent glutaraldehyde per 0-1 mol/1
cacodylate buffer for 2-18 h. The samples were then post-
osmicated (1 per cent osmium in cacodylate buffer) and
embedded in Araldite (Ciba Geigy, Cambridge, UK). Two blocks
of tissue were taken from each sample and sections (0-5-10 ^im)
were cut and stained with a mixture of 0-8 per cent toluidine
blue and 0-2 per cent pyronin B. The sections were viewed under
light microscopy to select appropriate areas from which ultrathin
sections could be prepared subsequently. These were stained
with uranyl acetate and lead acetate and viewed on a Philips
(Eindhoven, The Netherlands) 301 electron microscope.
Electron micrographs were taken of all capillaries present. The
median number of capillaries examined in each patient was nine
(ranging from six to 12).
Each electron micrograph was assessed blindly by three
independent observers who graded each capillary for the
presence or absence of luminal processes, budding, irregularity
of the basement membrane and the presence of intracellular
vesicles. Luminal processes were defined as broad-based
processes projecting into the lumen. Processes which occurred at
the site of cellular junction were excluded as these processes,
known as marginal folds, are normal findings4. Budding was
defined as the presence of three or more circular structures,
approximately 0-1-0-5 pm in diameter, occurring on or near the
luminal surface of the cell. Intracellular vesicles were defined as
three or more cytoplasmic vesicles approximately 0-1-0-5 pm in
diameter4-5.
All patients having ruptured aneurysms were hypotensive on
admission and one patient had an established coagulopathy at
the start of the operation. No patient had received any blood
products before operation. Two patients, both of whom had
intraperitoneal rupture, died on the table. The patient with the
coagulopathy on admission died in the early postoperative period
with lower limb ischaemia and multiple organ failure. The two
remaining patients had an uncomplicated recovery.
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Fig. 1 Capillary from abdominal wall adipose tissue in a patient
undergoing elective aortic surgery. Scale bar indicates 5 trm. A
red blood cell is present in the lumen of the capillary
9
Fig. 3 Capillary from abdominal wall adipose tissue in a patient
with ruptured aortic aneurysm. Processes (P) on the luminal
surface are present. Scale bar indicates 2 /rm
Fig. 2 Capillary from abdominal wall adipose tissue in a patient
with ruptured aortic aneurysm. Endothelial cell budding (B) and
basal membrane irregularity (BMI) are present. Scale bar
indicates 5 pm
Results
Typical electron micrographs from patients in the control
and study groups are illustrated in Figs 1-3. Examples of
luminal processes, budding and irregularity of the
basement membrane are shown. The numbers of
capillaries in the control and study patients with each
feature are shown in Table 1. Process formation on the
luminal surface was significantly more common in patients
who had suffered rupture than in the control group.
Budding of the luminal surface was found in 11 of 45 of
the capillaries from patients with ruptured aneurysms but
in none of the capillaries from control patients (PC 0-005,
Fisher's exact test). Budding was found in at least one
capillary from all patients with rupture but in none of the
control patients (P<0-05, Fisher's exact test). The
presence of intracellular vesicles, a sign of normal cellular
ultrastructure5, was more frequent in control patients,
although this difference was not statistically significant.
Discussion
This study has demonstrated that there are ultrastructural
differences between endothelial cells in patients under-
Table 1 Distribution of normal and abnormal ultrastructural





(n = 44) p *
Luminal processes 37 26 <0-05
Irregularity of basal 12 11 n.s.
membrane
Budding 11 0 <0-005
Intracellular vesicles 9 15 n.s.
*Fisher's exact test, n.s., Not significant
going operation for ruptured aortic aneurysm and patients
undergoing elective operation for aortic aneurysm. The
differences were observed in tissue samples taken at the
start of operation and are thus unlikely to be attributable
to artifacts generated by surgery or anaesthesia. The most
marked difference observed was the presence of budding
which was found in at least one capillary from all patients
with rupture but in none of the capillaries from the
patients in the control group. Although the authors have
termed these structures 'budding' it must be remembered
that transmission electron microscopy produces two-
dimensional images and these structures may be
cylindrical processes rather than spherical buds.
The ultrastructural changes in endothelial cells found in
this study are similar to those described in heart
capillaries of dogs subjected to a period of hypoxia pro¬
duced by ligation of a coronary artery6-8. These studies
describe loss of cytoplasmic vesicles after 10-30 min, and
the production of blebs on the luminal surface of the cell
after more prolonged ischaemia (60-180 min), although
the blebs described are of greater size than the budding
found in the present study. The endothelial cell budding
observed has the appearance of shedding of membrane-
bound vesicles9. Shedding is the release of cell surface
constituents either in soluble form or in association with
plasma membrane. Tissue factor, being an integral
membrane glycoprotein, can be expressed in the plasma in
this way10-11.
The cause of the endothelial cell changes found in these
patients has not been determined in this study. Several
stimuli are known to cause endothelial cell activation:
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hypoxia, cytokines, endotoxin, activated leucocytes, throm¬
bin and histamine12. In septic shock the trigger for
endothelial cell activation3 is endotoxin via TNF-a, but
while patients with ruptured aneurysm may have some
degree of endotoxaemia at the time of admission, it seems
more likely that in these patients the stimulus is direct
endothelial cell hypoxia. All patients studied were
hypotensive on admission and it is not practice in this
department to resuscitate aggressively to achieve normal
blood pressure before operation but rather to proceed as
quickly as possible to operation13,14. Hypovolaemic shock
results in widespread tissue hypoperfusion and hypoxia
which should be most marked in tissues such as
subcutaneous fat. Such hypoxia has been shown to cause
endothelial cell activation in cell culture and animal
models15.
The functional significance of these structural changes
is a matter for speculation. No correlation has been
shown in human studies between activation (expression of
activation antigens) and the ultrastructural cell appear¬
ance. As stated above, it has been shown that hypoxia
induces structural changes in endothelial cells in canine
models and in one study it was shown that such cells
demonstrate abnormal function in terms of vasodilatory
reserve16. It has been shown in cell culture models that
hypoxia can induce endothelial cells to express tissue
factor17-19. This has not yet been demonstrated to be of
direct clinical relevance in human studies but it does
indicate that a mechanism exists whereby endothelial
cells, activated by hypoxia, could stimulate thrombin
production and trigger disseminated intravascular
coagulation. It is of interest that only one of the patients
in this study had evidence of an established coagulopathy;
this suggests that the ultrastructural changes precede the
development of coagulopathy in hypotensive shock, and
that they may be an essential part of the process of
development of disseminated intravascular coagulation in
this clinical setting. If such functional changes can be
demonstrated, these would have considerable clinical
significance. However, further work, using techniques such
as immunogold electron microscopy to examine cellular
activity and function, is required to confirm this
hypothesis.
In conclusion, this study shows that there are ultra-
structural changes present in endothelial cells in adipose
tissue at the start of operation in patients admitted with
ruptured aortic aneurysm that warrant further
investigation. In addition, the study has demonstrated that
electron microscopic examination of tissue obtained at the
start of operation is a feasible method for the detailed
examination of pathological processes affecting endothelial
cells in small vessels.
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Randomized double-blind placebo-controlled trial of early octreotide
in patients with postoperative enterocutaneous fistula
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Somatostatin and octreotide both enhance closure of
gastrointestinal fistulas. The present trial was undertaken
to test whether early combined treatment with parenteral
nutrition and octreotide 100 jug every 8 h by subcutaneous
injection had a beneficial effect compared with parenteral
nutrition plus placebo. Thirty-one patients with post¬
operative gastrointestinal or pancreatic fistula were
randomly assigned to receive parenteral nutrition plus
octreotide (14 patients) or placebo (17) within 8 days of
fistula onset. The percentage reduction in output and rate
of spontaneous closure within 20 days were analysed.
Mean(s.d.) reduction in output was similar after octreotide
and placebo at 24 h (66(43) versus 68(47) per cent,
P = 0-9), 48 h (60(46) versus 57(43) per cent, P = 0-8) and
72 h (62(50) versus 66(49) per cent, P = 0-9) after starting
the combined treatment. Closure within 20 days was
observed in eight of 14 fistulas in patients given octreotide
and in six of 17 in those receiving placebo (P = 0-4).
Administration of octreotide, within 8 days of fistula
onset, associated with parenteral nutrition does not
significantly increase the spontaneous fistula closure rate
compared with parenteral nutrition plus placebo.
The powerful inhibitory effects of somatostatin on
gastrointestinal secretion and motility fostered research
on its use in the treatment of gastrointestinal fistula with
encouraging initial results'-3. Three major limitations of
native somatostatin are its very short plasma half-life
(which makes continuous intravenous administration
mandatory), the hormonal rebound phenomenon after
stopping administration and its inhibitory effects on
pancreatic insulin secretion, which may cause glucose
intolerance4. Octreotide is a synthetic octapeptide
analogue of somatostatin with a plasma half-life5 of
90 min and a prolonged duration of action that makes
subcutaneous administration possible6.
Uncontrolled observations of reduced fistula output and
enhanced closure after somatostatin or octreotide admini¬
stration have been published7-9. In a placebo-controlled
clinical trial octreotide effectively reduced small bowel
fistula output in patients without sepsis10 and a pilot
clinical study demonstrated octreotide shortening the
period of closure of well established intestinal fistulas11.
The only open clinical trial published to date suggests a
reduction in fistula output and shortening of closure
interval with native somatostatin12. None of these studies,
however, was designed as a double-blind trial. In a small
placebo-controlled study, octreotide did not increase the
spontaneous fistula closure rate or reduce fistula output13.
In this study the time interval between fistula appearance
and octreotide administration was not evaluated; the
timing of administration may be a critical factor for
octreotide to show any benefit. A multicentre, prospective,
randomized, placebo-controlled, double-blind clinical trial
was therefore undertaken to compare early administration
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Between October 1988 and May 1992, all patients with
postoperative enterocutaneous fistula of less than 8 days in
duration with a daily output greater than 50 ml diagnosed at the
surgical departments of any of the five participating centres were
considered candidates to enter the trial.
Fistula classification
The origin of the fistula was proved in all patients by
fistulography and/or upper gastrointestinal contrast studies and
the lesion classified according to the anatomy and output as
previously described14. Fistulas considered for the study
belonged to group 1 (stomach and small bowel origin) either in
the la (output less than 1000 ml per 48 h) or lb (output more
than 1000 ml per 48 h) categories. Pure pancreatic fistula was
also included.
Exclusion criteria
Patients with a fistula arising from neoplastic or irradiated tissues
were excluded from the trial. No fistula originating from gross
anatomical abdominal wall defects and/or mucocutaneous con¬
tinuity (type 2) or from colonic anatomoses (type 3) was
included.
Ethics
The protocol and consent forms were approved by the Clinical
Trials National Board of the Spanish Ministry of Health. The
protocol was also approved by the clinical trial and ethics
committee of the Hospital Universitari del Mar and other
participating institutions. Informed consent was obtained from
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Fibrin Sealant Reduces Suture Line Bleeding During Carotid
Endarterectomy: A Randomised Trial
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Objectives: To determine whether topical fibrin sealant reduced suture line bleeding during carotid endarterectomy with
polytetrafluoroethylene (PTFE) patch closure.
Design: Prospective randomised non-blinded control trial.
Setting: Regional vascular surgery unit.
Materials: Seventeen patients undergoing carotid endarterectomy were randomised either to receive fibrin sealant as a
topical haemostatic agent at the arteriotomy suture line or to act as control.
Outcome measures: Time taken to achieve haemostasis at the suture line. Intraoperative blood loss. Total operative
time
Results: The median time to achieve haemostasis was 5.5 min (range 4—31 min) in the treatment group and 19 min (range
10-47 min) in the control group. This difference was statistically significant p <0.005 by Mann-Whitney test. There was
no statistical difference in total operative time. Operative blood loss was lower in the treatment group (median 420ml, range
300-500ml) than in the control group (median 550ml, range 350-1200ml) but this difference was not statistically
significant. One patient in the control group suffered a perioperative thrombo-embolic event.
Conclusion: Fibrin sealant is an effective topical haemostatic agent for arteriotomy suture lines involving PTFE
material.
Key Words: Controlled randomised trial; Polytetrafiuoroethylene; Carotid surgery; Fibrin sealant; Haemostasis.
Introduction
Suture line bleeding at vascular anastomoses is a
problem which can increase operative blood loss and
lengthen operating time. This is especially a problem
in anastomoses involving polytetrafluoroethylene
(PTFE) grafts and patches and may be exacerbated by
the use of intraoperative heparin.
Fibrin sealant is a topical haemostatic agent which
consists of two principal components, fibrinogen and
thrombin, which are mixed, in the presence of Factors
Vm and XIII, fibronectin and calcium to produce
insoluble fibrin. Thus the main components of the
final stage in the physiological pathway of coagulation
are present.
Fibrin sealant of this form was first described in
1972 as a tissue adhesive for nerve repair.1 Since then
Please address all correspondence to: Dr A A Milne, Vascular
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it has been used in a wide variety of clinical settings:
otolaryngology,2 plastic surgery,3'4 neurosurgery, I7
thoracic surgery,8/ 2 hepatobiliary surgery,13'14 pancre¬
atic surgery/3'16 colorectal surgery,17 gynaecology18'19
and cardiac surgery.20/26
The possibilities for using fibrin sealant in cardio¬
vascular surgery were recognised by Spangler early
on during its development.27 Borst and Haverich
(1982) further developed and promoted the use of
fibrin sealant in this field describing its use for sealing
knitted Dacron aortic grafts, puncture holes and
suture lines in vascular anastomoses.20,21
The success of fibrin sealant in cardiac surgery
would suggest that it may also be useful in peripheral
vascular surgery. Flowever there have been few
studies of fibrin sealant in this setting. In randomised
trials using an animal model of peripheral vascular
surgery with PTFE grafts, fibrin sealant was shown to
be more effective than oxidised regenerated cellulose
in controlling anastomotic bleeding.28,29 However
there are no reports of the clinical use of fibrin sealant
1078-5884/95/000000 + 00 $08 00/0 © 1995 W. B. Saunders Company Ltd.
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in peripheral vascular surgery. Carotid endarter-
ectomy using a PTFE patch is associated with pro¬
longed anastomotic bleeding and the aim of this study
wa£ to determine whether fibrin sealant could sig¬
nificantly reduce suture line bleeding in these
patients.
Material and Methods
The study was a prospective, randomised non-blinded
trial. An initial pilot study involving eight patients
was carried out in order to familiarise surgeons and
theatre staff with the use of fibrin sealant prior to the
commencement of the trial.
Patients and operative details
Patients were recruited from the vascular surgery unit
of the Royal Infirmary of Edinburgh. All patients gave
informed written consent and the trial was approved
by the local ethical committee. Past medical history
and drug use within the previous 14 days was
recorded. To allow assessment of the viral safety of the
sealant (as part of a larger safety study) patients who
were known to be seropositive for anti-HTV, who had
a history of hepatitis or whose liver function tests were
outside the normal range were excluded. In addition,
patients with a history of severe reactions to blood
products or concurrent disease which might com¬
promise their ability to be retained within the study
were also excluded. A venous blood sample was taken
for haemoglobin, haematocrit, platelet and white cell
count, prothrombin time, activated partial thrombo¬
plastin time and liver function tests. A serum sample
was stored at -40°C for later viral studies if
required.
The mean age of patients was 64.5 years (range
48-75 years) and there was no difference in mean age
between the patients in the treatment and control
groups. Fifteen patients were taking regular aspirin;
both the patients not taking aspirin were in the control
group. No patient had any abnormality on pre¬
operative coagulation screen.
Following entry into the trial the patients were
randomised in a computer-generated sequence to
treatment or control groups. In the treatment group,
following completion of the vascular anastomosis,
fibrin sealant was applied to the suture line using a
dual syringe technique.30 In the control group nothing
was applied to the suture line. The clamps were
released 2 min after application was complete. Pres¬
sure was applied with surgical swabs if there was
significant bleeding. The surgeon was allowed to use
haemostatic gauze at any time. The arteriotomy was
inspected frequently and the time taken to achieve
haemostasis from release of the clamps was
recorded.
Surgical treatment was otherwise identical in the
two groups. All operations were performed under
general anaesthetic with subcutaneous local anaes¬
thetic infiltration. The operations were all performed
(6/9 control; 5/8 treatment) or supervised by one
surgeon (C.V.R.). All patients received intraoperative
heparin, 5000 I.U. before the artery was clamped. The
heparin was not reversed. Arteriotomy closure was
performed using a 0.5 mm PTFE patch (WL Gore) and
7.0 Coretex suture. In both groups any further
manoeuvres, such as application of pressure or hae¬
mostatic gauze, required to achieve haemostasis were
recorded. The length of operation, blood product
usage were recorded and a personal assessment by the
surgeon of effectiveness and ease of use was also
recorded.
Patients were followed-up for 26 weeks. Blood was
taken at 24 h and 5 days for haemoglobin, haematocrit,
platelet count and white cell count; at 6 weeks and 12
weeks for liver function tests and at 26 weeks for
virology testing. Virology testing consisted of deter¬
mining the presence of hepatitis B surface antigen and
enzyme immunoassay for antibodies to hepatitis A
and hepatitis C, bioluminescence assay for antibodies
to hepatitis B surface antigen, and radioimmunoassay
for antibodies to hepatitis B core antigen.
Fibrin sealant kit was provided for the study by the
Scottish National Blood Transfusion Service (SNBTS).
Heat-treated human fibrinogen was manufactured at
the SNBTS Protein Fractionation Centre from pooled
donor plasma cryosupernatant. Solvent detergent
treated human thrombin preparation was supplied by
the Centre Regional de Transfusion Sanguine (CRTS)
(Lille, France). The fibrin sealant supplied by SNBTS
uses concentrations of thrombin between 200-500
I.U./ml and fibrinogen 29-39g/l.31
After 17 patients had been randomised it appeared
to the surgeon and anaesthetist that there was a
clinical benefit in patients treated with fibrin sealant
and an interim analysis of the data was requested.
This confirmed that there was a statistically significant
benefit and the trial was stopped. Statistical analysis
was carried out using a Mann-Whitney U test.
Results
The median time to achieve haemostasis was 5.5 min
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(range 4r-31 min) in the treatment group and 19 min
(range 10-47 min) in the control group (Fig. 1). This
difference was statistically significant p< 0.005 by
Mann-Whitney test. There was no statistical difference
in total operative time. Operative blood loss was
lower in the treatment group (median:420ml,
range:300-500ml) than in the control group (median
550ml, range 350-1200ml) but this difference was not
statistically significant. All patients (9/9) in the control
group and one patient (1/8) in the fibrin sealant group
required the use of oxidised cellulose gauze to aid
haemostasis. In no cases were further sutures required
to achieve haemostasis. There were no significant
differences in the drop in haemoglobin following
operation. There was no serological evidence of
hepatitis A, B or hepatitis C transmission at 6 months
and no patients developed abnormal liver function
tests during follow-up.
One patient in the control group suffered a post¬
operative cerebrovascular accident on the ipsilateral
side to operation. There was no evidence of arterial
embolism or thrombosis in the treatment group. No
patients required reoperation for control of haemor¬
rhage or evacuation of haematoma. There were no







This study has shown that fibrin sealant is an effective
topical haemostatic agent in vascular surgery. The
only statistically significant benefit was a shorter time
to achieve haemostasis. Blood loss was lower in the
treatment group but this did not attain statistical
benefit. This may be a type II statistical error: the trial
was terminated after interim analysis was requested
by the surgical team to confirm a clinical impression of
haemostatic effectiveness.
It may be expected that fibrin-based adhesives and
sealants are likely to be useful agents for surgical
haemostasis and tissue adhesion since fibrin plays a
central role in the physiological process of wound
healing. Thus problems of foreign body reaction,
delayed healing and fibrosis, which are associated
with other haemostatic agents, might be avoided. The
major advantages of fibrin-based glues over other
tissue adhesives are tissue compatibility, biodegrad-
ability and the ability to adhere to wet surfaces. It may
even promote healing since the first stage in normal
wound healing is the production of a fibrin network
into which fibroblasts and capillaries migrate. Evi¬
dence in support of this has been derived from several
animal studies.28,29'31/34
Concern has been expressed that viral transmission
could occur as a result of fibrin sealant use. Theoret¬
ically virus remaining in the preparation could be
adsorbed and retained by the patient and there are
reports in the literature which implicate cryoprecipi-
tated fibrinogen as a mechanism for the transmission
of HTV-1 and hepatitis.35,36 Therefore the method of
production has been designed to minimise the risk of
viral transmission. The safety of fibrin sealant is
further supported by this study in which no evidence
of viral transmission could be found. The study of
viral safety of this product is continuing, involving
approximately 100 patients in detailed follow-up.
A further concern over the use of fibrin sealant on
arterial suture lines is that it may promote intra¬
vascular thrombosis or embolism. No evidence to
support such concerns was found in this study or has
been reported elsewhere. There was only one embolic
event and that was in a patient in the control group.
This study demonstrates that fibrin sealant is an
effective and safe haemostatic agent for vascular
suture lines involving PTFE.
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